Retention and Accumulation of Low Density Lipoprotein Particles in the Extracellular Matrix of the Arterial Intima in Atherogenesis by Pentikäinen, Markku
1RETENTION AND ACCUMULATION OF LOW DENSITY
LIPOPROTEIN PARTICLES IN THE EXTRACELLULAR
MATRIX OF THE ARTERIAL INTIMA
IN ATHEROGENESIS
Markku O. Pentikäinen
Wihuri Research Institute
Helsinki, Finland
and
University of Helsinki
Faculty of Medicine
Helsinki, Finland
ACADEMIC DISSERTATION
To be publicly discussed, with the permission of the Medical Faculty of the
University of Helsinki, in auditorium 1, Meilahti Hospital, Haartmaninkatu 4,
on December 17th, 1999, at 12 noon.
HELSINKI 1999
2Supervisor
Professor Petri T. Kovanen, M.D.
Wihuri Research Institute
Helsinki, Finland
Reviewers
Professor J. Peter Slotte, Ph.D.
Åbo Akademi
Turku, Finland
and
Docent Timo Kuusi, M.D.
University of Helsinki,
Helsinki, Finland
Official opponent
Professor Germán Camejo, Ph.D.
Göteborg University, Gothenburg
and
AstraZeneca, Mölndal
Sweden
ISBN 951-45-8985-8 (PDF version)
Helsingin yliopiston verkkojulkaisut
HELSINKI 1999
3To Virve
4Contents
Contents
  page
ORIGINAL PUBLICATIONS ............................................................................................................. 6
ABBREVIATIONS ................................................................................................................................ 7
SUMMARY ....................................................................................................................................... 8
INTRODUCTION .................................................................................................................................. 9
REVIEW OF THE LITERATURE
THE ARTERIAL INTIMA
The normal arterial intima ....................................................................................................... 10
Endothelium
Intimal cells and stroma
Internal elastic lamina
Morphologic changes in the arterial intima during atherogenesis .................................. 11
THE LOW DENSITY LIPOPROTEIN PARTICLE
Physiological function of LDL .............................................................................................. 12
Structure ................................................................................................................................... 13
Lipids
Apolipoprotein B-100
RETENTION OF LDL IN THE INTIMA
Evidence for LDL retention in vivo ..................................................................................... 15
Interaction between LDL and the arterial extracellular matrix............................................. 16
Structure of the extracellular matrix
Evidence of the interaction of LDL with different components of the ECM
Molecules that modulate the binding of lipoproteins to ECM and cell surfaces
Lipoprotein lipase
Apolipoprotein E
Significance of LDL retention ............................................................................................... 22
ACCUMULATION OF LDL IN THE ARTERIAL INTIMA
Lipids in the atherosclerotic arterial intima ......................................................................... 22
 Morphology of lipid particles in the arterial intima
Chemistry of lipids in the arterial intima
Evidence for the presence of modified LDL in vivo ........................................................... 24
Immunological evidence
Evidence based on properties of lipid particles isolated from the arterial intima
Methodological aspects of extraction
Properties of isolated lipid particles
Evidence for the presence of enzymes and agents potentially capable
of modifying LDL in the extracellular space of the arterial intima .................................... 28
Proteases
Oxidants
Lipases
5Contents
Aggregation and fusion of modified LDL particles in vitro ............................................. 29
Methodological aspects
Modifications that cause aggregation and fusion of LDL particles in vitro
Effect of extracellular matrix on LDL modification
Modification of the structure of apoB-100 by glycosaminoglycans
Alteration in the rate of LDL modificaiton
AIMS OF THE STUDY ........................................................................................................................ 34
METHODS
ISOLATION AND MODIFICATION OF LIPOPROTEINS .............................................................................. 35
Preparation and labeling of lipoproteins
Modification of LDL
ANALYSIS OF MODIFIED LDL ............................................................................................................ 35
Biochemical analysis
Determination of particle size
Electron microscopy of LDL particles
Fluorescent resonance energy transfer (RET)
1H NMR
ISOLATION AND MODIFICATION OF EXTRACELLULAR MATRIX COMPONENTS ...................................... 36
Isolation and modification of decorin from feral bovine skin
Isolation of proteoglycans from human aorta
Isolation of lipoprotein lipase from bovine milk
INTERACTION OF NATIVE AND MODIFIED LDL WITH EXTRACELLULAR MATRIX COMPONENTS ............ 38
Affinity chromatography
Microtiter well binding assay
Gel mobility shift assay
IMMUNOHISTOCHEMISTRY .................................................................................................................. 39
RESULTS AND DISCUSSION
ASSOCIATION OF NATIVE AND OXIDIZED LDL WITH COLLAGEN TYPE I ............................................. 40
Binding of LDL to decorin-coated collagen
Binding of oxLDL to decorin-coated collagen
Effect of LPL on the binding of LDL and oxLDL to decorin-coated collagen
Interaction of lipoproteins with LPL
Ultrastructural localization of LDL, oxidized lysines, lipoprotein lipase,
decorin, and collagen type I
AGGREGATION AND FUSION OF MODIFIED LDL ................................................................................ 44
Ability of various modifications to trigger fusion of LDL particles
Characterization of proteolytic fusion of LDL by 1H NMR
Effect of human arterial proteoglycans on proteolytic fusion of LDL
GENERAL DISCUSSION ....................................................................................................................... 48
FUTURE PERSPECTIVES ....................................................................................................................... 50
CONCLUSIONS .................................................................................................................................. 51
ACKNOWLEDGMENTS .................................................................................................................. 53
REFERENCES ...................................................................................................................................... 54
6Original Publications
Original Publications
This thesis is based on the following original publications, which are referred to in the text by
Roman numerals.
I. Pentikäinen, M.O., Öörni, K., Lassila, R., and Kovanen, P.T. The proteoglycan decorin
links low density lipoproteins with collagen type I. J. Biol. Chem. 272:7633-7638, 1997.
II. Pentikäinen, M.O. Öörni, K., Kovanen, P.T. Lipoprotein lipase (LPL) strongly links  both
native and oxidized low density lipoprotein particles to decorin-coated collagen. Roles for
both dimeric and monomeric forms of LPL. Submitted, 1999.
III. Pentikäinen, M.O., Lehtonen, E.M.P., and Kovanen, P.T. Aggregation and fusion of
modified low density lipoprotein. J. Lipid Res. 37:2638-2649, 1996.
IV. Ala-Korpela, M., Pentikäinen, M.O., Korhonen, A., Hevonoja, T., Lounila, J., and
Kovanen, P.T. Detection of low density lipoprotein particle fusion by proton nuclear
magnetic resonance spectroscopy. J. Lipid Res. 1998, 39:1705-1712.
V. Pentikäinen, M.O., Lehtonen, E.M.P., Öörni, K., Lusa, S., Somerharju, P., Jauhiainen,
M., and Kovanen, P.T. Human arterial proteoglycans increase the rate of proteolytic
fusion of low density lipoprotein particles. J. Biol. Chem. 272: 25283-25288, 1997.
In addition, some unpublished data are presented.
The original publications are reproduced with permission of the copyright holders.
7Abbreviations
Abbreviations
4-HNE 4-hydroxynonenal
AAPH 2,2’-azobis(2-amidino-
propane)hydrochloride
apo apolipoprotein
BH Bolton-Hunter
BHT butylated hydroxytoluene
BM basement membrane
BODIPY-CE cholesteryl 4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-
s-indacene-3-dodecanoate
BSA bovine serum albumin
C-4-S chondroitin-4-sulfate
C-6-S chondroitin-6-sulfate
CL cholesteryl linoleate
CE cholesteryl ester
CEL carboxyl ester lipase
CETP cholesteryl ester transfer
protein
CS chondroitin sulfate
α-CT α-chymotrypsin
D
2
O deuterium oxide
DAG diacylglycerol
DS dermatan sulfate
DxSO
4
dextran sulfate
ECM extracellular matrix
EM electron microscopy
EC endothelial cell
FC free (unesterified) cholesterol
FID free induction decay
GAG(s) glycosaminoglycan(s)
1H NMR proton nuclear magnetic
resonance
HDL high density lipoprotein(s)
HOCl hypochlorite
HPLC high pressure liquid chroma-
tography
HS heparan sulfate
IDL intermediate density
lipoprotein(s)
LDL low density lipoprotein(s)
IEL internal elastic lamina
KS keratan sulfate
LPL lipoprotein lipase
LRP low density lipoprotein
receptor-related protein
MDA malondialdehyde
ONOO peroxynitrite
oxLDL oxidized LDL
PBS phosphate buffered saline
PC phosphatidylcholine
PG(s) proteoglycan(s)
PL phospholipid(s)
PLA2 phospholipase A2
PLC phospholipase C
Pyr10CE cholesteryl 1-pyrenedecanoate
RET resonance energy transfer
SLO soybean 15-lipoxygenase
SM sphingomyelin
SMC smooth muscle cell
SMase sphingomyelinase
S-SMase secretory sphingomyelinase
TBARS thiobarbituric acid-reactive
substances
TCA trichloroacetic acid
TG triglyceride
TSP sodium 3-
trimethylsilyl[2,2,3,3-D
4
]
propionate
VLDL very low density lipoprotein(s)
WHHL Watanabe heritable hyperlipi-
demia
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Summary
Atherosclerosis is characterized by accumulation of low density lipoprotein (LDL)-derived cho-
lesterol in the intima, the inner layer of the arterial wall. Initial extracellular lipid deposition in the
subendothelial layer of the arterial intima is followed both by intracellular lipid deposition caus-
ing foam cell formation and by the development of an extracellular lipid core deep in the intima.
The reason for LDL deposition in the arterial intima is not clear, but appears to be due to forma-
tion of modified LDL, which, in contrast to native LDL, tends to accumulate both intra- and
extracellularly. LDL modification in the arterial intima, in turn, appears to require binding of the
LDL particles to the extracellular matrix, where they are exposed to noxious cell-derived en-
zymes and agents for prolonged periods of time.
The present study focused on i) the interaction of LDL with different components of the extracel-
lular matrix, ii) the production of modified forms of LDL morphologically resembling those present
in the arterial intima, and iii) the effect of arterial proteoglycans on the modification of LDL in
vitro. Specifically, the binding of LDL to collagen type I in the presence of the small collagen-
binding proteoglycan decorin and the enzyme lipoprotein lipase was studied. In addition, LDL
particles were modified in vitro by mechanical forces, by proteolysis of apolipoprotein B-100
(apoB-100), by lipolysis of LDL surface lipids, by glycosylation of the particles and by oxidation,
and the effects of these modifications on the physicochemical properties and integrity of the par-
ticles were studied. The proteolytic modification was studied in greater detail in the fluid phase
using proton nuclear magnetic resonance spectroscopy and when bound to arterial proteoglycans
using fluorescence spectroscopy.
The small proteoglycan decorin was found to bind apoB-100 of LDL by its glycosaminoglycan
chain and so link LDL to collagen. Lipoprotein lipase, by binding to both the glycosaminoglycan
chain of decorin and to the lipids of LDL, was able to significantly strengthen the binding of LDL
to decorin. In addition, even larger amounts of oxidized LDL bound to the decorin-coated col-
lagen in the presence of LPL. This was found to depend on the ability of oxidized LDL to bind to
the dimeric form of LPL, whereas native LDL bound only monomeric LPL. Extensive modifica-
tion of the surface of LDL particles by proteolysis or oxidation, or lipolysis of sphingomyelin was
found to generate fused particles resembling the lipid droplets found in the arterial intima. From
these modifications, proteolysis also generated membrane material sprouting from the fused par-
ticles, which occasionally formed vesicles and multilayered membranous structures. Interestingly,
binding of LDL to human arterial proteoglycans was found to increase the rate of proteolytic LDL
fusion by enhancing LDL proteolysis. Finally, to monitor fusion of LDL particles and simulta-
neously to detect changes in the individual classes of surface lipids a novel 1H NMR methodology
was devised. Taken together, the present study suggests some plausible mechanisms for the reten-
tion and accumulation of LDL in the arterial intima, and has led to the use of novel tools for
investigation of the physicochemical properties of native and modified LDL particles.
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Introduction
Atherosclerosis is a disease of the inner layer of
the arterial wall, the intima. It mainly affects
the large arteries and has a strong predilection
for certain areas of the arterial tree, i.e. the
branching sites and bifurcations. Clinical symp-
toms occur late in the course of the disease and
are most commonly caused by obstruction, ei-
ther partial or total, of the affected artery.
The importance of cholesterol in the pathogen-
esis of the disease was discovered in the begin-
ning of the century by Anitchkov (1933), who
fed rabbits with cholesterol and found that the
animals developed atherosclerotic lesions. To-
day, we know that the major source of the cho-
lesterol in the atherosclerotic lesions is the
plasma low density lipoprotein (LDL) particles.
Their infiltration into the intima through the
endothelial cell layer is followed by their reten-
tion in the intima, where they reach very high
local concentrations. An important factor con-
tributing to the retention of LDL is its binding
to the intimal extracellular matrix. Retention for
prolonged periods of time exposes the LDL par-
ticles to modifications. Modified forms of LDL
in the arterial intima can be detected initially as
small lipid droplets and vesicles within the ex-
tracellular matrix by electron microscopic tech-
niques, especially in the vicinity of collagen fi-
bers (Fig. 1). They appear to attract monocytes
into the intima and lead to formation of foam
cells, i.e. intracellular accumulations of lipid.
The hallmark of the early atherosclerotic lesion
is the presence of lipid-laden foam cells in the
intima.
The present study attempts to characterize some
of the potential modifications of LDL particles
in the arterial intima, and their effect on particle
stability and on the interaction of the particles
with the extracellular matrix.
Fig. 1. Freeze-etch
electron photomi-
crograph from the
intima of a 3-week-
old apoE-deficient
mouse aorta. Lipid
particles (arrows) are
aligned along the col-
lagen fibers (arrow-
heads). Reproduced
from Tamminen et al.
(1999) with permis-
sion of Dr. Joy Frank
and the American
Heart Association.
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The arterial intima
The normal arterial intima
The arterial wall is composed of three histologi-
cally distinct layers. It is the inner layer of the
arterial wall, the intima, that is primarily affected
by atherosclerosis. This layer is composed of
the endothelium with its basement membrane,
and of smooth muscle cells, which are the main
source of the extracellular matrix of the arterial
intima. The intima is separated from the media
by the internal elastic lamina (IEL), which is
considered to be part of the media. Unlike all
other extravascular tissues, the intima lacks lym-
phatic capillaries (Groszek & Grundy 1980), and
this severely limits the removal of macromol-
ecules from the tissue. The middle layer of the
arterial wall, the media, is composed of layers
of contractile smooth muscle cells separated by
elastic laminae. The outermost elastic lamina,
called the external elastic lamina, separates the
media from the outermost layer of the arterial
wall, the adventitia. The adventitia is composed
of highly vascularized, loose connective tissue
rich in collagen.
The endothelium
The arterial endothelium is composed of a single
continuous layer of endothelial cells, which are
normally connected with each other by both
tight and gap junctions. The endothelial cells
are polarized: they secrete a heparan sulfate
matrix capable of binding lipoprotein lipase on
their apical surfaces, and a basement membrane
on their basolateral surfaces.
The endothelium has an important role in regu-
lating the vascular tone. Endothelial cells secrete
prostacyclin and nitric oxide, both of which
cause relaxation of vascular smooth muscle
cells, and endothelin, which causes vasocon-
striction. Furthermore, in response to various
stimuli from the intima, the endothelial cells
express adhesion molecules whose role is to
recruit inflammatory cells from the circulation.
Finally, the heparan sulfate proteoglycans
(HSPGs) on the luminal surface of the endothe-
lial cells bind lipoprotein lipase (LPL), the ma-
jor lipolytic enzyme involved in the hydrolysis
of triglyceride-rich lipoproteins. LPL is secreted
by parenchymal cells and not by the endothe-
lial cells themselves. According to a recent re-
port, on their basolateral surfaces endothelial
cells express heparinase, which can release LPL
in its active form from the underlying extracel-
lular matrix (Pillarisetti et al. 1997). Further-
more, endothelial cells can actively transport
LPL from their basolateral to their luminal sur-
face (Stins et al. 1992).
The endothelium is classically considered to be
a major barrier that regulates the entrance of
macromolecules into the arterial wall. Despite
extensive studies, it is not clear whether macro-
molecules, such as LDL particles, enter the ar-
terial intima between the normal endothelial
cells (Kao et al. 1994; Kao et al. 1995), or
through rare cellular leakage sites associated
with endothelial cell turnover (Chuang et al.
1990; Barakat et al. 1992), or through endothe-
lial cells via transcytosis (Vasile et al. 1983;
Navab et al. 1986; Snelting-Havinga et al.
1989). Even the barrier function of the endot-
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helium has been questioned, since the LDL con-
centration in the intima equals or even exceeds
the plasma LDL concentration (Smith 1990). In
addition, in a model of arterial injury, LDL ac-
cumulation in the intima was shown not to be
increased in de-endothelialized areas but to be
greatly increased in re-endothelialized areas
(Day et al. 1985; Chang et al. 1992).
Intimal cells and stroma
The normal arterial intima consists mainly of
smooth muscle cells with a few isolated mac-
rophages. In contrast to the media, where the
smooth muscle cells are rich in myofilaments,
i.e. are of contractile phenotype, in the intima
some of the smooth muscle cells are poor in
myofilaments but rich in rough endoplasmic
reticulum, i.e., are of synthetic phenotype. These
cells are specialized in producing the extracel-
lular matrix of the intima, which consists mainly
of proteoglycans, collagens and elastin. In ath-
erosclerotic lesions, the smooth muscle cells
especially produce a characteristically thick
basement membrane, which is a special type of
extracellular matrix (the structure described in
“Structure of the extracellular matrix”, p. 16).
(Stary et al. 1992)
Internal elastic lamina
The innermost continuous elastic lamina of the
arterial wall separates the intima from the me-
dia and is called the internal elastic lamina (IEL).
Similar, although usually thinner, elastic lami-
nae are found between the smooth muscle cell
layers of the media. Except for the presence of
fenestrae (reported to be as large as ~2 µm in
diameter (Kwon et al. 1998)), which permit the
passage of solvent and small molecules, the IEL
is an impermeable barrier. Interestingly, the high
density lipoprotein (HDL) particles appear to
be able to pass the IEL, whereas LDL particles
are not (Nordestgaard et al. 1990). Moreover,
the IELs of normal arteries have been shown to
be impermeable to antibodies (Bendeck et al.
1994) and oligonucleotides (Guzman et al.
1994). Therefore, the IEL has been suggested
to be a molecular sieve that concentrates LDL
in the intima (Gofman & Young 1963; Smith
1990; Penn et al. 1997).
Morphologic changes in the arte-
rial intima during atherogenesis
In human coronary arteries the arterial intima is
especially thickened, which is considered to rep-
resent a physiological adaptation to changes in
blood flow, wall tension, or both, rather than to
be an initial atherosclerotic change. The intima
of the coronary arteries is thickened diffusely,
except at the branches and orifices, where the
thickenings are eccentric. Interestingly, as dis-
cussed in more detail below, advanced athero-
sclerotic lesions tend to develop preferentially
at arterial sites with eccentric intimal thicken-
ings. (Stary et al. 1992)
A thickened arterial intima characteristically has
two distinct layers, which can be detected mi-
croscopically. The superficial ”proteoglycan-
rich layer” contains large amounts of extracel-
lular matrix consisting of proteoglycans and
collagen, isolated smooth muscle cells of syn-
thetic phenotype, and macrophages. The deep
”musculoelastic layer”, in contrast, contains
smooth muscle cells of contractile phenotype
and elastin arranged as elastic fibers. Although
no lipid deposits are evident in the grossly nor-
mal intima on light microscopic examination,
accumulation of small lipid droplets and vesicles
in the extracellular space has been demonstrated
already at this stage by electron microscopy
(EM) (Tirziu et al. 1995).
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According to the classification of the American
Heart Association (Stary et al. 1992; Stary et al.
1994; Stary et al. 1995), the presence of isolated
macrophages that have been transformed into
foam cells in the intima is considered to indicate
the type I lesion (Fig. 2). Accumulation of large
numbers of macrophages with or without lipid
deposits as layers in the intima, together with
the presence of some lipid-filled smooth muscle
cells represent type II lesion. When present in a
thin intima, this type of lesion can be seen as a
“fatty streak” with the naked eye, but may be
undetectable if present deep in a thickened in-
tima. Type II lesions that colocalize with adap-
tive intimal thickening in atherosclerosis-prone
regions may undergo transformation into type
III (intermediate) lesions. In these lesions, small
pools of extracellular lipid are present in the
musculoelastic layer, covered by layers of mac-
rophage-derived foam cells, and some macroph-
ages without lipid deposits are present in the
subendothelial space. Confluence of the lipid
pools of the type III lesions to form a large lipid
core is characteristic of type IV lesions. These
lesions have no signs of fibrosis, and the intima
above the lipid core appears similar to the intima
in type II and type III lesions. However, capillar-
ies that point to the lumen of the vessel are found
around the lipid core. The smooth muscle cells
in the core have an especially thick basement
membrane that separates the cells from the lipid.
Formation of fibrous connective tissue around
the core is characteristic of type V lesions. Type
V
a
 lesions have a lipid core surrounded by a fi-
brous cap and are called fibrolipid lesions. Cal-
cified type V
a
 lesions are termed V
b
 lesions, and
lipid-poor fibrotic lesions, found especially in
the lower extremities, are termed Vc lesions. Fi-
nally, when type IV or V lesions are complicated
by surface disruption, hemorrhage, or thrombo-
sis, the lesions are termed VIa, VIb, and VIc, re-
spectively.
The low density lipoprotein
particle
Physiological function of LDL
The bulk of the cholesterol in the plasma circu-
lates in LDL particles. These LDL particles pro-
Review of the literature
Fig. 2. Changes in the arterial intima dur-
ing atherogenesis. Adapted from Stary et
al. (1995).
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vide the cells with the cholesterol they need
(Brown & Goldstein 1986). They bind to the LDL
receptors on the cell surface, after which they
are endocytosed (Brown et al. 1981). Within ly-
sosomes, acidic proteases hydrolyze the
apolipoprotein B-100 (apoB-100) and acidic li-
pases hydrolyze the lipids of the particles. The
cholesterol released from the particles crosses
the lysosomal membrane, and is incorporated
into the cellular membranes where cholesterol
is needed. Uptake of cholesterol by cells is regu-
lated by synthesis of LDL receptors, which pre-
vents intracellular accumulation of cholesterol
(Brown & Goldstein 1986).
Structure
LDL particles are spherical lipoproteins with
diameters between 18 and 25 nm and densities
of 1.019 – 1.063 g/ml. Each particle contains a
single apolipoprotein, apolipoprotein B-100
(apoB-100), which partially covers the lipid.
LDL particles are heterogeneous, consisting of
several subfractions that differ in size, compo-
sition, and conformation of apoB-100 (Musliner
& Krauss 1988; Austin et al. 1988).
Lipids
On average, an LDL particle contains 500 mol-
ecules of phosphatidylcholine (PC), 200 mol-
ecules of sphingomyelin (SM), 600 molecules
of unesterified cholesterol, 1500 molecules of
cholesteryl esters (CE), and 200 molecules of
triacylglycerols (TG). In addition, a particle con-
tains lipophilic antioxidants, 80% of which is α-
tocopherol (on average 6 molecules/particle)
(Esterbauer et al. 1992).
The phospholipids (PC and SM) and two-thirds
of the unesterified cholesterol form an oriented
amphipathic surface monolayer on the LDL
particles, their polar heads being oriented out-
ward and their nonpolar tails inward (Fig. 3).
ApoB-100 has been specifically shown to asso-
ciate with PC (Sommer et al. 1992; Murphy et
al. 1997), and unesterified cholesterol prefer-
ably interacts with SM (Porn et al. 1993; Mattjus
& Slotte 1996). These findings reveal that lip-
ids are not homogeneously distributed over the
surface of LDL particles.
The core of the particles contains the cholesteryl
esters, the triacylglycerols, and one-third of the
unesterified cholesterol. As illustrated in Fig. 3,
2-6% of the TG and CE penetrate the surface
layer (Lund-Katz & Phillips 1986; Kroon 1994).
At around 30°C, there is a thermal transition of
the core lipids of the LDL particles from a liq-
uid crystalline to a liquid-like state, a process
controlled by the amount of TG present in the
particles and the degree of saturation of the fatty
acids of the cholesteryl ester molecules
(Deckelbaum et al. 1975; Deckelbaum et al.
1977; Kroon 1981).
Analysis of plasma and its isolated lipoproteins
by proton nuclear magnetic resonance (1H
NMR) spectroscopy has revealed a lipoprotein
size-dependent shift in the resonances of lipid
hydrocarbon chains (Hiltunen et al. 1991). This
phenomenon has allowed quantification of lip-
ids in different classes of lipoproteins and even
in their subclasses (Otvos et al. 1992) in plasma
in a single measurement (Freedman et al. 1998).
The basis of this kind of behavior has been ex-
plained by a physical lipoprotein model, in
which lipoproteins consist of an isotropic core
and a radially oriented surface (Lounila et al.
1994). (For further details of this model see
“Methods”)
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Apolipoprotein B-100
ApoB-100 consists of 4536 amino acids and has
a calculated molecular weight of about 513,000
(Knott et al. 1986; Yang et al. 1986; Chen et al.
1986; Law et al. 1986; Cladaras et al. 1986). Se-
Review of the literature
Fig. 3. Schematic representation of  the structure of  the LDL particle. Inset
shows folding of apoB-100 on the surface of the LDL particle. Adapted from Borén
et al. (1998). The main picture shows organization of lipids in a cross-section of
the LDL particle. apoB-100, apolipoprotein B-100; PC, phosphatidylcholine; SM,
sphingomyelin; C, cholesterol; CE, cholesteryl ester; TG, triglyceride
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quence analyses have suggested that apoB-100
has amphipathic α-helices and β-strands orga-
nized into a NH
2
-α
1
-β
1
-α
2
-β
2
-α
3
-COOH
pentapartite structure. The α
1
 domain contains
many disulfide bridges, is suggested to be
globular in shape, and to be able to associate
with lipid. The α
2
 and α
3
 domains are
amphipathic α-helices that can bind lipids re-
versibly, and the β
1
 and β
2
 strands bind lipids
irreversibly (Segrest et al. 1994). Cryo-EM has
suggested that apoB-100 forms a ring around
the LDL particle (van Antwerpen et al. 1997).
More detailed analysis by immuno-EM using
monoclonal antibodies directed against defined
segments on apoB-100 has suggested that 89%
of the N-terminal apoB-100 forms a ribbon that
wraps around the LDL particle, and the remain-
ing 11% forms a bow that crosses the ribbon
(Fig. 3, inset) (Chatterton et al. 1995). In a recent
study by Borén et al. (1998), it was shown with
the aid of transgenic animals that it is the argin-
ine residue at 3500 in the “ribbon” that interacts
with the C-terminal ”bow” of apoB-100 and al-
lows binding of the LDL receptor to residues
3359-3369 of apoB-100.
In addition to binding to the LDL receptor, LDL
has been shown to interact with glycosaminogly-
cans (GAGs) via apoB-100. Analysis of peptides
of apoB-100 showed eight potential heparin bind-
ing sites (Weisgraber & Rall, Jr. 1987; Hirose et
al. 1987; Camejo et al. 1988). However, in an-
other study by Borén et al., mutation of only a
single lysine residues at 3363 was shown to ef-
fectively inhibit interaction between apoB-100
and PGs (Borén et al. 1998a). Interestingly, lipo-
proteins comprising only apoB-48, i.e. those lack-
ing the 52% of apoB-100 that contains the pro-
posed PG binding site, also interact with PGs
(Borén et al. 1998a). Moreover, the N-terminal
part of apoB-100 that lacks the proposed PG bind-
ing site has been shown to bind to heparin even
more strongly than intact apoB-100 (Goldberg
et al. 1998). Thus, the GAG binding site(s) of
apoB-100 are not fully characterized. The N-ter-
minus of apoB-100 has been suggested to bind
the enzyme lipoprotein lipase (Sivaram et al.
1994; Choi et al. 1995; Choi et al. 1997), although
binding of LPL to the lipids of LDL has also
been suggested (Makoveichuk et al. 1998). Fi-
nally, the C-terminus of apoB-100 has been shown
to be important in association with the enzyme
platelet-activating factor acyl-hydrolase, a phos-
pholipase A
2
 (PLA
2
) that hydrolyzes biologically
active oxidized phospholipids (PL) of LDL (Tew
et al. 1996), with LDL particles (Stafforini et al.
1999).
Retention of LDL in the in-
tima
Evidence for LDL retention in vivo
Increased concentrations of intact undegraded
LDL have been detected in early atherosclerotic
lesions (Hollander et al. 1979; Hoff & Bond
1982; Smith 1990). But is the increased con-
centration of LDL due to increased influx into
the intima or to increased retention in the in-
tima? This question was experimentally ad-
dressed by Schwenke and Carew (1989a), who
found that the residence time of LDL in a grossly
normal arterial intima at sites prone to develop
atherosclerotic lesions was dramatically in-
creased. More recently, using a more sophisti-
cated kinetic approach, Tozer and Carew (1997)
found no difference in LDL residence time be-
tween lesion-resistant and lesion-prone arterial
sites without signs of atherosclerosis, but ob-
served a dramatic increase in LDL residence
time after the development of fatty streak le-
sions. The cause of retention of LDL in the ar-
Review of the literature
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terial intima is not known, but it is widely be-
lieved to be due to interaction of LDL with the
various components of the extracellular matrix
of the arterial intima.
Interaction between LDL and the
arterial extracellular matrix
Structure of the extracellular matrix
The extracellular matrix (ECM) gives the vascu-
lar wall tensile strength, elastic recoil, compress-
ibility, and viscoelasticity. The intimal cells in-
teract with the extracellular matrix, which regu-
lates cell adhesion, migration, and proliferation.
In addition, the extracellular matrix molecules bind
plasma proteins, growth factors, cytokines, and
enzymes (reviewed by Wight 1996).
As pointed out above, the extracellular space of
the arterial intima is composed of large amounts
of interstitial ECM, in which collagen and elas-
tic fibers are embedded in a viscoelastic gel con-
taining proteoglycans, hyaluronan, glycopro-
teins, and water. In addition, a specialized type
of ECM, the basement membrane, is present on
the basolateral surface of endothelial cells and
around smooth muscle cells.
The bulk of the ECM is produced by the smooth
muscle cells, although endothelial cells and vari-
ous inflammatory cells present in the arterial
intima have been shown to express various ex-
tracellular matrix molecules. Production of
ECM by smooth muscle cells can be regulated
by other cells of the intima (Edwards et al.
1990). Expression of ECM molecules is also regu-
lated by the phenotype of the smooth muscle
cells (contractile vs. synthetic), and whether the
cells are quiescent or stimulated to proliferate
(Nikkari et al. 1994; Camejo et al. 1993). Interest-
ingly, expression of individual types of ECM
molecules are differentially regulated by
cytokines (Schönherr et al. 1991; Schönherr et
al. 1993; Edwards et al. 1994).
Proteoglycans are composed of glycosami-
noglycans (GAGs) that are linked to a core pro-
tein. Proteoglycans have been traditionally clas-
sified according to their GAGs into chondroitin
sulfate (CS), dermatan sulfate (DS), heparan
sulfate (HS), and keratan sulfate (KS)
proteoglycans. Staining of the arterial intima for
glycosaminoglycans has revealed that the most
of the CS is present in the interstitium, whereas
DS is associated with collagen fibers, and HS
with cell surfaces and with elastin (Völker et al.
1986; Völker et al. 1987). In atherosclerosis,
the amount of HS is decreased and the amount
of DS is increased (Wagner & Salisbury 1978;
Hollmann et al. 1989; Cherchi et al. 1990).
Cloning of the core proteins of proteoglycans
has allowed characterization of a number of dis-
tinct molecules that are characteristically en-
riched with one type of GAG. Quantitatively,
the major PG of the extracellular matrix is the
large interstitial CS-rich proteoglycan versican
(Yao et al. 1994), which comprises ~60-70%
of the proteoglycans. In the interstitium, versican
interacts with link protein (LeBaron et al. 1992)
and hyaluronan (Binette et al. 1994), and com-
plexes of these molecules fill the interstitial
space of the vascular ECM not occupied by cells
or the fibrous component (Fig. 4) (Galis et al.
1992). The amount and size of the CSPG
(versican)-hyaluronan aggregate has been found
to be decreased in atherosclerosis (Wagner et
al. 1983). The ECM also contains the small DS-
rich proteoglycans decorin and biglycan.
Decorin is found in large amounts in primary
atherosclerotic plaques associated with types I
and III collagens (Riessen et al. 1994). In vitro,
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decorin has been shown to control collagen
fibrillogenesis (Vogel et al. 1984). Biglycan, in
turn, has been located pericellularly (Riessen et
al. 1994) and associated with elastin (Evanko et
al. 1998) in primary atherosclerotic plaques. In
contrast to decorin, it has been shown to be
greatly increased in amount in restenotic lesions
(Riessen et al. 1994). In vitro, reports on bind-
ing of biglycan to collagen are conflicting in that
biglycan has been shown either to bind or not
to bind to collagen type I (Schönherr et al. 1995).
Interestingly, the amount of biglycan synthe-
sized by smooth muscle cells in culture was
shown to be greatly increased when the cells
were treated with oxidatively modified LDL
(Chang et al. 1996). Perlecan (Murdoch et al.
1994), an HSPG containing LDL-receptor domain
(binding repeats), is found in basement mem-
branes, which are composed of polymer networks
of collagen type IV and laminin, which are linked
with entactin/nidogen and by perlecan
(Yurchenco & Schittny 1990). In addition, the
presence of the KS-rich lumican (Funderburgh
et al. 1991) and keratocan (Corpuz et al. 1996),
PG-100 (PG-M-CSF) (Suzu et al. 1992), bamacan
(Wu & Couchman 1997), and agrin (Tsen et al.
1995) in the extracellular matrix have been re-
ported. The surfaces of endothelial cells and
smooth muscle cells have been shown to con-
tain the HSPG syndecans 1, 2, and 4 which are
attached to the cell via hydrophobic sequences
of the core proteins, and glypican-1, which is
linked to the cell membranes by
phosphatidylinositol linkages (Rosenberg et al.
1997).
Interestingly, although the different PGs are gen-
erally diffusely located, recent immunostaining
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Fig. 4. Organization of extracellular matrix in the arterial intima.
EC, endothelial cell; BM basement membrane; HSPG, heparan sulfate
proteoglycan; MO, macrophage; SMC, smooth muscle cell.
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experiments have shown that, in the vascular
ring, PGs may be concentrated in quite distinct
sectors (Riessen et al. 1994; O’Brien et al. 1998;
Evanko et al. 1998; Radhakrishnamurthy et al.
1998).
Collagen is the major extracellular protein in
advanced lesions, and amounts to up to 60% of
the proteins in the lesions. The predominant
types of collagen in the intima are types I and
III, but the presence of types IV, V, VI, and VIII
has also been demonstrated (Mayne 1986). Of
note, the basement membranes typically con-
tain large amounts of collagen type IV. Collagen
types I and III are organized into distinct fibril-
lar bundles, which are stabilized by the collagen-
binding small proteoglycan decorin, and possi-
bly also by biglycan (Wight 1996).
Elastin in the arterial intima is in the form of elastic
fibers, which are complex structures containing
elastin protein, microfibrils made of aggregates
of proteins and glycoproteins, and GAGs
(Pasquali-Ronchetti et al. 1995). Staining of
GAGs in human arterial intima has shown
association of heparan sulfate (HS), chondroitin-
4-sulfate (C-4-S), and chondroitin-6-sulfate
(C-6-S) with elastin (Wight & Ross 1975; Völker
et al. 1986; Völker et al. 1987; Pasquali-
Ronchetti et al. 1995). Isolated elastin from the
human arterial intima has been shown to con-
tain HSPG and some DSPG (Radha-
krishnamurthy et al. 1977; Dalferes, Jr. et al.
1987; Vijayagopal et al. 1983). Although both
decorin and biglycan have been shown to be
associated with human skin elastin (Baccarani-
Contri et al. 1990), only biglycan has been shown
to be associated with human arterial elastin
(Evanko et al. 1998). The elastin in
atherosclerotic lesions contains large amounts
of lipids and calcium, which is likely to derange
its elastic properties.
The major glycoproteins found in the vascular
wall are fibronectin, laminin, thrombospondin,
and osteopontin (Wight 1996). They contain
multiple domains that allow self-aggregation,
and interaction between cells and other compo-
nents of the extracellular matrix.
Evidence for interaction of LDL with
different components of the ECM
Proteoglycans
LDL has been shown to be co-localized with
GAGs in the arterial intima in animals and hu-
mans (Curran & Crane 1962; Walton &
Williamson 1968; Hoff et al. 1974; Hoff & Bond
1983; Galis et al. 1993). Complexes of lipopro-
teins and GAGs or PGs have been isolated from
human atherosclerotic lesions (Srinivasan et al.
1975; Hollander 1976; Woodard et al. 1976;
Camejo et al. 1985a). LDL has been shown to
be able to bind to GAGs in vitro through bind-
ing of positively charged lysine and arginine
residues of apoB-100 to the negatively charged
sulfate and carboxyl groups of the glycosami-
noglycans (Iverius 1972; Camejo 1982). Ac-
cordingly, modification of the lysine or argin-
ine residues of LDL by acetylation or by treat-
ment with cyclohexanedione, respectively
(Mahley et al. 1979), or desulfatation of gly-
cosaminoglycans (Vijayagopal et al. 1981) have
been shown to block binding of LDL to GAGs.
As discussed above in greater detail in “apoB-
100” (p. 14) it is surprising that mutation of lysine
3363 to valine in apoB-100 markedly decreased
the affinity of LDL for GAGs (Borén et al. 1998a).
Whether this single lysine is responsible for
binding of LDL to GAGs is not known.
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The strength of the interaction between apoB-
100 and GAGs can be modulated both by GAG-
dependent and LDL-dependent factors. When
the abilities of different GAGs to bind to LDL
were compared, they were arranged in the order
heparin > DS > HS > C-4-S (Iverius 1972). The
degree of sulfatation appears to be critical, as
LDL was shown to bind to C-6-S, which con-
tains oversulfated regions but failed to bind to
C-6-S, which lacks oversulfated regions
(Sambandam et al. 1991). Furthermore, the
length of the glycosaminoglycan chains may be
of importance, since smooth muscle cells stimu-
lated to proliferate (Camejo et al. 1993) and
cholesterol-enriched smooth muscle cells
(Vijayagopal et al. 1996) were shown to pro-
duce GAGs of increased size with increased
capacity to bind LDL. The large versican-like
proteoglycans isolated from atherosclerotic
plaques appear to have longer GAG chains than
those isolated from normal intima (Wagner et
al. 1986). Moreover, PGs isolated from athero-
sclerosis-prone areas of the arterial tree bind
increased amounts of LDL (Cardoso & Mourão
1994).
The size of the LDL particles also affects the
binding of LDL to GAG, the small dense LDL
having the strongest interaction (Hurt-Camejo
et al. 1990; Anber et al. 1997). This has been
suggested to depend on a difference in the con-
formation of apoB-100 between small and large
LDL, which favors the binding of small LDL to
GAGs. Consistently, LDL isolated from patients
suffering from coronary heart disease are en-
riched in small dense particles and bind more
avidly to PGs and GAGs in vitro (Camejo et al.
1976; Camejo et al. 1980; Lindén et al. 1989).
The sialic acid content of LDL has also been
suggested to influence the interaction between
LDL and PGs in one study (Camejo et al. 1985b)
although no association between PG binding
and sialic acid content was observed in another
study (Anber et al. 1997). Recently, aggregation
and fusion of LDL particles, two processes that
form particles which can bind to GAGs with mul-
tivalent apoB-100, have been shown to increase
the binding strength to GAGs (Paananen &
Kovanen 1994; Paananen et al. 1995). In con-
trast, oxidative modification, which modifies the
lysine residues of LDL, has been shown to de-
crease or block the binding of LDL to GAGs
(Öörni et al. 1997) and suggested even to re-
lease LDL from GAGs (Pentikäinen et al. 1997).
Collagen
That LDL particles are associated with collagen
fibers has been shown by immunofluorescence
(Walton & Williamson 1968; Hoff et al. 1974)
and by EM techniques (Guyton et al. 1985;
Pasquinelli et al. 1989; Frank & Fogelman 1989;
Nievelstein et al. 1991; Tamminen et al. 1999).
Incubation of rabbit aortic leaflets with gold-
labeled LDL led to preferential accumulation
of the gold particles along collagen fibers
(Nievelstein-Post et al. 1994). Ultrastructural
analysis of collagen fibers by freeze-etch EM
revealed that the lipid particles were bound to
small fibrils, which were tethered to the collagen
fibrils (Fig. 1).
In vitro, native and especially oxidized LDL have
been shown to interact with isolated and in vitro
reconstructed collagen by ionic interactions
(Hoover et al. 1988; Kalant et al. 1991; Kalant &
McCormick 1992; Kalant et al. 1993; Jimi et al.
1994; Greilberger et al. 1997). Moreover, glycated
collagen has been shown to bind LDL covalently
(Brownlee et al. 1985). However, the collagen
used in these experiments was isolated by meth-
ods that had dissociated the collagen-associ-
ated proteoglycans present in the arterial intima.
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Elastin
The human arterial intima has been shown to
contain large amounts of “perifibrous lipid”
(Smith et al. 1967). Ultrastructural analysis by
EM has revealed that this lipid consists of small
lipid droplets and vesicles associated with elas-
tin (Guyton et al. 1985). Similarly, biochemi-
cal measurements have shown an increased lipid
content in elastin isolated from atherosclerotic
arterial intimas (Claire et al. 1976; Sandberg et
al. 1981; Winlowe et al. 1988; Robert et al.
1998). Moreover, elastin-lipid complexes have
been isolated from atherosclerotic human arte-
rial intima (Srinivasan et al. 1980). Staining of
neutral lipids and unesterified cholesterol in the
intimal elastin has shown that these lipids are
deposited to some extent independently, but are
mostly colocalized (Bobryshev & Lord 1999).
In agreement with the above-mentioned stud-
ies, LDL has been shown to bind to elastin in
vitro (Kramsch & Hollander 1973; Tokita et al.
1977; Srinivasan et al. 1980; Noma et al. 1982;
Noma et al. 1983; Winlowe et al. 1985; Orekhov
et al. 1987; Winlowe et al. 1988; Podet et al.
1991). In these studies, it has been shown that
elastin binds LDL lipids rather than apoB-100,
and moreover, LDL binds more avidly to elas-
tin extracted from atherosclerotic intimas than
to that extracted from normal arterial intimas.
Elastin is a strongly hydrophobic substance, and
accordingly, lipids are thought to bind to ath-
erosclerotic elastin by hydrophobic interactions.
Molecules that modulate binding of
lipoproteins to extracellular matrix
and cell surfaces
Lipoprotein lipase (LPL)
LPL is a 55-kD glycoprotein secreted as a cata-
lytically active homodimer. LPL interacts with
heparan sulfate and dermatan sulfate GAGs,
which stabilizes the dimer, and in the absence
of GAGs, it rapidly dissociates into catalytically
inactive monomers. LPL has triglyceride lipase
activity, which is activated by apoCII and phos-
pholipase A
1
 activity.
LPL is the major lipolytic enzyme involved in
the intravascular metabolism of postprandial
triglyceride-rich lipoproteins. Its physiological
function is to hydrolyze the triglycerides of chy-
lomicrons, very low density lipoprotein
(VLDL), and intermediate density lipoprotein
(IDL) particles on the capillary endothelium,
with release of free fatty acids for tissue energy
metabolism (reviewed by Goldberg (1996)). There
is increasing evidence, however, that LPL is also
involved in the pathophysiology of atheroscle-
rosis. Thus, LPL has been shown to be present
in the atherosclerotic arterial wall, where it is
synthesized by smooth muscle cells and
macrophages (Jonasson et al. 1987; Ylä-
Herttuala et al. 1991a; O’Brien et al. 1992;
O’Brien et al. 1994; Semenkovich et al. 1998;
Araki et al. 1998). High levels of LPL secretion
in isolated macrophages in vitro have been
shown to be associated with susceptibility to
atherosclerosis in inbred mouse strains (Renier
et al. 1993). The physiological and pathophysi-
ological function of LPL has been studied in
transgenic animals, but the studies have been
hindered by the finding that homozygous defi-
ciency of LPL is lethal in the neonatal period
(Coleman et al. 1995; Weinstock et al. 1995).
Mice heterozygous for LPL deficiency did not
have increased atherosclerosis despite an athero-
genic plasma lipoprotein profile, suggesting that
decreased levels of LPL in the arterial wall also
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protected the mice against atherosclerosis
(Semenkovich et al. 1998). Finally, the effect of
LPL secretion in macrophages in the arterial wall
was studied in C57Bl/6 mice on an atherogenic
diet, and mice with normal LPL expression in
macrophages were found to be more suscep-
tible to atherosclerosis than mice lacking mac-
rophage LPL expression (Babaev et al. 1999).
This study shows that LPL in the arterial wall is
atherogenic, but whether its effect is structural
or enzymatic is not yet known.
In vitro, LPL has been shown to bind to HS and
DS, but not to CS, collagen, fibronectin, or
vitronectin (Saxena et al. 1993a). However, dif-
ferentiated macrophages have been shown to
synthesize oversulfated CSPG that can bind LPL
(Edwards et al. 1995). LPL has been shown to
link LDL and VLDL strongly to HS GAGs of
basement membranes (Eisenberg et al. 1992;
Saxena et al. 1992; Saxena et al. 1993b) and to
isolated CS-rich and especially DS-rich PGs
from the human aorta (Edwards et al. 1993).
Oxidation has been shown further to enhance
the interaction between lipoproteins and GAGs
in the presence of LPL (Auerbach et al. 1996;
Makoveichuk et al. 1998). Although LPL has
been reported to bind to the apoB-100 moiety
of LDL (Sivaram et al. 1994; Choi et al. 1995;
Choi et al. 1997), other studies strongly sug-
gest that LPL actually binds to the surface lip-
ids of LDL, just as it binds to lipid emulsions in
the absence of apolipoproteins (Fielding 1969;
Lookene et al. 1997b; Makoveichuk et al. 1998).
Finally, pre-injection of LPL has been shown
to increase retention of LDL in the walls of per-
fused microvessels (Rutledge & Goldberg 1994)
and aortas (Rutledge et al. 1997).
Apolipoprotein E
ApoE is a 34-kD exchangeable apolipoprotein
which is present in chylomicrons and their rem-
nants, and in VLDL, IDL, and HDL particles,
but not in LDL particles. The N-terminal do-
main of apoE contains heparin and receptor-
binding sites, the C-terminal domain contains
amphipathic helices that mediate binding of lip-
ids, and a hinge region connects these two do-
mains. ApoE is a key regulator of plasma lipid
levels, affecting both lipoprotein lipolysis and
the uptake of lipid particles by the liver. Thus,
apoE on the particles at the expense of apoCII
inhibits their lipolysis by LPL. ApoE mediates
uptake of the particles by cell receptors, which
are the LDL receptor, low density lipoprotein
receptor-related protein (LRP), and HSPG.
(Mahley & Huang 1999)
In addition to regulating lipoprotein metabolism
in blood plasma, apoE is likely to be important
in the regulation of lipid metabolism in the ar-
terial wall. ApoE is secreted by macrophages in
the arterial wall (Basu et al. 1981; Chait et al.
1982). It is located predominantly on the sur-
faces of macrophages and in the extracellular
matrix surrounding them (O’Brien et al. 1994).
ApoE, like LPL, binds to HSPG. LPL did not
inhibit the binding of apoE to the subendothe-
lial matrix, suggesting that apoE and LPL have
different binding sites on the matrix. However,
apoE was shown to reduce LPL-mediated re-
tention of LDL in the subendothelial matrix
(Saxena et al. 1993a). Other reports have shown
that LPL and apoE have additive effects on the
binding of TG-rich lipoproteins to heparan sul-
fate (van Barlingen et al. 1996; Lookene et al.
1997a) and to cells (Mann et al. 1999). Inter-
estingly, LPL reduced the secretion of apoE by
macrophages (Lucas et al. 1997), possibly by
sequestering apoE on the cell surface. In addi-
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tion to its potential atherogenic effects, apoE
may be antiatherogenic because of its ability to
mediate cholesterol efflux from cells (Mazzone
& Reardon 1994).
The role of arterial apoE in the development of
atherosclerotic lesions has been studied in
transgenic animals. Expression of human apoE
in vascular endothelial cells and smooth muscle
cells inhibited diet-induced atherosclerosis in
normal mice (Shimano et al. 1995) and mac-
rophage expression of human apoE inhibited
atherosclerosis in apoE-deficient mice (Bellosta
et al. 1995). However, elimination of apoE
expression in macrophages was shown either to
promote (Linton et al. 1995) or to inhibit
(Boisvert & Curtiss 1999) diet-induced
atherosclerosis in normal mice.
Significance of LDL retention
Although various aspects of retention of LDL
in the ECM of the arterial wall have been stud-
ied for decades, little evidence is available for
its causal role in the development of atheroscle-
rotic lesions. However, a number of indirect
lines of evidence for the significance of LDL
retention have emerged. Retention increases the
residence time of LDL in the arterial intima,
which allows LDL to be modified. Unlike na-
tive LDL, modified LDL can accumulate extra-
cellularly or intracellularly, and these processes
are known to be the key elements of atheroscle-
rotic lesions. Moreover, retention of LDL at
certain sites in grossly normal aortas was shown
to predict subsequent lesion formation in the
cholesterol-fed rabbit (Schwenke & Carew
1989b).
Recently, gene technology has made it possible
to test the atherosclerotic potential of one as-
pect of LDL retention, namely interaction with
GAGs. Thus, as noted above, Borén et al. (1998a)
generated transgenic mice expressing mutated
human apoB-100, which interacted weakly if at
all with glycosaminoglycans in vitro. Exposure
of these animals to diet-induced hypercholes-
terolemia caused significantly delayed athero-
sclerosis compared with mice expressing human
apoB-100 (Borén et al. 1998b). This strongly
suggests that interaction of LDL with glycosami-
noglycans in the arterial intima has a causal role
in the development of atherosclerosis.
Accumulation of LDL in
the arterial intima
Lipids in the atherosclerotic
arterial intima
Morphology of lipid particles in the
arterial intima
Atherosclerotic plaques contain both extracel-
lular and intracellular lipid deposits. Originally
Smith et al. observed, with light microscopic
techniques, using lipid-soluble dyes, that extra-
cellular lipid droplets were smaller than intrac-
ellular lipid droplets (Smith et al. 1967). Later,
Hoff and Gaubatz (1977) found aggregated LDL-
sized and larger spheres positive for apoB in the
necrotic core of atherosclerotic plaques. Electron
microscopic analysis using lipid-preserving
techniques subsequently showed that the
extracellular lipids in the arterial lesions are in
the form of small droplets containing neutral
lipids (diameters 60-200 nm) and vesicles,
whereas the intracellular lipid droplets in foam
cells are greater than 400 nm in diameter (Bocan
et al. 1986).
Even the grossly normal human arterial intima
has been shown to contain small lipid droplets
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and vesicles in the extracellular space (Tirziu et
al. 1995). In a systematic study in human carotid
arteries, Pasquinelli et al. showed that the initial
lipid deposits were small lipid droplets located
subendothelially in the extracellular matrix. These
droplets largely disappeared when monocytes
entered the intima, where they bacame
macrophages, and formed foam cells, suggesting
that the foam cells had ingested the droplets
(Pasquinelli et al. 1989). The presence of initial
deposition of extracellular lipid droplets and
vesicles before monocyte infiltration has also
been shown in experimental animals. Thus, in
Watanabe heritable hyperlipidemic (WHHL) and
in cholesterol-fed rabbits (Amanuma et al. 1986;
Simionescu et al. 1986; Mora et al. 1987a; Frank
& Fogelman 1989; Guyton & Klemp 1992), in
monkeys (Masuda & Ross 1990), in hamsters
(Filip et al. 1987), and in apoE-knockout mice
(Tamminen et al. 1999), small extracellular lipid
droplets and vesicles have been observed in the
ECM of the arterial intima very soon after
exposure to hypercholesterolemia. Importantly,
Mora et al. found that accumulation of apoB and
lipids in the arterial intima coincided both
spatially and temporally, strongly suggesting
that these lipids are derived directly from apoB-
containing lipoproteins (Mora et al. 1989b).
Enlarged lipid particles have been observed in
the extracellular matrix of rabbits 2 hours after
infusion of large amounts of human LDL
(Nievelstein et al. 1991), showing rapid fusion
of human LDL particles into the small lipid
droplets in the extracellular matrix in vivo. A
similar finding was made in rabbit aortic leaflets
incubated for 4 hours with human LDL in vitro
(Nievelstein-Post et al. 1994).
Whether the lipid core of an advanced athero-
sclerotic lesion develops from degeneration of
foam cells in a fatty streak lesion or by direct
deposition of lipid is still open to debate. The
foam cells in fatty streak lesions are located in
the superficial intima, whereas the lipid core of
a fibrolipid lesion develops deep in the
musculoelastic layer of the intima. Guyton et
al. have shown that lipids in the early core re-
gions of transitional small fibrolipid lesions were
mostly composed of small vesicles within the
extracellular matrix deep in the musculoelastic
layer beneath the foam cells. Upon development
of a fibrous plaque, the lipid deposition varied:
in some plaques, vesicles and cholesterol crys-
tals were the predominant form of lipid deposit
in the core, but, in other fibrous plaques, small
lipid droplets predominated, with a notable ab-
sence of cholesterol crystals. Interestingly, it
appeared that foam cells were more consistently
present in caps of fibrolipid lesions rich in
vesicles and cholesterol crystals than in caps of
fibrous plaques rich in small lipid droplets.
(Guyton & Klemp 1994) Thus, it appears that
accumulation of cholesterol in the cores of early
lesions is dependent on the presence of
macrophage foam cells.
Chemistry of lipids in the arterial in-
tima
The predominant lipids accumulating in the ar-
terial intima are cholesteryl esters, unesterified
cholesterol, and phospholipids. Interestingly,
their accumulation appears to be both tempo-
rally (Guyton & Klemp 1992; Chao et al. 1994;
Guyton & Klemp 1994) and spatially (Kruth
1984a; Kruth 1984b) distinct. Although plasma
triglyceride-rich VLDL and IDL particles, and
possibly also chylomicron remnants, have been
suggested to participate in the lipid accumula-
tion, triglycerides have been shown to account
for only ~1% of the lesion lipids (Rokosova et
al. 1986).
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Comparison of the composition of lipids of the
arterial wall with plasma LDL particles has been
made and the results are compatible with the
notion that the major source of the lipid in the
atherosclerotic lesions is plasma low density li-
poprotein particles. Smith et al. made the inter-
esting original observation that the fatty acid
composition of cholesteryl esters in areas pos-
sessing either intra- or extracellular lipids de-
posits differed markedly, the former being en-
riched in oleate and the latter in linoleate like
the plasma LDL (Smith et al. 1968). That intra-
cellular lipids rich in cholesteryl oleate can also
be derived from plasma LDL rich in cholesteryl
linoleate has later been shown to be possible in
vitro. Thus, LDL taken up by cells via the LDL-
receptor is targeted into lysosomes, where its
cholesteryl esters are hydrolyzed. The liberated
unesterified cholesterol is transported into the
cytosol, where it is re-esterified by acyl-coen-
zyme A:cholesterol acyltransferase, which has
a preference for oleyl coenzyme A over linoleyl
coenzyme A (Brown & Goldstein 1983). Taken
together, the intracellular lipids may be envi-
sioned as being derived either directly from
plasma LDL or from extracellular lipid particles.
The extracellular lipid particles, however, are
not likely to be derived directly from the intra-
cellular cytoplasmic deposits.
The proportion of cholesterol in esterified form
in a lesion was recently correlated with the ul-
trastructure of the lesion core. The lesions rich
in small vesicles and cholesteryl crystals were
highly enriched in unesterified cholesterol,
whereas, in the cores of lesions with predomi-
nance of small lipids droplets, up to 95% of the
cholesterol was esterified (Guyton & Klemp
1994).
The presence of oxidized lipids, notably
oxysterols, in the arterial wall has been recog-
nized a long time ago (Brooks et al. 1966). Al-
though oxysterols seem to be present only in
small amounts, their presence may be signifi-
cant because of their potent effects on cells
(Chisolm et al. 1994; Hulten et al. 1996). Re-
cent careful analysis of the oxidation state of
lipids and antioxidants has shown that the nor-
mal intima almost totally lacks oxidized lipids,
whereas in atherosclerotic plaques, ~30% of
cholesteryl linoleate is in oxidized form despite
the presence of large amounts of water-soluble
and lipid-soluble antioxidants (Suarna et al.
1995).
Evidence for the presence of
modified LDL in vivo
Although alterations in LDL can occur in the
blood plasma (Avogaro et al. 1988), possibly
induced by a recently described transsialidase
(Tertov et al. 1998; Tertov et al. 1995; Demuth
et al. 1996), it is widely accepted that the major
modifications of LDL occur in the arterial in-
tima, where the LDL particles may have lost
the protection against modification afforded by
the plasma antioxidants and protease inhibitors.
Immunological evidence
Torzewski et al. produced monoclonal antibod-
ies against LDL modified by trypsin, cholesterol
esterase, and neuraminidase. One of the anti-
bodies reacted in vitro with trypsin-modified
LDL, whereas the other reacted with LDL modi-
fied by a combination of trypsin and cholesteryl
esterase. Both of these antibodies reacted with
epitopes in human arterial intima that were
colocalized with the terminal complement
(Torzewski et al. 1998). The presence of oxida-
tively modified (lipo)proteins both in the circu-
lation and in the arterial intima has been stud-
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ied extensively. Autoantibodies against LDL
modified by malondialdehyde (MDA), copper,
peroxidase, and 2,2’-azobis(2-
amidinopropane)hydrochloride (AAPH) have
been found in the circulation (Palinski et al.
1989; Salonen et al. 1992; Seccia et al. 1997).
In the arterial intima, epitopes can be detected
with antibodies against MDA-modified LDL
(Haberland et al. 1988; Palinski et al. 1989), 4-
hydroxynonenal (HNE)-modified LDL
(Palinski et al. 1989), oxidized phospholipids
(Itabe et al. 1994), hypochlorite-modified LDL
(Hazell et al. 1996), and nitrotyrosine
(Beckmann et al. 1994). Furthermore,
immunocomplexes of oxLDL have been de-
tected in the arterial intima (Ylä-Herttuala et al.
1994). Finally, different advanced glycosylation
end products (AGEs) have been detected
immunohistochemically, and found to
colocalize with oxidized LDL (Sakata et al.
1998).
Evidence based on properties of lipid
particles isolated from the arterial
intima
Methodological aspects of extraction
In most studies, lipoproteins have been isolated
from cadavers, which may have resulted in post-
mortem artifacts. In fact, it was recently shown
that apoB-100 of LDL isolated from a fresh sur-
gical sample was minimally fragmented,
whereas the LDL isolated from an aorta obtained
at autopsy was extensively fragmented (Rapp
et al. 1994). Significant differences may also
result from the extraction method used. Thus,
mild buffer extraction of minced tissue produces
the fewest artifacts, but has a low yield. The yield
can be increased by disruption of the tissue by
homogenization (Hoff et al. 1991) or with hydro-
lytic enzymes (Hoff & Gaubatz 1979), but these
treatments give rise to modification of the par-
ticles. Homogenization has been shown to con-
vert LDL into larger (Hoff et al. 1991) and smaller
lipid particles (Kruth 1997). Hydrolytic enzymes
(collagenase, chondroitinase, and elastase) de-
grade apoB-100, precluding analysis of the in-
tactness of apoB-100, and may also convert LDL
into larger particles (Piha et al. 1995; Kruth 1997).
Finally, tightly bound LDL has been released by
the combination of homogenization and deter-
gent extraction (Hoff et al. 1978b; Hoff et al.
1978c), but the material released is suitable only
for protein quantitation.
Properties of isolated lipid particles
Lipid particles extracted from the arterial intima
can be grossly divided into four categories: (1)
small lipid vesicles rich in unesterified choles-
terol and lacking immunoreactive apoB-100, (2)
small lipid droplets rich in esterified cholesterol
and lacking immunoreactive apoB-100, (3) ar-
terial IDL/VLDL, i.e. lipoproteins containing
both apoB-100 and apoE that have the density
of plasma VLDL and are larger than plasma
LDL, but, in contrast to plasma VLDL and IDL,
are triglyceride-poor, and (4) lipoproteins
closely resembling plasma LDL. In advanced
atherosclerotic lesions, the proportion of cho-
lesterol in particles containing immunoreactive
apoB-100 has been estimated to be only ~5%
(Hoff et al. 1978a). Therefore, unless LDL is
carefully isolated, the “arterial LDL” prepara-
tion will be contaminated with lipid particles
lacking apoB-100 that may or may not be de-
rived directly from plasma LDL particles. There-
fore, analysis of the properties and composition
of LDL in the arterial intima should be restricted
to LDL isolated from fresh arterial intimas by a
combination of immuno-affinity chromatography
and either gel filtration or density gradient ultra-
centrifugation, since other lipid particles have
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been shown to have densities overlapping that
of LDL particles (Chao et al. 1994).
1. Unesterified cholesterol-rich vesicles
Chao et al. and Tirziu et al. have isolated and
characterized unesterified cholesterol-rich
vesicles from the arterial intima (Chao et al.
1988; Chao et al. 1990; Chao et al. 1994; Tirziu
et al. 1995). The density of the vesicles ranged
between 1.01 g/ml, and 1.05 g/ml. They con-
tained no immunoreactive apoB-100, but had
albumin in their cores. Cholesterol in the vesicles
was mostly unesterified, and the predominant
phospholipid was found to be sphingomyelin.
Electron microscopy confirmed that the particles
were uni- and multilamellar vesicles, and the
presence of albumin in the core of the vesicles
strongly suggested that they had been formed
extracellularly.
2. Cholesteryl ester-rich lipid droplets
Chao et al. (1990) isolated and purified
cholesteryl ester-rich lipid particles from minced
human aortas by microfiltration, gel filtration
chromatography, and density gradient ultracen-
trifugation. These particles correspond to the
small lipid droplets containing neutral lipids
detected microscopically (Kruth & Shekhonin
1994; Guyton & Klemp 1988). The particles had
a density <1.01 g/ml; 76% of their cholesterol
was esterified, linoleate was the major fatty acid
esterified to cholesterol, and the particles con-
tained only small amounts (<10%) of phospho-
lipids, most of which was sphingomyelin. Elec-
tron microscopy confirmed that these particles
were small spherical lipid droplets having a sur-
face monolayer with diameters between 40 and
200 nm. Scanning EM revealed the presence of
pits on the surface of the particles, which is con-
sistent with other reports on lipid particles of a
similar kind isolated from the arterial intima (Hol-
lander et al. 1979; Guyton et al. 1990).
3. Arterial VLDL/IDL
Rapp et al. (1994) and Ylä-Herttuala et al. (1988)
found apoB-100- and apoE-containing lipopro-
teins in the VLDL-IDL density range, which, in
contrast to plasma VLDL and IDL particles, were
poor in triglycerides and rich in cholesteryl es-
ters. The high content of apoE could reflect the
presence of infiltrated β-VLDL-like particles, or
the acquisition of apoE from tissue macroph-
ages (Basu et al. 1982). Immunohistochemical
demonstration of apoC-III, a component of
plasma VLDL particles, in human atherosclerotic
plaques suggests that the particles could have
infiltrated from plasma (Hoff et al. 1976). How-
ever, the notable absence of apoE in atheroscle-
rotic lesions in mice lacking macrophage apoE
secretion (Fazio et al. 1997; Boisvert & Curtiss
1999) suggests that most of the apoE in the ath-
erosclerotic intima is due to local synthesis,
rather than to plasma infiltration. ApoB-100 of
the arterial VLDL/IDL was found to be nearly
intact (Rapp et al. 1994). Electron microscopy
showed that the particles were solid spheres of
the size of plasma VLDL and larger (Rapp et al.
1994).
4. Arterial LDL
LDL isolated from surgical samples of athero-
sclerotic intima by a combination of immuno-
affinity chromatography and density gradient
ultracentrifugation closely resembled plasma
LDL particles. Thus, in contrast to previous re-
ports, which included particles not containing
immunoreactive apoB, the arterial LDL did not
differ from plasma LDL in lysoPC, SM, or PL
content (Tailleux et al. 1993), or FC/TC or TC/
TG ratios (Rapp et al. 1994). Interestingly, LDL
isolated from atherosclerotic lesions was shown
to be 10 to 50-fold enriched in ceramide, a cleav-
age product of sphingomyelin, and ceramide was
found to be present only in aggregated forms of
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LDL (Schissel et al. 1996). In contrast, no
diacylglycerol, a product of PC cleavage by phos-
pholipase C, was found. Electron microscopy
showed that the arterial LDL particles were solid
spherical particles larger than plasma LDL (Rapp
et al. 1994). In addition, density gradient ultra-
centrifugation showed that the LDL-sized par-
ticles had a slightly lower and more heteroge-
neous hydrated density than plasma LDL
(Morton et al. 1986).
ApoB-100 in LDL isolated from cadaveric nor-
mal human arterial intima has been shown to be
almost intact (Ylä-Herttuala et al. 1988;
Steinbrecher & Lougheed 1992), but in many
reports, apoB-100 of LDL isolated from a ca-
daveric atherosclerotic arterial wall has been
shown to be hydrolyzed to variable degrees
(Clevidence et al. 1984; Daugherty et al. 1988;
Ylä-Herttuala et al. 1989; Hoff & O’Neil 1991;
Steinbrecher & Lougheed 1992; Tailleux et al.
1993). However, LDL, IDL, and VLDL isolated
from surgical samples of the human atheroscle-
rotic arterial intima by buffer extraction and then
an anti-apoB column showed minimal hydroly-
sis of apoB-100, whereas lipoproteins isolated
from cadaveric aortas 10 hours after death, even
in the presence of protease inhibitors, showed
extensive degradation of apoB-100 (Rapp et al.
1994). Thus, it appears that detection of hydro-
lyzed apoB-100 in LDL isolated from cadav-
eric atherosclerotic intima even in the presence
of protease inhibitors and antioxidants should
be viewed with caution. Hydrolysis of apoB-
100 is not necessarily a marker of proteolytic
cleavage since oxidation has also been shown
to cleave apoB-100 (Schuh et al. 1978).
Arterial LDL has been shown to have an in-
creased electrophoretic mobility relative to
plasma LDL (Hoff & Gaubatz 1982). Shaikh et
al. showed that the electrophoretic mobility of
LDL is increased in vivo in the arterial intima
as little as 24 hours after injection of radiola-
beled LDL into humans. This increase in elec-
trophoretic mobility is not associated with hy-
drolysis of apoB-100, which suggests that it may
not be dependent on lipid peroxidation (Shaikh
et al. 1991). In fact, Ylä-Herttuala et al. showed
that LDL obtains an increased electrophoretic
mobility even when mixed with minced arterial
tissue (Ylä-Herttuala et al. 1990b).
Oxidative damage to arterial LDL has been de-
tected by various more or less specific markers.
Thus, LDL isolated from aortas of WHHL rab-
bits was shown to have an increased amount of
thiobarbituric acid-reactive substances
(Daugherty et al. 1988). Arterial LDL cross-re-
acted with an antibody raised against
malondialdehyde modified LDL (Haberland et
al. 1988). LDL isolated from atherosclerotic
lesions had fluorescent properties similar to LDL
oxidized in vitro (Hoff & O’Neil 1991). More
specific markers of oxidative damage that are
unique for a distinct type of oxidative damage
have also been determined. Thus, o´, o´-
dityrosine, produced from tyrosine by
myeloperoxidase (Heinecke et al. 1993) was
increased 100-fold in LDL isolated from ath-
erosclerotic lesions as compared with plasma
LDL (Leeuwenburgh et al. 1997b). 3-
Chlorotyrosine, another marker of
myeloperoxidase-mediated oxidation, was
markedly elevated in LDL isolated from ath-
erosclerotic plaques (Hazen & Heinecke 1997).
Lipoxygenase oxidation products have been
detected in early atherosclerotic lesions of rab-
bits (Kühn et al. 1994) and humans (Kühn et al.
1997) and in human atherosclerotic plaques
(Folcik et al. 1995). Elevated levels of
nitrotyrosine, a marker of reactive nitrogen spe-
Review of the literature
28
cies, were found in LDL isolated from the arterial
intima (Leeuwenburgh et al. 1997a). Finally, o
and m-tyrosine, markers of metal-ion damage,
are increased in LDL isolated from advanced
atherosclerotic plaques (Leeuwenburgh et al.
1997b)
In summary, the arterial intima contains plasma-
derived LDL particles that showing signs of
modification of several different types. More-
over, the lipid particles, in the form of both
vesicles and lipid droplets, have features sug-
gesting that they are derived from plasma LDL
by extensive modification.
Evidence for the presence of en-
zymes and agents potentially ca-
pable of modifying LDL in vivo in
the extracelular space of the ar-
terial intima
Proteases
Mast cells have been shown to be present in the
normal and atherosclerotic arterial intima, and
to contain the proteolytic enzyme chymase ca-
pable of degrading apoB-100 (Kaartinen et al.
1994). The arterial intima has been suggested
to contain large amounts of plasmin (Hendriks
et al. 1998), also capable of cleaving apoB-100.
Lysosomal proteases of macrophages have been
shown to degrade apoB-100 at acidic pH (Leake
et al. 1990). Finally, atherosclerotic plaques
contain a number of specific enzymes capable
of degrading the extracellular matrix, e.g. ma-
trix metalloproteinases (Henney et al. 1991;
Galis et al. 1994; Galis et al. 1995; Sukhova et
al. 1998), which are also capable of degrading
apoB-100 to some extent (Kruth 1997).
Oxidants
The cells in the normal arterial intima express
nitric oxide synthetase and cyclooxygenase I
constitutively. The cells in atherosclerotic le-
sions also express an inducible form of nitric
oxide synthetase, NADPH oxidase, and
cyclooxygenase II, which produces free radi-
cals potentially capable of oxidizing LDL (Ylä-
Herttuala 1998). In addition, the arterial intima
has been shown to express the enzymes 15-
lipoxygenase (Ylä-Herttuala et al. 1990a; Ylä-
Herttuala et al. 1991b), myeloperoxidase
(Daugherty et al. 1994), and heme-oxygenase-
1 (Wang et al. 1998) capable of enzymatic oxi-
dation of LDL. Finally, atherosclerotic plaques
have been shown to contain transition metals
potentially capable of oxidizing LDL nonenzy-
matically (Smith et al. 1992; Evans et al. 1995;
Lamb et al. 1995). Interestingly, iron was shown
to colocalize with ceroid, an insoluble complex
of oxidized lipid and protein, in human athero-
sclerotic lesions (Lee et al. 1998).
Lipases
Secretory nonpancreatic PLA
2
 is present in the
human arterial intima (Menschikowski et al.
1995; Hurt-Camejo et al. 1997), being especially
located along collagen fibers (Romano et al.
1998). This type of PLA2 has been shown to be
active against human LDL, and its activity is
increased by GAGs (Sartipy et al. 1996; Sartipy
et al. 1998).
The arterial wall has been shown to possess
SMase activity, which increases during athero-
genesis (Rachmilewitz et al. 1967; Portman &
Alexander 1970). The arterial enzyme has been
identified as secretory SMase (S-SMase)
(Schissel et al. 1996). Recently, macrophages
(Schissel et al. 1996) and human vascular en-
dothelial cells (Marathe et al. 1998) have been
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shown to express this enzyme. S-SMase has an
acid pH optimum, but can hydrolyze SM of
oxidized LDL, and LDL treated with PLA
2
 or
enriched with apoCIII in vitro (Schissel et al.
1998). Interestingly, S-SMase was recently
shown to associate with laminin and collagen in
vitro (Marathe et al. 1999)
The arterial intima has been shown to contain
bile acid-stimulated cholesterol esterase activ-
ity. This activity could be precipitated with an-
tibody raised against the enzyme carboxyl ester
lipase (CEL) (Shamir et al. 1996). CEL is a pan-
creatic lipolytic enzyme that exhibits bile acid-
independent lysophospholipase activity and bile
acid-stimulated cholesterol esterase activity.
CEL was recently shown to be able to hydro-
lyze lysophosphatidylcholine (lysoPC) in oxi-
dized LDL, and cholesteryl esters in LDL in the
presence of circulating levels of bile acids
(Shamir et al. 1996). Interestingly, endothelial
cells and macrophages have been shown to se-
crete CEL in culture (Li & Hui 1997; Li & Hui
1998). Endothelial cells in culture (Sando et al.
1990), and macrophages and macrophage-de-
rived foam cells in the vessel wall have been
shown to synthesize lysosomal acid lipase
(Davis et al. 1985). Whether this enzyme is ac-
tive in the intimal extracellular space is not
known.
Finally, endothelial cells have been shown to
secrete a novel LPL-like lipolytic enzyme (Jaye
et al. 1999; Hirata et al. 1999) that has phos-
pholipase A1 activity but no triglyceride lipase
activity. Overexpression of this enzyme in mice
was capable of decreasing HDL levels (Jaye et
al. 1999). Whether this lipase is also involved
in LDL metabolism remains to be studied.
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Aggregation and fusion of modi-
fied LDL particles in vitro
Methodological aspects
Aggregation and fusion of LDL have been de-
tected by various methods based on the physi-
cochemical properties of the particles and on
particle morphology, but little effort has been
devoted to distinguishing these two processes.
The turbidity of the lipoprotein solution, which
can be caused by either aggregation or fusion,
has been used in many studies as an indicator
of particle size (Khoo et al. 1988). Turbidity is
easy and quick to measure, which enables mea-
surement of large aggregates. However, it is
nonquantitative and very nonspecific. Gel fil-
tration of lipoprotein particles, using columns
that allow separation of native LDL from larger
structures, has also been used in many studies
(Piha et al. 1995). The advantages of gel filtra-
tion are that it is quantitative, sensitive to small
increases in particle size, and reproducible.
However, it lacks the specificity to distinguish
aggregation from fusion, and recovery of large
lipid particles is often poor. Rate zonal flota-
tion of LDL (Polacek et al. 1988) has the ad-
vantage of almost complete recovery of LDL
from the gradients, but may give false results if
the density of the particles has been consider-
ably changed during LDL modification. Dy-
namic laser scattering has also been used to
measure lipoprotein size, but appearsto be un-
able to distinguish fused from aggregated par-
ticles (Kawabe et al. 1994).
Electron microscopic techniques are able to dis-
tinguish particle fusion from aggregation and
to reveal gross changes in particle morphology.
However, electron microscopy is not quantita-
tive, is time-consuming, and has many poten-
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tial artifacts. Negative staining (Forte &
Nordhausen 1986) of lipoprotein preparations
is rapid and allows measurement of particle size.
However, large aggregates of LDL are not vis-
ible, staining of the grid is usually highly vari-
able, and usually only a small proportion of the
grid can be examined. Therefore, there is a dan-
ger of analyzing a selected population of the
sample. Casting of the lipoprotein sample into
agarose and staining of thin sections with lipid
preserving techniques (Guyton et al. 1991;
Steinbrecher & Lougheed 1992) gives superior
morphological images of modified LDL par-
ticles and allows analysis of LDL particles even
in large aggregates. However, native-sized LDL
particles are poorly visible and their retention
in the gel during processing is not guaranteed.
Taken together, the methods used to quantify
LDL particle aggregation and fusion in the lit-
erature have several drawback. Therefore, ex-
tensive efforts have been made in the present
study to develop and validate methods for study-
ing LDL particle aggregation and fusion.
Modifications that cause aggrega-
tion and fusion of LDL particles in
vitro
Mechanical stress induced by vortexing of LDL
has been shown to cause turbidity of an LDL
sample (Khoo et al. 1988). Ultrastructural EM
analysis has shown that vortexed LDL is in the
form of aggregated native-sized LDL particles,
small lipid droplets and vesicles (Guyton et al.
1991). The effect of vortexing could be inhib-
ited by exchangeable apolipoproteins (apoE,
apoC, and apoA-I) that, in contrast to phospho-
lipase C-induced aggregation, were not associ-
ated with LDL after vortexing (Khoo et al.
1990). Thus, it appears that, during exposure of
LDL to mechanical stress, hydrophobic spots
emerged. In the absence of exchangeable
apolipoproteins, these spots can trigger particle
aggregation and fusion, and binding of ex-
changeable apolipoproteins to these spots can
inhibit aggregation and fusion of LDL. The in
vivo significance of this fusion induced by me-
chanical stress is possible but, at present, is not
shown.
Proteolytic degradation of apoB-100 of LDL has
been shown to cause aggregation and fusion of
LDL. Thus, degradation of LDL with neutro-
phil elastase has been shown to cause dimeriza-
tion of LDL particles (Polacek et al. 1988). LDL
particle fusion was first observed on the sur-
face of mast cell granules to which both the neu-
tral proteases chymase and carboxypeptidase A
and also LDL were bound (Kokkonen &
Kovanen 1989). Experiments with a number of
different proteases have later shown that release
of fragments of apoB-100 is a prerequisite for
LDL fusion (Piha et al. 1995). ApoB-100 cov-
ers ~30% of the surface volume of LDL, and
proteolysis of apoB-100 must lead to reorgani-
zation of both surface and core lipids of LDL,
resulting in fusion of the particles. This is sup-
ported by the finding that, despite extensive pro-
teolysis, fusion of proteolyzed LDL is slow at
15°C, a temperature at which the core lipids of
the LDL particles are highly organized and re-
organization of LDL lipids is hindered
(Paananen & Kovanen 1994).
Phospholipase A
2
 (PLA
2
) is a lipolytic enzyme
that hydrolyzes phospholipids into
lysophospholipids and free fatty acids. In the
presence of albumin, most of the free fatty acid
and some of the lysophospholipids leave the
LDL particles (Kleinman et al. 1988). Treatment
of LDL with bee venom PLA
2 
in the presence of
albumin has been shown to lead to formation of
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aggregated LDL particles which, in electron mi-
croscopy, appear to be smaller than native
LDL particles (Öörni et al. 1998). The decrease
in particle size is thought to be due to reorgani-
zation of LDL lipids (Kleinman et al. 1988;
Gorshkova et al. 1996), which leads to increased
interpenetration of surface and core lipids
(Gorshkova et al. 1996). In contrast, PLA
2
 treat-
ment of LDL in the presence of heparin was
shown to result in fusion of LDL particles
(Hakala et al. 1999). The fact that fusion was
observed even if LDL was pretreated with hep-
arin and lipolyzed in the absence of heparin,
suggests that heparin caused an irreversible con-
formational change in apoB-100 which pro-
moted LDL particle fusion after lipolysis.
Phospholipase C (PLC) hydrolyzes phospholip-
ids into phosphocholine and diacylglycerol
(DAG). Phosphocholine is hydrophilic and is
released from the LDL particles, whereas DAG
is hydrophobic and appears to be able to reside
both in the surface and in the core of the par-
ticles (Wang et al. 1995). PLC treatment of LDL
has been shown to result in instability of the
particles (Pollard et al. 1969), increased turbid-
ity of the sample (Suits et al. 1989), and both
aggregation and fusion of the particles (Liu et
al. 1993). The aggregation and fusion of the
PLC-treated LDL particles appears to be caused
by formation of a hydrophobic surface on the
LDL particles, a phenomenon that depends on
both an increase in the neutral lipid content of
the particles by DAG and loss of surface phos-
pholipids (Singh et al. 1992). Consistently, ex-
changeable apolipoproteins A-I, E (Khoo et al.
1990), and Manduca sexta apolipophorin III
(Liu et al. 1993) have been shown to inhibit
PLC-induced aggregation and fusion of LDL
by binding to the particles and potentially cov-
ering the hydrophobic domains formed. The
physiological significance of PLC treatment is
uncertain, since LDL isolated from an athero-
sclerotic intima does not contain detectable
amounts of DAG (Schissel et al. 1996) and no
evidence has been found for the presence of
secreted PLC in the arterial intima.
Sphingomyelinase (SMase) hydrolyzes the sph-
ingomyelin (SM) molecules in LDL particles
into phosphocholine molecules, which are re-
leased from the particles, and ceramide mol-
ecules, which are retained in the particles
(Schissel et al. 1996). Treatment of LDL with
SMase from Bacillus ceraus has been shown to
induce both aggregation and fusion of LDL par-
ticles (Xu & Tabas 1991; Paananen & Kovanen
1994). This has been shown to depend on the
increase in the ceramide content and to be inde-
pendent of the SM content of particles (Schissel
et al. 1996). The mechanism could involve
microdomain formation of ceramide molecules
(Holopainen et al. 1998) that can act as hydro-
phobic spots. This is supported by the finding
that treatment of LDL with sphingomyelinase
at 15°C, which allows sphingomyelin hydroly-
sis, but hinders lateral diffusion of surface phos-
pholipids, did not lead to particle aggregation
or fusion (Öörni et al. unpublished).
Oxidation by copper (Hoff & O’Neil 1991), AAPH
(Kawabe et al. 1994), and hypochlorite (HOCl)
(Hazell & Stocker 1993; Hazell et al. 1994) have
been shown to cause aggregation of LDL. Inter-
estingly, modification of LDL by 4-HNE, a prod-
uct of lipid peroxidation, has also been shown
to aggregate LDL (Hoff et al. 1989). However,
aggregation of LDL must depend on additional
factors, since co-modification of LDL with MDA,
another product of lipid peroxidation, can inhibit
4-HNE-mediated LDL aggregation, and aggre-
gation of LDL occurs after oxidation with HOCl,
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which causes little lipid peroxidation (Hazell et
al. 1994). Extensive oxidation of LDL by copper
or AAPH, and extensive modification of LDL
by 4-HNE have been shown to result in loss of
particle integrity. Thus, particles of increased
size (Hoff et al. 1989; Hoff & O’Neil 1991;
Kawabe et al. 1994) and lipid vesicles have been
observed (Dobrian et al. 1993).
Hydrolysis of the cholesterol esters of LDL with
fungal cholesterol esterase was shown to pro-
duce small lipid droplets and vesicles from LDL
(Chao et al. 1992; Bhakdi et al. 1995). The LDL
particles had to be trypsinized before this fun-
gal enzyme was able to act on the particles, but
it appeared that trypsinization alone was unable
to cause morphological changes in the LDL
particles. According to Bhakdi et al., the de-
gree of morphological modification increased
still further if the particles were additionally
treated with neuraminidase (Bhakdi et al. 1995).
Finally, Tertov et al. have shown that both
glycosylated LDL and desialylated LDL, two
forms of LDL found in the circulation, aggre-
gated in vitro (Tertov et al. 1989; Tertov et al.
1992). Interestingly, the same group has pro-
vided evidence for a sialyltransferase in blood
plasma that can deplete isolated LDL of sialic
acid and start a cascade of LDL modifications
(Tertov et al. 1998).
Effect of extracellular matrix on LDL
modification
The ECM of the arterial intima, especially
GAGs, can actively participate in the modifi-
cation of LDL, not only by binding of LDL and
various enzymes, but also by modifying LDL
and the activity of the enzymes
Modification of the structure of apoB-100 by
glycosaminoglycans
Binding of glycosaminoglycans to apoB-100 in
LDL has been shown to induce a conformational
change in apoB-100 and also changes in the
organization of LDL lipids. Thus, binding of
glycosaminoglycans to apoB-100 has been
shown to increase the microviscosity of the LDL
lipids and reduce the thermal stability of the
particles (Nakashima et al. 1975; Bihari-Varga
et al. 1981; Camejo et al. 1991; Cherchi et al.
1994). Moreover, exposure of the polar seg-
ments of apoB-100, containing lysine and argi-
nine residues, has been shown to be increased
irreversibly (Camejo et al. 1991). Consistently,
lysine residues of heparin-bound LDL were
more readily modified by MDA than of LDL in
the fluid phase (Haberland et al. 1984). Bind-
ing of LDL to GAGs has been shown to alter
the pattern of apoB-100 proteolysis by specific
proteases (Camejo et al. 1991). In addition, oxi-
dation of LDL by copper has been shown to be
enhanced after LDL has been released from
GAGs (Hurt-Camejo et al. 1992). Finally, PLA
2
-
treated LDL has been shown to undergo aggre-
gation but notably also fusion if the particles
have been bound to glycosaminoglycans, an
effect that is independent of the degree of phos-
pholipid hydrolysis of LDL (Hakala et al. 1999).
Alteration in the rate of LDL modification
A variety of enzymes are able to bind glycosami-
noglycans, because they contain “heparin bind-
ing sequences”. Changes in the rate of LDL
modification by GAGs may be due either to
enzyme activation/inhibition by GAGs or to al-
terations in the availability of LDL to the en-
zyme. As an example of the former alternative,
the activity of secretory nonpancreatic phospho-
lipase A
2
 against LDL was shown to be in-
creased by CSPG, but decreased by heparin
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(Sartipy et al. 1996; Sartipy et al. 1998). As an
example of the second alternative, mast cell
chymase, which is bound to the heparin chains
of mast cell granules, was shown to hydrolyze
preferentially LDL particles also bound to the
heparin chains of the granule proteoglycans
(Kovanen & Kokkonen 1991).
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Aims of the Study
Aims of the Study
Characteristic of the initiation of atherosclerosis is accumulation of small lipid droplets in the
vicinity of collagen fibers, bound to small fibrils tethered to the collagen fibers (Frank & Fogelman
1989). The finding of similar lipid deposits in normal rabbit aorta 2 hours after an intravenous
infusion of human LDL showed that these lipid droplets can be formed from human LDL (Nievelstein
et al. 1991). Kokkonen and Kovanen (1989) demonstrated that similar droplets could also be formed
from human LDL on the surface of mast cell granules in vitro. This process depended on retention
of native LDL by the heparin proteoglycans of the surface of the granules, modification of
proteoglycan-bound LDL by proteoglycan-bound protease chymase, and fusion of the modified
LDL particles.
On the basis of these findings, experiments were set up to elucidate the mechanisms of formation
of the small lipid droplets similar to those associated with collagen in the arterial intima in vivo.
More specifically, the experiments aimed at studying
i) the factors present in the arterial intima that can explain the preferential accumulation of
LDL along collagen fibers (I, II)
ii) the modification(s) of LDL that lead to formation of the small lipid droplets from the
LDL particles (III, IV, V)
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Methods
Isolation and modifications
of lipoproteins
Preparation and labeling of lipo-
proteins
VLDL, IDL, LDL, and HDL were isolated from
plasma of healthy volunteers by sequential ul-
tracentrifugation (Havel et al. 1955).
Apolipoprotein B-100 of LDL was tritiated by
the Bolton-Hunter procedure (Bolton & Hunter
1973) with N-succinimidyl[2,3-3H]propionate
and iodinated using the iodine monochloride
method as described (McFarlane 1958;
Bilheimer et al. 1972). [3H]cholesteryl linoleate
was incorporated into LDL by incubating LDL
with solid dispersions of [3H]cholesteryl li-
noleate on acid-washed Celite 545 in the pres-
ence of isolated cholesteryl ester transfer pro-
tein (Piha et al. 1995).
Fluorescent cholesteryl esters were incorporated
into LDL by incubating microemulsions (Via
et al. 1982) containing 5866 nmol of cholesteryl
linoleate, 845 nmol of triolein, 1411 nmol of
cholesterol, 1970 nmol of 1-palmitoyl-2-
oleoylphosphatidylcholine, and 652 nmol of
either Pyr
10
CE or BODIPY-CE with isolated
LDL in the presence of isolated cholesteryl es-
ter transfer protein. The labeled LDL was iso-
lated from the donor microemulsions and CETP
by density gradient ultracentrifugation and size-
exclusion chromatography. The fluorescently
labeled LDL preparations were analyzed for
lipid composition and ability to bind to heparin,
and no significant changes from native LDL
were observed.
Modification of LDL
Lysine and arginine residues of apoB-100 were
blocked by treatment of LDL with acetic anhy-
dride (Basu et al. 1976) and with 1,2-
cyclohexanedione (Mahley et al. 1977), respec-
tively. LDL was modified with malondialdehyde
(MDA) by incubation with increasing amounts
of MDA, freshly prepared by acid hydrolysis
of 1,1,3,3-tetramethoxypropane, in an ice bath
for 3 h (Ylä-Herttuala et al. 1989). LDL was
glycosylated by incubation in buffer contain-
ing 200 mM glucose at 37°C. LDL (1 mg/ml)
was proteolyzed by incubation with α-chymot-
rypsin (0.1 mg/ml) or with trypsin (0.1 mg/ml).
LDL was oxidized by copper, by the free radi-
cal generating 2,2’-azobis(2-amidino-
propane)hydrochloride (AAPH), by hypochlo-
rite (HOCl), and by soybean 15-lipoxygenase
(SLO).
Aggregates of LDL were prepared by vortexing
a solution of LDL (1 mg/ml) in a conical 10-ml
tube at room temperature with a table vortex at
full speed. Large and small LDL-antibody com-
plexes were prepared by adding sheep anti-hu-
man apoB-100 antibody (Boehringer
Mannheim) and goat anti-human apoB-100 an-
tibody (Biodesign International) to LDL, respec-
tively.
Analysis of modified LDL
Biochemical analysis
The charge of LDL was analyzed by electro-
phoresis on cellulose acetate to measure the
degree of acetylation, oxidation, glycosylation,
and treatment with 1,2-cyclohexanedione or
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MDA. Thiobarbituric acid-reactive substances
were measured essentially as described (Hessler
et al. 1983) to assess the degree of LDL oxida-
tion and modification by MDA. The degree of
LDL glycosylation was measured by boronate
affinity chromatography (Makino et al. 1995).
The degree of LDL proteolysis was analyzed
by SDS-PAGE on 4-20% gels (Laemmli 1970)
and by measuring the amount of trichloroacetic
acid (TCA)-soluble apoB-100 radioactivity. The
amount of sphingomyelin degraded was mea-
sured by thin-layer chromatography (Xu &
Tabas 1991). LDL density was measured by
equilibrium density gradient ultracentrifugation
(Redgrave et al. 1975).
Determination of particle size
The degree of LDL aggregation was measured
by the turbidity of modified LDL at 680 nm, by
the sedimentation of LDL at 14,000g for 10 min,
and by the ability of LDL to enter 0.5% agarose
gel in electrophoresis. The degree of both LDL
aggregation and fusion was measured by gel fil-
tration on two Superose 6 HR 10/30 columns
connected in series, and by rate zonal flotation
of LDL in a linear 7.5-30% gradient of NaBr
centrifuged at 285,000g for 1 h as described
(Polacek et al. 1988).
Electron microscopy of LDL par-
ticles
To assess small changes in LDL particle size,
LDL samples were negatively stained with 1%
potassium phosphotungstate, pH 7.4, and
viewed and photographed in a JEOL JEM-
100CX transmission electron microscope (Forte
& Nordhausen 1986). To assess the morphol-
ogy of the aggregated and fused particles,
samples were prepared for thin-section EM.
Briefly, LDL samples were cast into 2% agar-
ose gel, fixed with 3% glutaraldehyde, and
stained with the osmium/tannic acid/para-phe-
nylenediamine technique (Guyton & Klemp
1988). Thin sections were then viewed and pho-
tographed in a JEOL JEM-1200EX transmis-
sion electron microscope.
Fluorescent resonance energy
transfer (RET)
For typical experiments, equal concentrations
(50 µg/ml) of Pyr
10
CE-LDL and BODIPY-CE-
LDL were incubated at 37°C in buffer contain-
ing 20 µM butylated hydroxytoluene (BHT) in
the absence and presence of α-chymotrypsin (10
µg/ml) and PGs/GAGs (10 µg/ml). Fluorescent
measurements were performed with a Hitachi
F-4000 spectrofluorometer equipped with a
thermostated cuvette holder. Excitation and
emission wavelengths were set at 346 and 395
nm for direct excitation of pyrene, at 346 and
530 nm for indirect excitation of BODIPY, and
at 510 and 530 for direct excitation of BODIPY.
RET was expressed as the ratio of indirect to
direct excitation of BODIPY.
1H NMR
For most of the NMR experiments, buffer of
the LDL samples was changed to 137 mM NaCl,
2.7 mM KCl, 10 µM Na
2
EDTA, 10 mM phos-
phate, pD 7.0 in D2O by gel filtration twice
through PD-10 columns. Measurements were
made at 37° on a Bruker DRK 500 MHz spec-
trometer equipped with a 5-mm NMR tube con-
taining external standard (8 mM 3-
trimethylsilyl[2,2,3,3-D
4
]propionate) in a sealed
coaxial insert. In each experiment, 16-256 free
induction decay signals (FIDs) of 64k data
points were accumulated, using a pulse repeti-
tion time of 6.6 s and 90° pulses. The spectral
widths were 6.25 kHz. When H
2
O was used in
the measurements, the water peak was sup-
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pressed by the SHAKA-180° pulse sequence
(Hwang & Shaka 1995).
The measured FIDs were Fourier-transformed
without apodization to the frequency domain
spectra, in which the cholesterol backbone
–C(18)H
3
, the terminal methyl –CH
3
 and the me-
thylene =CH-CH
2
-CH= resonances were sub-
jected to lineshape fitting with one, one, and
three Lorenzians, respectively. The particles
sizes were calculated from the chemical shifts
according to Eq. 1, which, in a spherical par-
ticle with an isotropic core and a radially ori-
ented surface (Lounila et al. 1994), links the
frequency of the ith NMR line, v
i
, and the lipo-
protein particle radius, R,
where vi
o is the asymptotic value of vi at limit
R à  ∞, v
0
 is the operating frequency of the
spectrometer, ∆χ is the anisotropy of the mag-
netic susceptibility of the particle surface, and
∆ is the thickness of the surface. For the calcu-
lations, constant values of 2.0 nm for ∆ and
–0.223 ppm for ∆χ were used (Lounila et al.
1994).
Isolation and modification
of extracellular matrix com-
ponents
Isolation and modification of
decorin from fetal bovine skin
Proteoglycans were isolated from fetal bovine
skin essentially as described (Choi et al. 1989).
PG were extracted with 7.8 M urea, 0.15 M
NaCl, 5 mM EDTA, 25 mM Tris, pH 6.6, in the
presence of 5 mM ε-aminocaproic acid, 0.2 mM
phenylmethylsulfonyl fluoride, and 0.02%
(w/v) NaN
3
.The mixture was filtered and centri-
fuged at 100,000g for 60 min, the supernatant
was batch-adsorbed with CM-Sepharose, and
the CM-Sepharose was removed by centrifuga-
tion. The supernatant was adsorbed with DEAE-
Sepharose, which was packed into a column, and
the bound material was eluted with extraction
buffer containing 1 M NaCl. The eluted peaks
were adjusted to 0.15 M NaCl, loaded on a
HiTrap Q column, and eluted with a linear gradi-
ent of 0.15-1.0 M NaCl in the extraction buffer.
The disaccharides of two proteoglycan prepa-
ration were 68% and 63% of dermatan sulfate,
3% and 12% of chondroitin-6-sulfate, and 29%
and 25% of chondroitin-4-sulfate. The purity of
the preparations was analyzed by N-terminal
sequencing, which revealed that the preparations
contained >90% of decorin. Decorin core pro-
tein was prepared by chondroitinase ABC treat-
ment of the decorin. 35S-Decorin was prepared
by labeling the core protein of decorin with 35S-
labeling reagent (Bolton & Hunter 1973).
Isolation of proteoglycans from
human aorta
Human aortas were obtained at necropsy within
24 h of accidental death. Proteoglycans were
isolated from intima-media and purified by ion-
exchange chromatography on a Q HiTrap col-
umn in 6 M urea, essentially as described pre-
viously (Paananen et al. 1995; Hurt-Camejo et
al. 1990). The proteoglycan preparation con-
tained 56% chondroitin-6-sulfate, 25% chon-
droitin-4-sulfate, and 19% dermatan sulfate.
Isolation of lipoprotein lipase
from bovine milk
LPL was isolated from fresh bovine milk by the
Intralipid binding method, essentially as de-
scribed by Posner et al. (1983). Briefly, 10 ml of
Intralipid (300 mg/ml) was added to 210 ml of
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skim milk, incubated for 30 min at 37°, and col-
lected and washed by centrifugation. Thereaf-
ter, the floating cakes were delipidated by addi-
tion of 40 vol of acetone, filtered through a sin-
tered glass filter covered by another filter
(Millipore FH; cat. no. FHUP04700), and washed
twice with 40 ml of diethyl ether. The powder
was dissolved in 0.75 M NaCl, 0.1% Triton X-
100, 20 mM Tris-HCl, pH 7.4, and applied to a
heparin column (~30 ml). The column was washed
with buffer containing 1 M NaCl, 20 mM Tris-
HCl, pH 7.4, and 30% glycerol, and LPL was
eluted with buffer containing 2 M NaCl, 20 mM
Tris-HCl, pH 7.4, and 30% glycerol. The isolated
LPL migrated as a single major band in 4-20%
SDS-PAGE gel and, with 3H-triolein as substrate
(Saxena et al. 1989), was found to have an activ-
ity of ~5 mmol oleic acid released/h/mg. LPL was
inactivated either by incubation with 1 M GuHCl
for 1 h at room temperature or by incubation as
dilute solution (10 µg/ml) for 1 h at 37°C.
Interaction of native and
modified LDL with extracel-
lular matrix components
Affinity chromatography
Affinity chromatography was performed with a
SMART system from Amersham Pharmacia.
Binding of LDL to decorin was studied in a 1-
ml N-hydroxysuccinimidyl ester-activated
HiTrap column coupled with 1 mg of decorin.
Binding of decorin to LDL was studied in a 1-
ml N-hydroxysuccinimidyl ester-activated
HiTrap column coupled with 1 mg of LDL.
Binding of lipoproteins to monomeric and
dimeric LPL was studied in a 1-ml HiTrap col-
umn coupled with 10 mg of porcine heparin, into
which 100 µg of native or monomeric LPL was
injected. In some experiments, monomeric LPL
was washed from the column with buffer con-
taining 1 M NaCl, leaving dimeric LPL in the col-
umn. The components studied were eluted with
a linear gradient of NaCl, elution was monitored
by UV absorbance at 280 nm, and the NaCl gra-
dient was controlled by measuring the conduc-
tance of the eluent. 500-µl fractions were col-
lected and analyzed for radioactivity.
Microtiter well binding assay
Proteins were adsorbed on microtiter wells
(Labsystems, Helsinki) by incubation with
decorin (10 µg/ml) in PBS at 37° for 18 h, or
LPL (10 µg/ml) in PBS containing 10% glyc-
erol at 4°C for 4 h, or fibrillar collagen type I
from calf skin (100 µg/ml) in 67 mM phosphate
buffer, pH 7.2, at 37°C for 18 h. Nonspecific
binding sites in the wells were blocked by incu-
bation at room temperature for 1 h with 250 µl
buffer containing the indicated concentration of
bovine serum albumin (BSA). Microtiter well
assays were performed by incubating the com-
pound to be tested in 50 µl of buffer at room
temperature for 1-2 h. BSA-coated wells served
as controls for nonspecific binding. Unbound
compounds were removed by aspirating the in-
cubation medium, and the wells were then rinsed
three times with 250 µl of buffer. The wells were
detached and their radioactivities were deter-
mined by liquid scintillation counting. The data
points indicate the amounts of ligands specifi-
cally bound to the compound(s) tested, which
were calculated by subtracting the amounts of
the ligands bound to the BSA-coated wells from
the amounts of the ligands bound to the wells
coated with the compound(s) tested.
Gel mobility shift assay
The affinity of LDL for decorin and heparin was
measured by the gel mobility shift assay, essen-
tially as described (Camejo et al. 1993). In this
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assay, fixed trace amounts of 35S-decorin and
3H-heparin were incubated with increasing
amounts of LDL in buffer containing 140 mM
NaCl, 2 mM CaCl
2
, 2 mM MgCl
2
, and 5 mM
HEPES, pH 7.2. Thereafter, the samples were
electrophoresed in gels made of Nu-Sieve aga-
rose dissolved in buffer containing 2 mM CaCl
2
,
2 mM MgCl
2
, and 5 mM HEPES, pH 7.4. The gels
were fixed, dried, and autoradiographed, and the
ability of LDL to retard the electrophoretic
mobility of decorin and heparin was studied.
Immunohistochemistry
Samples of coronary arteries were obtained from
four hearts explanted at cardiac transplantation
and snap-frozen in OCT compound; serial fro-
zen sections were then cut at 5 µm. Sections
were either fixed with 4% p-formaldehyde and
stained with Oil Red O or fixed with acetone and
prepared for immunohistochemistry. The anti-
bodies used for immunohistochemistry were
Methods
MB-47 for apoB-100 (dilution 1:100; a kind gift
from Dr. J. Witztum, UCSD), MDA2 for
malondialdehyde-modified lysine residues
(1:100; produced in the Immunology Core
Laboratory of the La Jolla SCOR program, a
kind gift from Dr. J. Witztum), 5D2 for LPL
(1:100; a kind gift from Dr. J. Brunzell, Uni-
versity of Washington), LF-30 for decorin core
protein (1:100, a kind gift from Dr. L. Fisher,
National Institute of Dental and Craniofacial
Research, NIH), MAB1340 for collagen type I
(1:10, Chemicon International). Fixed sections
stained with standard protocols using the indi-
rect immunoperoxidase method with either
HRP-conjugated goat anti-mouse antibody for
mouse monoclonal antibodies or biotinylated
goat anti-rabbit antibody and HRP-conjugated
streptavidin for the rabbit polyclonal antibody.
3-Amino-9-ethylcarbazole was used as chro-
mogen.
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Association of native and
oxidized LDL with collagen
type I
Binding of LDL to decorin-coated
collagen
When decorin was adsorbed on microtiter wells,
increasing the concentrations of LDL, but not
HDL
3
, was found to lead to binding of increas-
ing amounts of lipoprotein to the decorin (I, Fig.
1). Under physiological ionic conditions, bind-
ing of LDL to decorin could be demonstrated
in the fluid phase, using a gel mobility shift as-
say (I, Fig. 3). This interaction was abolished
by degradation of the GAG chain of decorin (I,
Fig. 4), showing that decorin interacts with LDL
through its GAG chain. Finally, the effect of
decorin on the interaction between LDL and
collagen was studied. Decorin-collagen com-
plexes were allowed to form by incubating
decorin with collagen-coated microtiter wells.
Examination of the binding of LDL to the
decorin-collagen complexes formed showed that
native decorin was able to increase the amount
of LDL associated with collagen type I by 10-
fold, whereas chondroitinase ABC-treated
decorin had no effect (I, Fig. 7). Thus, decorin
was able to form a bridge between LDL and
collagen, by binding to collagen with its core
protein, and binding apoB-100 of LDL with its
glycosaminoglycan chain (Fig. 5).
Binding of oxLDL to decorin-
coated collagen
Preliminary experiments showed that oxidation
by copper, hypochlorite, and AAPH increased
the binding of oxidized LDL to collagen dose-
dependently. The different types of oxidants
studied similarly increased the binding of LDL
to collagen when the degree of oxidation was
similar, as judged by the electrophoretic mobil-
ity of LDL. When binding of the same oxida-
tively modified LDL preparations to immobi-
lized decorin was studied, it was found that,
consistently with previous experiments on other
types of PGs (Öörni et al. 1997), oxidation pro-
gressively decreased the amount of LDL bound
to decorin. Finally, when collagen was
preincubated with decorin, examination of the
binding of oxidized LDL to the decorin-coated
collagen showed that native decorin progres-
sively inhibited binding of oxLDL to collagen
to over 90%, whereas chondroitinase ABC-
treated decorin had no effect. Thus, the gly-
cosaminoglycan chains of decorin were able to
block the binding of oxidized LDL to collagen,
either by competing for binding to the positively
charged residues of collagen type I, or by giv-
ing the surface of the collagen a strong negative
charge that caused repulsion of the oxidized
LDL particles.
Effect of lipoprotein lipase (LPL)
on the binding of LDL and oxLDL
to decorin-coated collagen
When the experiments on microtiter wells were
conducted at physiological ionic strength, little
binding of native LDL to decorin took place,
and no specific binding of copper-oxidized LDL
to decorin was detected (II, Fig. 1). However,
preincubation of decorin-coated wells with LPL
isolated from bovine milk greatly increased the
amounts of both native and oxidized LDL bound
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to decorin, the dissociation constants being 12
and 5.9 nM, respectively. This increase in bind-
ing was found to depend on the binding of the
lipoproteins to LPL rather than on modulation
of the interaction between decorin and LDL by
LPL, since the binding of LDL to decorin-bound
LPL and to LPL directly immobilized to microtiter
wells were similar in affinity. Finally, the binding
of native and oxidized LDL to collagen was
tested in the absence and presence of decorin
and LPL. The binding of native and oxidized LDL
to collagen that had been pre-incubated with
decorin was dramatically increased by LPL (23-
and 7-fold, respectively), but the presence of
LPL had no effect on the binding of native and
oxidized LDL to collagen in the absence of
decorin (II, Fig. 2). Thus, the ability of collagen
to bind lipoproteins was markedly enhanced by
lipoprotein lipase, provided that decorin was
present on the collagen.
Interaction of lipoproteins with
LPL
Experiments on microtiter wells revealed that dif-
ferent preparations of LPL had different abilities
to link native and oxidized LDL to decorin. Thus,
the amount of oxidized LDL bound to LPL was
nearly constant whereas the amount of native
LDL bound to LPL differed markedly. Moreover,
oxLDL appeared to have a higher affinity for LPL
than native LDL. To study these differences, a
series of experiments was conducted using af-
finity chromatography. Preliminary experiments
on decorin (affinity) columns revealed that
preinjection of LPL retarded elution of native
LDL from 50 mM NaCl to ~600 mM NaCl from
the column. Thus, it appeared that native LDL
could be dissociated from LPL by increasing the
ionic strength of the buffer. Copper-oxidized LDL,
though it did not bind to the decorin column at
all in the absence of LPL, co-eluted from the col-
umn with LPL activity at ~800 mM NaCl after
pre-injection of LPL. To be able to use higher
NaCl concentrations that could potentially also
Fig. 5. Schematic picture of the binding of LDL to collagen type I in
the presence of decorin and lipoprotein lipase. Adapted from Kovanen
& Pentikäinen (1999).
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dissociate oxLDL from LPL, affinity chromatog-
raphy on heparin columns loaded with LPL was
also performed. In this system, native LDL was
found to elute from the column at ~750 mM NaCl,
and VLDL and IDL, which are substrates for LPL,
co-eluted from the column at 1.3 M NaCl (II, Fig.
3A). When LDL was oxidized with copper, we
found that after as little as 2 h the affinity of the
LDL for LPL was significantly increased, and at
18 h oxLDL eluted at the leading edge of LPL
activity (II, Fig. 3C). This was not dependent on
the type of LDL oxidation, since similar increases
in affinity were also observed with AAPH, HOCl,
and SLO-mediated oxidation (II, Fig. 3C). Be-
cause LPL is known to be present as a catalyti-
cally active dimer and a catalytically inactive
monomer, it was tested whether the difference
between binding of native and oxidized LDL to
LPL could be due to binding of the lipoproteins
to the different forms of LPL. Mild dissociation
of the isolated LPL into inactive monomers was
found to have no effect on the binding of native
LDL to LPL, whereas it totally abolished the high-
affinity binding of oxLDL (II, Fig. 4.). Moreover,
when the inactive LPL, which eluted at a lower
NaCl concentration than the catalytically active
LDL, was removed by washing the column with
buffer containing 1 M NaCl, the remaining dimeric
LPL had no effect on the binding of native LDL
to the heparin column, whereas oxLDL bound
to the dimeric LPL with high affinity. This did
not depend on the amount of LPL in the hep-
arin column, since similar results were obtained
when large amounts (400 µg) of LPL were
loaded on the column. Thus, native LDL bound
to monomeric LPL, whereas oxidized LDL
bound to dimeric LPL. The exact mechanism
accounting for this difference in binding could
not be resolved, but it appeared that hydrolysis
of apoB-100 in oxidation was most likely a con-
tributory factor, since, after extensive proteolytic
degradation of apoB-100, LDL was able to bind
to dimeric LPL (II, Fig. 5). Moreover, binding
to dimeric LPL was found to be mediated by
the lipids rather than by apoB-100, as previously
suggested, since lipid droplets made of LDL lip-
ids also bound effectively to dimeric LPL (II,
Fig. 5). Thus, the differences in the binding of
native and oxidized LDL to LPL can be ex-
plained at least partly by the binding of the li-
poproteins to the two different forms of LPL.
The finding that VLDL and IDL preferably bind
to dimeric LPL is interesting and most likely
important in allowing catalytically active LPL
to bind to its substrates.
Ultrastructural localization of
LDL, oxidized lysines, lipoprotein
lipase, decorin, and collagen
type I
To investigate the spatial relationship of the ex-
tracellular matrix components studied in vitro,
samples of coronary arteries were taken from
four explanted hearts, and frozen sections were
stained immunohistochemically for apoB-100,
MDA-lysines, LPL, decorin, and collagen type
I. ApoB-100, MDA-lysines, LPL, decorin, and
collagen were present in distinct, characteris-
tic, partially overlapping areas of the intima.
Thus, apoB-100 was present in all the early le-
sions (types I-III) in both the superficial
proteoglycan-rich and the deep musculoelastic
layer of the intima and was concentrated in dis-
tinct sectors of the arterial circumference. In
advanced lesions (type V), staining for apoB-
100 was most intense around the core and shoul-
der areas of the lesion. Staining for oxidized
epitopes (MDA-lysines) was weak or absent in
the grossly normal intima, but was clear in le-
sions of types I-III in the proteoglycan-rich
layer, being associated mainly with intracellu-
lar lipid deposits. In advanced lesions (type V),
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oxidized epitopes were concentrated, like apoB-
100, around the core and shoulder areas of the
lesion. In early lesions (types I-III), lipoprotein
lipase was present subendothelially and in the
proteoglycan-rich layer, but notably not in the
musculoelastic layer, of the intima. In advanced
lesions LPL was found in foam cell-rich areas
of the shoulders and sometimes also deeper
around the core. Decorin was present in the
proteoglycan-rich layer in early lesions (types
I-III), and around the core regions in advanced
lesions (type V). Staining for collagen type I
was weak in areas of thin, grossly normal in-
tima, but in thick intima was clearly present in
the proteoglycan-rich layer (lesion types I-III).
In advanced lesions, staining for collagen type
I was concentrated around the lesion core. In-
terestingly, we were able to find an early ath-
erosclerotic lesion, characterized by extracellu-
lar oil red O-positive material, in which all the
components studied were present (II, Fig. 6).
Thus, colocalization of LDL with LPL, decorin
and collagen type I suggests a role for LPL,
decorin, and collagen type I in retention of LDL
in the arterial intima.
The present experiments were conducted to find
out why LDL appears to be preferentially re-
tained along collagen fibers in the arterial in-
tima. Previous in vitro studies on LDL-collagen
interaction have used collagen that was isolated
and reconstructed in vitro and lacked collagen-
associated molecules present in the arterial in-
tima. In these studies, binding of native LDL to
collagen was poor, but was increased exponen-
tially if the LDL particles were oxidized (Hoover
et al. 1988; Kalant et al. 1991; Kalant &
McCormick 1992; Kalant et al. 1993; Jimi et
al. 1994; Greilberger et al. 1997). Because
decorin has been shown to colocalize with col-
lagen type I in the arterial wall and to bind to
collagen in vitro, the effect of decorin on the
interaction between LDL and collagen was stud-
ied. The results show that decorin was able to
link native LDL to collagen, whereas binding
of oxidized LDL to collagen was effectively
inhibited by decorin on collagen. While bind-
ing of the core protein of decorin to collagen
was evident on microtiter wells in physiologi-
cal ionic strength, detection of the interaction
between the glycosaminoglycan chains of
decorin and LDL at physiological ionic strength
required sensitive assays, such as the gel mo-
bility shift assay. The decorin for our experi-
ments was isolated from fetal bovine skin and
may have differed from human arterial decorin
in its ability to bind LDL. However, in affinity
chromatography, LDL bound to decorin even
more strongly than to a large versican-like
proteoglycan isolated from human arterial inti-
mas, implying that decorin from bovine skin was
a good model for human arterial decorin.
Is decorin specific in its ability to link LDL to
collagen? The arterial intima has been shown
to contain a number of different forms of
proteoglycan, but only decorin has been shown
to be associated with collagen (Riessen et al.
1994). Thus, binding of decorin to collagen ap-
pears to be specific. LDL was displaced from
decorin by several GAGs in vitro (I, Fig. 6),
suggesting that binding of LDL to decorin is
similar to binding of LDL to other GAGs and
PGs. However, decorin can potentially bind in-
termediary molecules both by its GAG chain
and by its core protein, which may be differ from
that of other proteoglycans, e.g. versican. A
study of the effect of decorin on the ability of
lipoprotein lipase to enhance binding of LDL
to collagen showed that in the absence of
decorin, LPL was unable to associate with col-
lagen. However, LPL was able to bind to the GAG
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chain of decorin, which allowed association of
LPL with collagen. Binding of LPL to decorin is
specific for dermatan sulfate, as LPL has been
reported not to bind to chondroitin sulfate, the
major GAG of versican (Saxena et al. 1993a). In-
terestingly, the ability of LPL to link LDL to
decorin and to biglycan were recently compared,
and, surprisingly, LPL only enhanced the bind-
ing of LDL to decorin (Wagner et al. 1997).
The ability of LPL to link lipoproteins to gly-
cosaminoglycans was discovered almost a de-
cade ago (Eisenberg et al. 1992; Saxena et al.
1992), but binding of lipoproteins to monomeric
and to dimeric LPL have not previously been
compared. In fact, in many studies in which the
structural linking function of LPL has been
evaluated, catalytically active LPL has been dis-
sociated into inactive monomers in order to
avoid confounding lipolytic activity of the en-
zyme. These studies have shown that VLDL and
LDL bind to the monomeric LPL, but that oxi-
dation decreases the binding of LDL to LPL
(Hendriks et al. 1996). In human plasma, how-
ever, monomeric, catalytically inactive LPL is
associated with LDL (Vilella et al. 1993),
whereas dimeric, catalytically active LPL is as-
sociated with triglyceride-rich lipoproteins
(Zambon et al. 1996), suggesting that the meric
state of LPL influences the binding of LPL to
lipoproteins. The present experiments showed
that native LDL preferentially bound to mono-
meric LPL, whereas oxLDL, IDL and VLDL
preferentially bound to dimeric LPL.
The role of LPL in promoting the development
of atherosclerosis in the arterial wall was ini-
tially proposed by Zilversmit (1973). Since then,
a great deal of indirect evidence has accumulated
in support of the proatherosclerotic role of LPL
in the arterial wall. Recently, the role of
macrophage lipoprotein lipase expression was
studied in C57Bl/6 mice transplanted with fetal
liver cells from LPL-/-, LPL+/-, and LPL+/+ mice. It
was found that lipoprotein lipase expression in
the arterial wall promoted the formation of foam
cells and the development of atherosclerotic le-
sions, but it could not be determined from the
experiments whether the effect of LPL was struc-
tural or enzymatic (Babaev et al. 1999). Our
immunostaining results in the arterial intima sug-
gest that LPL may be important for the retention
of LDL by collagen.
Aggregation and fusion of
modified LDL
Ability of the various modifica-
tions to trigger fusion of LDL par-
ticles
First, we studied the ability of the various modi-
fications of LDL established in vitro to cause
aggregation and fusion of the particles. A panel
of biochemical methods was used for analyz-
ing the formation of enlarged structures 1) to
compare the sensitivities and correlation of
methods that have been used individually in the
literature, 2) to study whether aggregation could
be distinguished from fusion by biochemical
methods, and 3) to find out whether any par-
ticular modification would show a characteris-
tic physicochemical “fingerprint” that could be
used for the characterization of LDL isolated
from the arterial intima.
As shown in (II), vortexing of LDL led to mas-
sive aggregation of LDL, which could be dem-
onstrated by the increased turbidity of the
sample, by the sedimentation of most of the LDL
in low-speed centrifugation, and by the flota-
tion of LDL in rate-zonal centrifugation. Consis-
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tently with previous results (Guyton et al. 1991),
thin-section EM revealed the presence of large
lipid droplets, lipid vesicles, and aggregates of
native-sized LDL. EM of negatively stained
samples showed the presence of massive ag-
gregates, but did not reveal the characteristics
of the aggregates. The mean density of the par-
ticles was unchanged, but the density distribu-
tion was significantly narrowed. Addition of
polyclonal sheep-anti apoB antibody to LDL that
had been developed for nephelometric determi-
nation of apoB concentration caused formation
of the largest aggregates of the modifications
studied. Again, thin-section EM was able to
show both the shape and the size of the whole
aggregate, and also the presence of only native-
sized LDL particles in the aggregates. Similarly,
all the biochemical tests showed that most of
the LDL particles were present as aggregates.
The density of the aggregates was slightly
greater than that of LDL, revealing increased
protein (antibody) in the aggregates. Proteoly-
sis by α-chymotrypsin triggered fusion of the
particles with a minimal degree of aggregation
of the fused particles. Thin-section EM also
showed the presence of membranous material
extending from the particles but no true vesicles
were observed. Loss of protein decreased the
density of the particles to the range of VLDL
and IDL lipoproteins. A notable feature was the
lack of turbidity and the material sedimenting in
low-speed centrifugation, even though other
methods showed that most of the LDL particles
were increased in size. Oxidation by copper led
to some degree of aggregation of the particles,
but this was not so extensive as was to be ex-
pected from previous studies (Hoff & O’Neil
1991; Dobrian et al. 1993). After extensive oxi-
dation, particle integrity was lost and fused par-
ticles as well as pieces of lipid structures were
found by EM. Consistent with previous results
by Fong et al. (1987), but in contrast to the results
of Hoff et al. (1992), SDS-PAGE showed
aggregated protein larger than apoB-100 and a
smear of fragments with no distinct bands.
Moreover, the density of the particles had
increased significantly. Lipolysis of the
sphingomyelin of LDL led to the formation of
small fused particles as well as particle
aggregates, and no individual native-sized par-
ticles were present, as judged by gel-filtration
chromatography and by rate-zonal flotation.
However, the aggregates formed were small, as
judged by the lack of turbidity of the samples.
Modification of LDL with MDA caused a slight
increase in the density of the LDL and a small
degree of aggregation of native-sized LDL par-
ticles, whereas, even after incubation with 200
mM glucose for 1 week, aggregation of LDL was
minimal.
From the results, it was clear that measurement
of turbidity and of sedimentation at low-speed
centrifugation revealed only the presence of
large aggregates. Gel filtration chromatography,
which has traditionally been used to measure
particle size, was sensitive in detecting increased
particle size, but did not differentiate large ag-
gregates from small aggregates or from fused
particles. Moreover, recoveries of samples con-
taining aggregates were poor and their applica-
tion led to deterioration of the performance of
the column. In contrast, rate zonal flotation
showed many favorable features in detecting
particles of enlarged size. Thus, recovery of the
samples, even when extensively aggregated, was
good. Moreover, the sensitivity was also fairly
good, as judged by the presence of particles
floating at an increased rate after modification
of LDL by MDA, despite the absence of signifi-
cant turbidity of the sample. Finally, small ag-
gregates/fused particles could be separated from
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larger particles or aggregates, as was shown for
example for SMase-treated LDL, which in gel fil-
tration eluted totally in the void volume. Finally,
the superiority of thin-section EM over nega-
tive staining EM was notable in analyses of ag-
gregated and fused particles.
From this study, it was evident that neither the
methods that measure particle size nor those that
measure particle density were able to distinguish
aggregation from fusion of the particles. There-
fore, a more sophisticated methodology was
devised. Finally, no physicochemical fingerprint
of the modifications was observed, except for a
marked increase in the density of oxidized LDL.
Therefore, specific chemical or immunological
markers of LDL modifications should be used
for characterization of LDL isolated from the
arterial intima. These include, for example,
measurement of ceramide as a marker of SMase
action (Schissel et al. 1996) and various stable
oxidation end-products as markers of lipid
peroxidation.
Characterization of proteolytic
fusion of LDL by 1H NMR
1H NMR has previously been used for the de-
termination of the lipids in VLDL, IDL, LDL,
and HDL on the basis of differences in the mag-
netic susceptibility of the particles that corre-
late with the size of the particles. Therefore,
experiments were conducted to find out whether
1H NMR could be devised to monitor LDL par-
ticle fusion. To be sure that aggregation of LDL
without particle fusion does not change the
chemical shift of the hydrocarbon 1H NMR spec-
tra, 1H NMR spectra of LDL aggregated with
heparin or anti-apoB antibodies were studied.
Neither heparin, which bound LDL reversibly,
nor goat anti-apoB, which produced aggregates
of LDL with a diameter of ~1 µm (i.e. aggregation
of hundreds of LDL particles) (IV, Fig. 4), had
any effect on the 1H NMR spectra (IV, Fig. 3).
But, aggregation of LDL by sheep anti-apoB,
which caused formation of massive insoluble
aggregates (IV, Fig. 4), caused significant broad-
ening of all lipid resonances, most likely indi-
cating restriction in the tumbling of the large
aggregates (IV, Fig. 3). However, the chemical
shift of the lipid resonances was unchanged even
in the large aggregates, indicating that aggrega-
tion does not cause changes in the chemical shift
in the 1H NMR spectra of lipid resonances.
With this methodology, the time course of the
LDL fusion triggered by α-chymotrypsin was
demonstrated. The size of the LDL particles was
found to increase exponentially during proteoly-
sis in the spectrometer (IV, Fig. 2).  This most
likely reflects the necessity for a certain degree
of proteolysis of apoB-100 before fusion of LDL
begins to take place (Piha et al. 1995). More-
over, when the average size of the particles was
derived from Eq. 1 during proteolysis, the val-
ues obtained correlated well with the values pre-
vious obtained with negative staining EM (Piha
et al. 1995).
Application of the 1H NMR methodology should
not be restricted to detection of changes in par-
ticle size but should also be used to detect physi-
cochemical changes in the particles. The reso-
nances of the phosphatidylcholine (PC) and sph-
ingomyelin (SM) headgroups have previously
been shown to be distinguishable (Murphy et
al. 1997). Our preliminary results suggest that,
during particle fusion, PC and SM behave dif-
ferently. Thus, the resonance for PC first in-
creased by 10-20% during the initial 3 h and then
decreased by 40-60% during 24 h, whereas that
of SM gradually decreased by 40-60% after ini-
tiation of proteolytic particle fusion. The rela-
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tive increase in PC can most likely be explained
by release of PC immobilized by apoB-100. The
relative decrease in the intensities of both PC
and SM, in turn, is likely to reflect the formation
of rigid structures from surface lipids of LDL
particles in which the mobilities of the PC and
SM headgroups are restricted. This is supported
by 1H NMR analysis of lipids extracted from
proteolyzed lipid particles, which showed that
the amounts of PC and SM in the samples were
unchanged.
Taken together, 1H NMR appears to be a pow-
erful tool for studies of LDL fusion, especially
if structural information about the particles is
looked for. One advantage is that it is non-inva-
sive, i.e. no labeling of particles is required, and,
in addition, it allows continuous measurements,
and gives information on particle structure at
the molecular level. However, its drawbacks are
the requirement of expensive equipment, and
difficult data analysis, and the fact that infor-
mation on large aggregates cannot be obtained.
Effect of human arterial
proteoglycans on proteolytic fu-
sion of LDL
To study the effect of proteoglycans and gly-
cosaminoglycans on the rate of LDL fusion, i.e.
on the fusion of LDL in aggregates, a novel type
of methodology was devised, based on fluores-
cent resonance energy transfer (RET). In this
system, two different fluorescent cholesteryl
ester analogs were incorporated into the cores
of different samples of LDL particles with the
aid of cholesteryl ester transfer protein (CETP),
and LDL fusion was studied in a mixture of the
two LDL preparations. The fluorescent probes
in the cores of separate LDL particles are, on
average, too far apart for RET to occur. How-
ever, fusion, though not aggregation, of the par-
ticles, allows mixing of the core lipids and RET.
Incubation of LDL in the presence, but not in
the absence, of α-chymotrypsin significantly
increased RET (V, Fig. 1). The increased RET
was limited to particles of increased size, indi-
cating detection of particle fusion (V, Fig. 2).
Importantly, the rate of proteolytic fusion of
LDL was increased when LDL was complexed
with PGs isolated from human arterial intima
and with GAGs isolated from the PGs (V, Fig.
3-5). Induction of the rate of particle fusion was
correlated both with the ability of the PGs and
GAGs to aggregate LDL and with the rate of
LDL proteolysis, suggesting that the LDL in the
aggregates were more efficiently proteolyzed.
Thus, it appears that even small amounts of pro-
teases are able to degrade large amounts of LDL
particles when these are aggregated, as in the
arterial intima. Moreover, the differences in the
ability of GAGs to enhance the rate of proteolytic
fusion is interesting in light of the presence in-
creased amounts of specific proteoglycans in
distinct regions of atherosclerotic lesions.
The methodology based on RET appeared suit-
able for studies on LDL fusion. Its strengths are
detection of particle fusion even in aggregates
with GAGs and continuous monitoring of the
process. However, it is laborious (requiring la-
beling of the LDL particles) and does not give
quantitative values for the extent of particle fu-
sion.
The finding that the proteolytic fusion of LDL is
enhanced by interaction of LDL with
proteoglycans is interesting. Previous work has
shown that proteoglycans can induce an irre-
versible conformational change in apoB-100,
which can enhance proteolysis of LDL (Camejo
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et al. 1991). Moreover, proteases that interact
with GAGs, i.e. have heparin-binding sites, have
been shown preferentially to hydrolyze a sub-
strate that is also bound to GAGs (Kovanen
1996). Finally, GAGs could activate a protease
by interaction with GAGs. All these possibili-
ties were tested, but no supporting evidence was
found for any of the above possibilities. Thus,
it appears that, after aggregation by GAGs,
which concentrates LDL, proteolysis is more
efficient.
General discussion
Characteristic of early atherosclerosis is accu-
mulation of “perifibrous” lipid in the arterial
intima (Smith et al. 1967). LDL has been shown
to accumulate preferentially in the vicinity of
collagen fibers, to small fibrils tethered to the
collagen fibers (Frank & Fogelman 1989;
Nievelstein-Post et al. 1994; Tamminen et al.
1999) (Fig. 1). The present work has shown that
both decorin and lipoprotein lipase may poten-
tially be involved in retaining LDL to collagen.
Is retention of LDL to collagen a prerequisite
for the development of atherosclerotic lesions?
Binding of LDL to proteoglycans, which is one
factor in the retention of LDL to collagen, has
been shown to be proatherogenic, as mice ex-
pressing proteoglycan-binding-deficient LDL
were resistant to the development of atheroscle-
rotic lesions despite hypercholesterolemia
(Borén et al. 1998b). Correspondingly, mac-
rophage LPL expression in the arterial wall,
which can also have structural, i.e. LDL-bind-
ing, effects, has been shown to be
proatherogenic (Babaev et al. 1999). Thus, in-
direct evidence suggested that molecules in-
volved in the retention of LDL in the extracel-
lular matrix promote the development of ath-
erosclerosis.
The present work offers mechanistic clues as to
how lipid droplets and vesicles can be derived
from modification and subsequent fusion of LDL
particles. What is the evidence that the intimal
lipid droplets and vesicles are derived from modi-
fication of LDL particles? Firstly, similar particles
can be found in the intima after intravenous in-
fusion of a large amount of human LDL in nor-
mal rabbits (Nievelstein et al. 1991) and after
incubation of rabbit aortic leaflets with human
LDL in vitro (Nievelstein-Post et al. 1994). Sec-
ondly, apoB is colocalized with similar particles,
suggesting that the particles are derived from
apoB-containing lipoproteins (Mora et al.
1987a). Thirdly, the particles are present in the
arterial intima before monocytes/macrophages
enter the intima (Simionescu et al. 1986; Guyton
& Klemp 1992), in areas of the arterial intima de-
void of macrophages and cell death (Slatter &
Smith 1972; Bocan et al. 1986; Guyton & Klemp
1993), which makes their cellular origin doubt-
ful. Fourthly, the particles are clearly smaller (di-
ameters 30-400 nm) than intracellular lipid drop-
lets (diameters >400 nm) (Guyton & Klemp 1989)
and closer to the sizes of plasma lipoproteins
after modifications. Fifthly, their fatty acid com-
position (rich in linoleate rather than in oleate)
also suggests that they are derived from direct
deposition of LDL rather than via cellular pro-
cessing. Taken together, there is a strong case
for direct deposition and modification of plasma
lipoproteins in the arterial intima. However, al-
ternative mechanisms for the formation of the
lipid droplets and vesicles have also been pro-
posed. Thus, it has been suggested that the small
lipid droplets and vesicles could be chylomicron
remnants that have entered the vascular wall
(Mamo & Wheeler 1994; Proctor & Mamo 1998),
or lipolytic remnants of VLDL particles, produced
either in the arterial intima in the presence of
small amounts of HDL or in the plasma by ab-
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normal lipolysis (Chung et al. 1994). Future work
will reveal the relative importance of these vari-
ous mechanisms.
Finally, what, if any, is the relevance of the small
lipid droplets and vesicles to the development
of atherosclerotic lesions? Their accumulation
in the arterial intima precedes infiltration of
monocytes into the arterial intima and coincides
with endothelial cell expression of VCAM-1
(Dansky et al. 1999), suggesting that the par-
ticles could be causing recruitment of monocytes
in the arterial intima. Aggregated and fused LDL
particles cause foam cell formation in vitro, and
extracellular lipid droplets and vesicles seemed
to disappear from the extracellular matrix as foam
cells were formed in the arterial intima (Pasquinelli
et al. 1989), strongly suggesting that the lipid
droplets and vesicles are directly involved in
the conversion of macrophages to foam cells in
vivo. Moreover, the morphology of the lipids in
the core of an atheroma closely resembles that
of the lipids initially deposited in the subendot-
helial space (Bocan et al. 1986) which have a
fatty acid composition compatible with direct
deposition of plasma lipoproteins (Smith 1965).
Thus, the lipid droplets and vesicles are likely to
account for the deposition of significant pro-
Results and Discussion
Fig. 6. Vicious circle in the arterial intima. Modification of LDL entrapped in the arterial
intima causes formation and release of potent inflammatory mediators. These mediators
cause intimal cells to secrete increasing amounts of enzymes capable of modifying LDL
and increasing amounts of proteoglycans capable of trapping LDL in the arterial intima.
SMase, sphingomyelinase; PLA2, phospholipase A2; CEase, cholesterol esterase. From
Pentikäinen et al. (2000) with permission.
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portions of both intra- and extracellular lipids.
Finally, modified LDL has recently been shown
to have potential proinflammatory properties (Fig.
6). Thus, even minimally oxidized LDL contains
modified phospholipids that are chemotactic for
monocytes (Berliner et al. 1990). Lipolysis of LDL
phospholipids by phospholipase A
2
 and lipid
peroxidation (Steinbrecher et al. 1984) gener-
ate lysophosphatidylcholine, which has poten-
tially a multitude of pro-inflammatory effects
in the arterial intima. Lysophosphatidylcholine
and oxidized LDL can be chemoattractants for
monocytes and T lymphocytes, induce expres-
sion of growth factors and adhesion molecules
in endothelial cells, and be mitogenic for mac-
rophages and smooth muscle cells (Hurt-Camejo
& Camejo 1997; Steinberg 1997). In addition,
oxidized LDL is immunogenic, and autoanti-
bodies are commonly found both in experimen-
tal animals and in human subjects with athero-
sclerotic lesions (Steinberg 1997). Lipolysis of
LDL releases free fatty acids, which may lower
smooth muscle cell proliferation and induce
secretion of ECM capable of trapping increas-
ing amounts of LDL (Olsson et al. 1999). Secre-
tory sphingomyelinase can hydrolyse sphingo-
myelin in modified LDL to ceramide, which, if
ingested by intimal cells in large amounts, could
escape lysosomal hydrolysis and enters the sig-
naling pathway (Schissel et al. 1996). The ter-
minal complement in human atherosclerotic le-
sions has been shown to be associated with lipid
vesicles, and LDL modified in vitro into the form
of vesicles by cholesteryl esterase has been
shown to activate complement by the alterna-
tive pathway and also to bind CRP (Bhakdi
1998). Taken together, lipid droplets and
vesicles appear not to be innocent by-standers
in the arterial wall, but rather participants ac-
tively involved in the process of atherosclero-
sis.
Future perspectives
The advent of modern gene technology includ-
ing transgenic mice during recent years has
changed atherosclerosis research dramatically
– the atherosclerotic potential of various pro-
teins can now be assessed in vivo by either in-
creasing or decreasing their expression. The
problem with the mouse models has been the
great differences in lipid metabolism as com-
pared with primates, mice having characteristi-
cally low levels of VLDL, IDL, and LDL cho-
lesterol and high levels of HDL cholesterol, and
being highly resistant to developing atheroscle-
rotic lesions. Inactivation of the apoE gene has
generated hypercholesterolemic mice, with high
levels of VLDL cholesterol that develop ath-
erosclerotic plaques similar to those of humans.
Importantly, the ultrastructure of the initial ex-
tracellular lipid deposits was found to be simi-
lar to that previously shown in the cholesterol-
fed rabbit, the WHHL rabbit, and rabbits in-
jected with human LDL (Frank & Fogelman
1989; Nievelstein et al. 1991; Tamminen et al.
1999). Using similar models, it remains an in-
teresting task for the future to evaluate the ath-
erosclerotic potential of the various proteins
characterized in the present study that are sug-
gested to be involved in the retention and accu-
mulation of LDL. So far, macrophage expres-
sion of LPL in the arterial wall has shown to
promote the development of atherosclerotic le-
sions in cholesterol-fed mice (Babaev et al.
1999).
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Conclusions
1. Decorin and LPL, two components of the extracellular matrix present in the arterial intima,
significantly influence the interaction between lipoproteins and collagen, the former al-
lowing binding of native, but not oxidized, LDL to collagen and the latter mediating high-
affinity binding of both native and oxidized LDL to decorin-coated collagen. Immunohis-
tochemical study of the human arterial intima suggested that these interactions are of
potential significance in LDL retention in the arterial intima.
2. Monomeric, i.e., catalytically inactive, and dimeric, i.e., catalytically active, forms of LPL
interact differently with lipoproteins, the former preferably binding native LDL and the
latter VLDL, IDL, and oxLDL. This finding may be important in understanding lipoprotein
physiology in the circulation, targeting catalytically active lipase to its substrates VLDL
and IDL, and catalytically inactive lipase to LDL, which can be effectively removed by the
liver. This finding is supported by previous studies showing association of catalytically
inactive LPL with LDL and of catalytically active LPL with lipoproteins larger than LDL in
human plasma. The preferential binding of oxLDL to dimeric LPL and of native LDL to
monomeric LPL, in turn, may have pathophysiological implications for the arterial wall.
Both monomeric and dimeric LPL have been found in a number of the tissues studied.
Whether native and oxLDL can be targeted differently by the LPL in the arterial intima
remains to be studied.
3. Particle fusion depends on extensive modification of the surface of LDL particles. Of a
set of established LDL modifications studied, only those that caused a significant surface
defect in the particles, i.e. proteolysis, oxidation, lipolysis of sphingomyelin, and the
strong mechanical force induced by vortexing, caused fusion of the particles.
4. Proteolytic fusion of LDL particles was enhanced by proteoglycans isolated from the
human arterial intima. This effect was found to correlate both with the ability of the
proteoglycans and glycosaminoglycans to form complexes with LDL and with the rate
of LDL proteolysis. Taken the presence of increased amounts of specific proteoglycans in
atherosclerotic lesions this finding may be of potential pathophysiological significance.
5. The novel methodology comprized application of 1H NMR and fluorescent resonance
energy transfer, allowing specific detection of particle fusion, and it is noteworthy that
the fluorescent resonance energy transfer methodology was not disturbed by particle
aggregation. Information of this kind opens up new possibilities for further studies on
LDL particle fusion, the key event in the accumulation of extracellular lipid.
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6. The work has provided mechanistic clues to the retention of LDL by collagen and the
formation of lipid droplets from LDL. A conceptually novel aspect is the taking into
account of the presence of collagen-associated molecules in the interaction between LDL
and collagen. Decorin may be important not only in the direct binding of LDL, but also
in the binding of such molecules as LPL, which structurally enhance the binding of LDL
to collagen, and enzymes like phospholipase A
2
, which cause aggregation and fusion of
the bound LDL.
Conclusions
53
Acknowledgments
Acknowledgments
This study was carried out at the Wihuri Research Institute during the years 1993-1999. I am
grateful to all the people involved in the work and my friends for making it a great period of time.
I owe my deepest thanks to professor Petri Kovanen, my supervisor and the head of the Wihuri
Research Institute. He has not only generously placed all the excellent laboratory facilities at my
disposal but also shared his enthusiasm for science, encouraged me continuously to pursue with
my work, and made working pleasant with his positive attitude.
I express my gratitude to all the personnel at Wihuri Research Institute and especially the members
of the lipoprotein research group for making the work enjoyable. Päivi Hiironen is acknowledged
for making progression of the work possible with her skillful and effective technical assistance,
cheering personality, and by being very flexible. I thank Erno Lehtonen for working as a two-man
team, ”the Boys”, during the early parts of the work and for a great time both at work and during
other activities. I acknowledge Kati Öörni for fruitful collaboration and discussions during the
work. I owe thanks to docent Ken Lindstedt for guiding me to the world of biochemistry and
inspiring collaboration during the initiation of my scientific work. I am indebted to docent Mika Ala-
Korpela for excellent collaboration on structural studies of the low density lipoprotein particles.
Mika is also acknowledged for generously providing me with all the necessary facilities while
heading the lipoprotein research group. Sanna Taskinen is acknowledged for technical assistance
during the last part of the work. In addition, it has been a privilege to guide her in her own
experiments. Docent Riitta Lassila is acknowledged for sharing her expertise is collagen research,
and Petri Laine is acknowledged for providing me with human arterial samples.
I thank Docent Pentti Somerharju at the Institute of Biomedicine for generously sharing his knowledge
in biochemistry and biophysics of lipids. Sari Löytökorpi is acknowledged for help during conduction
of studies on fluorescence spectrometry. Docent Matti Jauhiainen at the National Public Health
Institute is acknowledged for help in many experimental issues of the work and for nice discussions.
Personnel at the electron microscopy unit at the Institute of Biotechnology are given credit for help
in electron microscopy. I thank Ari Korhonen at the Department of Physical Sciences of University
of Oulu for fruitful collaboration on structural studies
Professor J. Peter Slotte and docent Timo Kuusi are acknowledged for critically reading the
manuscript and Mrs. Jean Margaret Perttunen for revision of the English language of the thesis and
the original publications.
I wish to express my warmest thanks to my parents Leena and Pertti for continuous support and
interest. Also my parents-in-law Eira and Jussi are acknowledged for kind care and my sister-in-law
Virpi for friendship.
Finally, I thank my wife Virve for love and support.
This study was financially supported by the following organizations: the Finnish Medical Founda-
tion, the Finnish Medical Society Duodecim, the Maud Kuistila Foundation, the Research and
Science Foundation of Farmos, and the Sigrid Jusélius Foundation.
Helsinki, December 1999
54
References
van Antwerpen R, Chen GC, Pullinger CR, Kane JP,
LaBelle M, Krauss RM, Luna-Chavez C, Forte TM,
and Gilkey JC: Cryo-electron microscopy of low
density lipoprotein and reconstituted discoidal high
density lipoprotein: imaging of the apolipoprotein
moiety. J Lipid Res 38: 659-669, 1997.
Amanuma K, Kanaseki T, Ikeuchi Y, Ohkuma S, and
Takano T: Studies on fine structure and location of
lipids in quick-freeze replicas of atherosclerotic aorta
of WHHL rabbits. Virchows Arch A 410: 231-238,
1986.
Anber V, Millar JS, McConnell M, Shepherd J, and
Packard CJ: Interaction of very-low-density, inter-
mediate-density, and low-density lipoproteins with
human arterial wall proteoglycans. Arteriosclerosis,
Thrombosis & Vascular Biology 17: 2507-2514,
1997.
Anitschkov N: Experimental arteriosclerosis in ani-
mals. In Arteriosclerosis: A Survey of the Problem.
Cowdry EV ed. Macmillan, New York. 1933, 271-
322.
Araki M, Fan JL, and Watanabe T: Immunohis-
tochemical localization of lipoprotein lipase and
apolipoprotein E in human atherosclerotic lesions.
Acta Histochem Cytochem 31: 485-492, 1998.
Auerbach BJ, Bisgaier CL, Wölle J, and Saxena U:
Oxidation of low density lipoproteins greatly en-
hances their association with lipoprotein lipase an-
chored to endothelial cell matrix. J Biol Chem 271:
1329-1335, 1996.
Austin MA, Breslow JL, Hennekens CH, Buring JE,
Willett, WC, and Krauss RM: Low-density lipopro-
tein subclass patterns and risk of myocardial infarc-
tion. JAMA 260: 1917-1921, 1988.
Avogaro P, Bon GB, and Cazzolato G: Presence of a
modified low density lipoprotein in humans.
Arterioscler 8: 79-87, 1988.
Babaev VR, Fazio S, Gleaves LA, Carter KJ,
Semenkovich CF, and Linton MF: Macrophage li-
poprotein lipase promotes foam cell formation and
atherosclerosis in vivo. J Clin Invest 103: 1697-1705,
1999.
Baccarani-Contri M, Vincenzi D, Cicchetti F, Mori
G, and Pasquali-Ronchetti I: Immunocytochemical
localization of proteoglycans within normal elastin
fibers. Eur J Cell Biol 53: 305-312, 1990.
Barakat AI, Uhthoff PA, and Colton CK: Topographi-
cal mapping of sites of enhanced HRP permeability
in the normal rabbit aorta. J Biomech Eng 114: 283-
292, 1992.
van Barlingen HH, de Jong H, Erkelens DW, and de
Bruin TW: Lipoprotein lipase-enhanced binding of
human triglyceride-rich lipoproteins to heparan sul-
fate: modulation by apolipoprotein E and
apolipoprotein C. J Lipid Res 37: 754-763, 1996.
Basu SK, Goldstein JL, Anderson RGW, and Brown
MS: Degradation of cationized low density lipopro-
tein and regulation of cholesterol metabolism in ho-
mozygous familial hypercholesterolemia fibroblasts.
Proc Natl Acad Sci U S A 73: 3178-3182, 1976.
Basu SK, Brown MS, Ho YK, Havel RJ, and
Goldstein JL: Mouse macrophages synthesize and
secrete a protein resembling apolipoprotein E. Proc
Natl Acad Sci U S A 78: 7545-7549, 1981.
Basu SK, Ho YK, Brown MS, Bilheimer DW, Ander-
son RG, and Goldstein JL: Biochemical and genetic
studies of the apoprotein E secreted by mouse mac-
rophages and human monocytes. J Biol Chem 257:
9788-9795, 1982.
Beckmann JS, Ye YZ, Anderson PG, Chen J,
Accavitti MA, Tarpey MM, and White CR: Exten-
sive nitration of protein tyrosines in human athero-
sclerosis detected by immunohistochemistry. Biol
Chem Hoppe-Seyler 375: 81-88, 1994.
Bellosta S, Mahley RW, Sanan DA, Murata J,
Newland DL, Taylor JM, and Pitas RE: Macroph-
age-specific expression of human apolipoprotein E
reduces atherosclerosis in hypercholesterolemic
apolipoprotein E-null mice. J Clin Invest 96: 2170-
2179, 1995.
Bendeck MP, Zempo N, Clowes AW, Galardy RE,
and Reidy MA: Smooth muscle cell migration and
matrix metalloproteinase expression after arterial in-
jury in the rat. Circ Res 75: 539-545, 1994.
References
55
Berliner JA, Territo MC, Sevanian A, Ramin S, Kim
JA, Bamshad B, and Fogelman AM: Minimally modi-
fied low density lipoprotein stimulates monocyte
endothelial interactions. J Clin Invest 85: 1260-1266,
1990.
Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J,
Weise E, Tranum J, Walev I, and Wieland E: On the
pathogenesis of atherosclerosis: enzymatic transfor-
mation of human low density lipoprotein to an athero-
genic moiety.  J Exp Med 182: 1959-1971, 1995.
Bhakdi S: Complement and atherogenesis: the un-
known connection. Ann Med 30: 503-507, 1998.
Bihari-Varga M, Sztatisz J, and Gal S: Changes in
the physical behavior of low density lipoprotein in
the presence of glycosaminoglycans and high den-
sity lipoprotein. Atherosclerosis 39: 19-23, 1981.
Bilheimer DW, Eisenberg S, and Levy RI: The me-
tabolism of very low density lipoprotein proteins. I.
Preliminary in vitro and in vivo observations. Biochim
Biophys Acta 260: 212-221, 1972.
Binette F, Cravens J, Kahoussi B, Haudenschild DR,
and Goetinck PF: Link protein is ubiquitously ex-
pressed in non-cartilaginous tissues where it enhances
and stabilizes the interaction of proteoglycans with
hyaluronic acid. J Biol Chem 269: 19116-19122,
1994.
Bobryshev YV and Lord RSA: Accumulation of co-
localised unesterified cholesterol and neutral lipids
within vacuolised elastin fibres in athero-prone ar-
eas of the human aorta. Atherosclerosis 142: 121-
131, 1999.
Bocan TM, Schifani TA, and Guyton JR: Ultrastruc-
ture of the human aortic fibrolipid lesion. Formation
of the atherosclerotic lipid-rich core. Am J Pathol
123: 413-424, 1986.
Boisvert WA and Curtiss LK: Elimination of mac-
rophage-specific apolipoprotein E reduces diet-in-
duced atherosclerosis in C57BL/6J male mice. J Lipid
Res 40: 806-813, 1999.
Bolton AE and Hunter WM: The labelling of pro-
teins to high specific activities by conjugating to a
125I-containing acylating agent. Biochem J 133: 529-
539, 1973.
Borén J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity,
and TL: Identification of the low density lipoprotein
receptor-binding site in apolipoprotein B100 and the
modulation of its binding activity by the carboxyl
terminus in familial defective apo-B100. J Clin In-
vest 101: 1084-1093, 1998.
Borén J, Olin K, Lee I, Chait A, Wight TN, and
Innerarity TL: Identification of the principal
proteoglycan-binding site in LDL. A single-point
mutation in apo-B100 severely affects proteoglycan
interaction without affecting LDL receptor binding.
J Clin Invest 101: 2658-2664, 1998a.
Borén J, Olin K, O’Brien KD, Arnold KS, Ludwig
EH, Wight TN, Chait A, and Innerarity TL: Engi-
neering non-atherogenic low density lipoproteins -
direct evidence for the “response-to-retention” hy-
pothesis of atherosclerosis. Circulation 98: I-314,
1998b. Abstract.
Brooks CJ, Harland WA, and Steel G: Squalene, 26-
hydroxycholesterol and 7-ketocholesterol in human
atheromatous plaques. Biochim Biophys Acta 125:
620-622, 1966.
Brown MS, Kovanen PT, and Goldstein JL: Regula-
tion of plasma cholesterol by lipoprotein receptors.
Science 212: 628-635, 1981.
Brown MS and Goldstein JL: Lipoprotein metabo-
lism in the macrophage: implications for cholesterol
deposition in atherosclerosis. Annu Rev Biochem 52:
223-261, 1983.
Brown MS and Goldstein JL: A receptor-mediated
pathway for cholesterol homeostasis. Science 232:
34-47, 1986.
Brownlee M, Vlassara H, and Cerami A: Nonenzy-
matic glycosylation products on collagen covalently
trap low-density lipoprotein. Diabetes 34: 938-941,
1985.
Camejo G, Waich S, Quintero G, Berrizbeitia ML,
and Lalaguna F: The affinity of low density lipopro-
teins for an arterial macromolecular complex. A study
in ischemic heart disease and controls. Atherosclero-
sis 24: 341-354, 1976.
Camejo G, Acquatella H, and Lalaguna F: The inter-
action of low density lipoproteins with arterial
proteoglycans. An additional risk factor? Atheroscle-
rosis 36: 55-65, 1980.
References
56
Camejo G: The interaction of lipids and lipoproteins
with the intercellular matrix of arterial tissue: its pos-
sible role in atherogenesis. Adv Lipid Res 19: 1-53,
1982.
Camejo G, Hurt E, and Romano M: Properties of li-
poprotein complexes isolated by affinity chromatog-
raphy from human aorta. Biomed Biochim Acta 44:
389-401, 1985a.
Camejo G, Lopez A, Lopez F, and Quinones J: Inter-
action of low density lipoproteins with arterial
proteoglycans. The role of charge and sialic acid con-
tent. Atherosclerosis 55: 93-105, 1985b.
Camejo G, Olofsson SO, Lopez F, Carlsson P, and
Bondjers G: Identification of Apo B-100 segments
mediating the interaction of low density lipoproteins
with arterial proteoglycans. Arterioscler 8: 368-377,
1988.
Camejo G, Hurt E, Thubrikar M, and Bondjers G:
Modification of low density lipoprotein association
with the arterial intima. A possible environment for
the antiatherogenic action of beta-blockers. Circula-
tion 84: VI17-VI22, 1991.
Camejo G, Hurt E, Wiklund O, Rosengren B, Lopez
F, and Bondjers G: Modifications of low-density li-
poprotein induced by arterial proteoglycans and chon-
droitin-6-sulfate. Biochim Biophys Acta 1096: 253-
261, 1991.
Camejo G, Fager G, Rosengren B, Hurt-Camejo E,
and Bondjers G: Binding of low density lipoproteins
by proteoglycans synthesized by proliferating and
quiescent human arterial smooth muscle cells. J Biol
Chem 268: 14131-14137, 1993.
Cardoso LEM and Mourão PAS: Glycosaminogly-
can fractions from human arteries presenting diverse
susceptibilities to atherosclerosis have different bind-
ing affinities to plasma LDL. Arterioscler Thromb 1:
115-124, 1994.
Chait A, Iverius PH, and Brunzell JD: Lipoprotein
lipase secretion by human monocyte-derived mac-
rophages. J Clin Invest 69: 490-493, 1982.
Chang MY, Lees AM, and Lees RS: Time course of
125I-labeled LDL accumulation in the healing, bal-
loon-deendothelialized rabbit aorta. Arterioscler
Thromb 12: 1088-1098, 1992.
Chang MY, Perigo S, Chait A, and Wight TN: Regu-
lation of vascular smooth muscle cell proteoglycan
genes by oxidized low-density lipoproteins. J Vasc
Res 33: S1-S49, 1996.
Chao FF, Amende LM, Blanchette-Mackie EJ,
Skarlatos SI, Gamble W, Mergner WT, and Kruth
HS: Unesterified cholesterol-rich lipid particles in
atherosclerotic lesions of human and rabbit aortas.
Am J Pathol  131: 73-83, 1988.
Chao FF, Blanchette-Mackie EJ, Chen YJ, Dickens
BF, Berlin E, Amende LM, Skarlatos SI, Gamble W,
Resau JH, Mergner WT, and Kruth HS: Character-
ization of two unique cholesterol-rich lipid particles
isolated from human atherosclerotic lesions. Am J
Pathol 136: 169-179, 1990.
Chao FF, Blanchette-Mackie EJ, Tertov VV,
Skarlatos SI, Chen YJ, and Kruth HS: Hydrolysis of
cholesteryl ester in low density lipoprotein converts
this lipoprotein to a liposome. J Biol Chem 267: 4992-
4998, 1992.
Chao FF, Blanchette-Mackie EJ, Dickens BF, Gamble
W, and Kruth HS: Development of unesterified cho-
lesterol-rich lipid particles in atherosclerotic lesions
of WHHL and cholesterol-fed NZW rabbits. J Lipid
Res 35: 71-83, 1994.
Chatterton JE, Phillips ML, Curtiss LK, Milne R,
Fruchart JC, and Schumaker VN: Immunoelectron
microscopy of low density lipoproteins yields a rib-
bon and bow model for the conformation of
apolipoprotein B on the lipoprotein surface. J Lipid
Res 36: 2027-2037, 1995.
Chen SH, Yang CY, Chen PF, Setzer D, Tanimura
M, Li WH, Gotto AMJ, and Chan L: The complete
cDNA and amino acid sequence of human
apolipoprotein B-100. J Biol Chem 261: 12918-
12921, 1986.
Cherchi GM, Coinu R, Demuro P, Formato M, Sanna
G, Tidore M, Tira ME, and De Luca G: Structural
and functional modifications of human aorta
proteoglycans in atherosclerosis. Matrix 10: 362-372,
1990.
Cherchi GM, Formato M, Demuro P, Masserini M,
Varani I, and DeLuca G: Modifications of low den-
sity lipoprotein induced by the interaction with hu-
man plasma glycosaminoglycan-protein complexes.
Biochim Biophys Acta 1212: 345-352, 1994.
Chisolm GM, Ma G, Irwin KC, Martin LL,
Gunderson KG, Linberg LF, Morel DW, and
DiCorleto PE: 7 beta-hydroperoxycholest-5-en-3
beta-ol, a component of human atherosclerotic le-
sions, is the primary cytotoxin of oxidized human
low density lipoprotein. Proc Natl Acad Sci U S A
91: 11452-11456, 1994.
References
57
Choi HU, Johnson TL, Pal S, Tang L-H, Rosenberg
L, and Neame PJ: Characterization of the dermatan
sulfate proteoglycans, DS-PGI and DS-PGII, from
bovine articular cartilage and skin isolated by octyl-
sepharose chromatography. J Biol Chem 264: 2876-
2884, 1989.
Choi SY, Sivaram P, Walker DE, Curtiss LK, Gretch
DG, Sturley SL, Attie AD, Deckelbaum RJ, and
Goldberg IJ: Lipoprotein lipase association with li-
poproteins involves protein-protein interaction with
apolipoprotein B. J Biol Chem 270: 8081-8086, 1995.
Choi SY, Pang L, Kern PA, Kayden HJ, Curtiss LK,
Vanni-Reyes TM, and Goldberg IJ: Dissociation of
LPL and LDL: effects of lipoproteins and anti-apoB
antibodies. J Lipid Res 38: 77-85, 1997.
Chuang PT, Cheng HJ, Lin SJ, Jan KM, Lee MM,
and Chien S: Macromolecular transport across arte-
rial and venous endothelium in rats. Studies with
Evans blue-albumin and horseradish peroxidase.
Arterioscler 10: 188-197, 1990.
Chung BH, Tallis G, Yalamoori V, Anantharamaiah
GM, and Segrest JP: Liposome-like particles isolated
from human atherosclerotic plaques are structurally
and compositionally similar to surface remnants of
triglyceride-rich lipoproteins. Arterioscler Thromb
14: 622-635, 1994.
Cladaras C, Hadzopoulou-Cladaras M, Nolte, RT,
Atkinson D, and Zannis VI: The complete sequence
and structural analysis of human apolipoprotein B-
100: relationship between apoB-100 and apoB-48
forms. EMBO Journal 5: 3495-3507, 1986.
Claire M, Jacotot B, and Robert L: Characterization
of lipids associated with macromolecules of the in-
tercellular matrix of human aorta. Connect Tissue Res
4: 61-71, 1976.
Clevidence BA, Morton RE, West G, Dusek DM,
and Hoff HF: Cholesterol esterification in macroph-
ages. Stimulation by lipoproteins containing apo B
isolated from human aortas. Arterioscler 4: 196-207,
1984.
Coleman T, Seip RL, Gimble JM, Lee D, Maeda N,
and Semenkovich CF: COOH-terminal disruption of
lipoprotein lipase in mice is lethal in homozygotes,
but heterozygotes have elevated triglycerides and
impaired enzyme activity. J Biol Chem 270: 12518-
12525, 1995.
Corpuz LM, Funderburgh JL, Funderburgh ML,
Bottomley GS, Prakash S, and Conrad GW: Molecu-
lar cloning and tissue distribution of keratocan. Bo-
vine corneal keratan sulfate proteoglycan 37A. J Biol
Chem 271: 9759-9763, 1996.
Curran RC and Crane WA: Mucopolysaccharides in
the atheromatous aorta. J Pathol Bacteriol 84: 405-
412, 1962.
Dalferes ER, Jr., Radhakrishnamurthy B, Ruiz HA,
Jr., and Berenson GS: Composition of proteoglycans
from human atherosclerotic lesions.  Exp Mol Pathol
47: 363-376, 1987.
Dansky HM, Charlton SA, Barlow CB, Tamminen
M, Smith JD, Frank JS, and Breslow JL: Apo A-I
inhibits foam cell formation in apoE-deficient mice
after monocyte adherence to endothelium. J Clin In-
vest 104: 31-39, 1999.
Daugherty A, Zwiefel BS, Sobel BE, and Schonfeld
G: Isolation of low density lipoprotein from athero-
sclerotic vascular tissue of Watanabe heritable hy-
perlipidemic rabbits. Arterioscler 8: 768-777, 1988.
Daugherty A, Dunn JL, Rateri DL, and Heinecke JW:
Myeloperoxidase, a catalyst for lipoprotein oxidation,
is expressed in human atherosclerotic lesions. J Clin
Invest 94: 437-444, 1994.
Davis HR, Glagov S, and Zarins CK: Role of acid
lipase in cholesteryl ester accumulation during athero-
genesis. Correlation of enzyme activity with acid li-
pase-containing macrophages in rabbit and human
lesions. Atherosclerosis 55: 205-215, 1985.
Day AJ, Alavi M, and Moore S: Influx of
[3H,14C]cholesterol-labelled lipoprotein into re-
endothelialized and de-endothelialized areas of bal-
looned aortas in normal-fed and cholesterol-fed rab-
bits. Atherosclerosis 55: 339-351, 1985.
Deckelbaum RJ, Shipley GG, Small DM, Lees RS,
and George PK: Thermal transitions in human plasma
low density lipoproteins. Science 190: 392-394, 1975.
Deckelbaum RJ, Shipley GG, and Small DM: Struc-
ture and interactions of lipids in human plasma low
density lipoproteins. J Biol Chem 252: 744-754, 1977.
Demuth K, Myara I, Chappey B, Vedie B, Pech-
Amsellem MA, Haberland ME, and Moatti N: A cy-
totoxic electronegative LDL subfraction is present
in human plasma. Arterioscler Thromb Vasc Biol 16:
773-783, 1996.
References
58
Dobrian A, Mora R, Simionescu M, and Simionescu
N: In vitro formation of oxidatively-modified and re-
assembled human low-density lipoproteins: anti-
oxidant effect of albumin. Biochim Biophys Acta
1169: 12-24, 1993.
Edwards IJ, Goldberg IJ, Parks JS, Xu H, and Wagner
WD: Lipoprotein lipase enhances the interaction of
low density lipoproteins with artery-derived extra-
cellular matrix proteoglycans. J Lipid Res 34: 1155-
1163, 1993.
Edwards IJ, Wagner WD, and Owens RT: Macroph-
age secretory products selectively stimulate dermatan
sulfate proteoglycan production in cultured arterial
smooth muscle cells. Am J Pathol 136: 609-621,
1990.
Edwards IJ, Xu H, Wright MJ, and Wagner WD:
Interleukin-1 upregulates decorin production by ar-
terial smooth muscle cells. Arterioscler Thromb 14:
1032-1039, 1994.
Edwards IJ, Xu H, Obunike JC, Goldberg IJ, and
Wagner WD: Differentiated macrophages synthesize
a heparan sulfate proteoglycan and an oversulfated
proteoglycan that bind lipoprotein lipase. Arterioscler
Thromb Vasc Biol 15: 409, 1995.
Eisenberg S, Sehayek E, Olivecrona G, and
Vlodavsky I: Lipoprotein lipase enhances binding of
lipoproteins to heparan sulfate on cell surfaces and
extracellular matrix. J Clin Invest 90: 2013-2021,
1992.
Esterbauer H, Gebicki J, Puhl H, and Jürgens G: The
role of lipid peroxidation and antioxidants in oxida-
tive modification of LDL. Free Radic Biol Med 13:
341-390, 1992.
Evanko SP, Raines EW, Ross R, Gold LI, and Wight
TN: Proteoglycan distribution in lesions of athero-
sclerosis depends on lesion severity, structural char-
acteristics, and the proximity of platelet-derived
growth factor and transforming growth factor-beta.
Am J Pathol 152: 533-546, 1998.
Evans PJ, Smith C, Mitchinson MJ, and Halliwell B:
Metal ion release from mechanically-disrupted hu-
man arterial wall. Implications for the development
of atherosclerosis. Free Rad Res 23: 465-469, 1995.
Fazio S, Babaev VR, Murray AB, Hasty AH, Carter
KJ, Gleaves LA, Atkinson JB, and Linton MF: In-
creased atherosclerosis in mice reconstituted with
apolipoprotein E null macrophages. Proc Natl Acad
Sci U S A  94: 4647-4652, 1997.
Fielding CJ: Purification of lipoprotein lipase from
rat post-heparin plasma. Biochim Biophys Acta 178:
499-507, 1969.
Filip DA, Nistor A, Bulla A, Radu A, Lupu F, and
Simionescu: Cellular events in the development of
valvular atherosclerotic lesions induced by experi-
mental hypercholesterolemia. Atherosclerosis 67:
199-214, 1987.
Folcik VA, Nivar-Aristy RA, Krajewski LP, and
Cathcart MK: Lipoxygenase contributes to the oxi-
dation of lipids in human atherosclerotic plaques. J
Clin Invest 96: 504-510, 1995.
Fong LG, Parthasarathy S, Witztum JL, and Steinberg
D: Nonenzymatic oxidative cleavage of peptide bonds
in apoprotein B- 100. J Lipid Res 28: 1466-1477,
1987.
Forte TM and Nordhausen RW: Electron microscopy
of negatively stained lipoproteins. Methods Enzymol
128: 442-457, 1986.
Frank JS and Fogelman AM: Ultrastructure of the
intima in WHHL and cholesterol-fed rabbit aortas
prepared by ultra-rapid freezing and freeze-etching.
J Lipid Res 30: 967-978, 1989.
Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ,
Anderson AJ, and Walker JA: Relation of lipopro-
tein subclasses as measured by proton nuclear mag-
netic resonance spectroscopy to coronary artery dis-
ease. Arteriosclerosis, Thrombosis & Vascular Biol-
ogy 18: 1046-1053, 1998.
Funderburgh JL, Funderburgh ML, Mann MM, and
Conrad GW: Arterial lumican. Properties of a cor-
neal-type keratan sulfate proteoglycan from bovine
aorta. J Biol Chem 266: 24773-24777, 1991.
Galis ZS, Alavi MZ, and Moore S: In situ ultrastruc-
tural characterization of chondroitin sulfate
proteoglycans in normal rabbit aorta. J Histochem
Cytochem 40: 251-263, 1992.
Galis ZS, Alavi MZ, and Moore S: Co-localization
of aortic apolipoprotein B and chondroitin sulfate in
an injury model of atherosclerosis. Am J Pathol 142:
1432-1438, 1993.
Galis ZS, Sukhova GK, Lark MW, and Libby P: In-
creased expression of matrix metalloproteinases and
matrix degrading activity in vulnerable regions of
human atherosclerotic plaques. J Clin Invest 94: 2493-
2503, 1994.
References
59
Galis ZS, Sukhova GK, and Libby P: Microscopic
localization of active proteases by in situ
zymography: detection of matrix metalloproteinase
activity in vascular tissue. FASEB J 9: 974-980, 1995.
Gofman JW and Young W: The filtration concept of
atherosclerosis and serum lipid in the diagnosis of
atherosclerosis. In Atherosclerosis and its origin.
Sandler M and Bourne GH eds. Academic Press, New
York. 1963, 197-229.
Goldberg IJ: Lipoprotein lipase and lipolysis: cen-
tral roles in lipoprotein metabolism and atherogen-
esis. J Lipid Res 37: 693-707, 1996.
Goldberg IJ, Wagner WD, Pang L, Paka L, Curtiss
LK, DeLozier JA, Shelness GS, Young CSH, and
Pillarisetti S: The NH2-terminal region of
apolipoprotein B is sufficient for lipoprotein asso-
ciation with glycosaminoglycans. J Biol Chem 273:
35355-35361, 1998.
Gorshkova IN, Menschikowski M, and Jaross W:
Alterations in the physiochemical characteristics of
low and high density lipoproteins after lipolysis with
phospholipase A2. A spin-label study. Biochim
Biophys Acta 1300: 103-113, 1996.
Greilberger J, Schmut O, and Jürgens G: In vitro in-
teractions of oxidatively modified LDL with type I,
II, III, IV, and V collagen, laminin, fibronectin, and
poly-D-lysine. Arterioscler Thromb Vasc Biol 17:
2728, 1997.
Groszek E and Grundy SM: The possible role of the
arterial microcirculation in the pathogenesis of ath-
erosclerosis. J Chron Dis 33: 679-684, 1980.
Guyton JR, Bocan TM, and Schifani TA: Quantita-
tive ultrastructural analysis of perifibrous lipid and
its association with elastin in nonatherosclerotic hu-
man aorta. Arterioscler 5: 644-652, 1985.
Guyton JR and Klemp KF: Ultrastructural discrimi-
nation of lipid droplets and vesicles in atherosclero-
sis: value of osmium-thiocarbohydrazide-osmium and
tannic acid-paraphenylenediamine techniques. J
Histochem Cytochem 36: 1319-1328, 1988.
Guyton JR and Klemp KF: The lipid-rich core re-
gion of human atherosclerotic fibrous plaques. Preva-
lence of small lipid droplets and vesicles by electron
microscopy. Am J Pathol 134: 705-717, 1989.
Guyton JR, Klemp KF, Black BL, and Bocan TM:
Extracellular lipid deposition in atherosclerosis. Eur
Heart J 11 Suppl E: 20-28, 1990.
Guyton JR, Klemp KF, and Mims MP: Altered ul-
trastructural morphology of self-aggregated low den-
sity lipoproteins: coalescence of lipid domains form-
ing droplets and vesicles. J Lipid Res 32: 953-962,
1991.
Guyton JR and Klemp KF: Early extracellular and
cellular lipid deposits in aorta of cholesterol-fed rab-
bits. Am J Pathol 141: 925-936, 1992.
Guyton JR and Klemp KF: Transitional features in
human atherosclerosis. Intimal thickening, cholesterol
clefts, and cell loss in human aortic fatty streaks. Am
J Pathol 143: 1444-1457, 1993.
Guyton JR and Klemp KF: Development of the ath-
erosclerotic core region. Chemical and ultrastructural
analysis of microdissected atherosclerotic lesions
from human aorta. Arterioscler Thromb 14: 1305-
1314, 1994.
Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG,
Epstein, SE, and Finkel T: In vivo suppression of
injury-induced vascular smooth muscle cell accumu-
lation using adenovirus-mediated transfer of the her-
pes simplex virus thymidine kinase gene. Proc Natl
Acad Sci U S A 91: 10732-10736, 1994.
Haberland ME, Olch CL, and Folgelman AM: Role
of lysines in mediating interaction of modified low
density lipoproteins with the scavenger receptor of
human monocyte macrophages. J Biol Chem 259:
11305-11311, 1984.
Haberland ME, Cheng L, and Fong D:
Malondialdehyde-altered protein occurs in atheroma
of Watanabe heritable hyperlipidemic rabbits. Sci-
ence 241: 215-218, 1988.
Hakala JK, Öörni K, Ala-Korpela M, and Kovanen
PT: Lipolytic modification of LDL by phospholipase
A2 induces particle aggregation in the absence and
fusion in the presence of heparin. Arterioscler Thromb
Vasc Biol 19: 1276-1283, 1999.
Havel RJ, Eder HA, and Bragdon JH: The distribu-
tion and chemical composition of ultracentrifugally
separated lipoproteins in human serum. J Clin Invest
34: 1345-1353, 1955.
Hazell LJ and Stocker R: Oxidation of low-density
lipoprotein with hypochlorite causes transformation
of the lipoprotein into a high-uptake form for mac-
rophages. Biochem J 290: 165-172, 1993.
References
60
Hazell LJ, van den Berg JJ, and Stocker R: Oxidation
of low-density lipoprotein by hypochlorite causes
aggregation that is mediated by modification of lysine
residues rather than lipid oxidation. Biochem J 302:
297-304, 1994.
Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E,
and Stocker R: Presence of hypochlorite-modified
proteins in human atherosclerotic lesions. J Clin In-
vest 97: 1535-1544, 1996.
Hazen SL and Heinecke JW: 3-Chlorotyrosine, a
specific marker of myeloperoxidase-catalyzed oxi-
dation, is markedly elevated in low density lipopro-
tein isolated from human atherosclerotic intima. J Clin
Invest 99: 2075-2081, 1997.
Heinecke JW, Li W, Daehnke HL, and Goldstein JA:
Dityrosine, a specific marker of oxidation, is synthe-
sized by the myeloperoxidase-hydrogen peroxide
system of human neutrophils and macrophages. J Biol
Chem 268: 4069-4077, 1993.
Hendriks WL, van der Boom H, van Vark LC, and
Havekes LM: Lipoprotein lipase stimulates the bind-
ing and uptake of moderately oxidized low-density
lipoprotein by J774 macrophages. Biochem J 314:
563-568, 1996.
Hendriks WL, van Vark LC, Schoonderwoerd K,
Jansen H, and Havekes LM: Not the mature 56 kDa
lipoprotein lipase protein but a 37 kDa protein co-
purifying with the lipase mediates the binding of low
density lipoproteins to J774 macrophages. Biochem
J 330: 765-769, 1998.
Henney AM, Wakeley PR, Davies MJ, Foster K,
Hembry R, Murphy G, and Humphries S: Localiza-
tion of stromelysin gene expression in atherosclerotic
plaques by in situ hybridization. Proc Natl Acad Sci
U S A 88: 8154-8158, 1991.
Hessler JR, Morel DW, Lewis LJ, and Chisolm GM:
Lipoprotein oxidation and lipoprotein-induced cyto-
toxicity. Arterioscler 3: 215-222, 1983.
Hiltunen Y, Ala-Korpela M, Jokisaari J, Eskelinen
S, Kiviniitty K, Savolainen M, and Kesaniemi YA:
A lineshape fitting model for 1H NMR spectra of
human blood plasma. Magnetic Resonance in Medi-
cine 21: 222-232, 1991.
Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper
NJ, Quintana L, Kronmal, GS, Cooper AD, and
Quertermous T: Cloning of a unique lipase from en-
dothelial cells extends the lipase gene family. J Biol
Chem 274: 14170-14175, 1999.
Hirose N, Blankenship DT, Krivanek MA, Jackson
RL, and Cardin AD: Isolation and characterization
of four heparin-binding cyanogen bromide peptides
of human plasma apolipoprotein B. Biochemistry 26:
5505-5512, 1987.
Hoff HF, Jackson RL, Mao SJT, and Gotto AM, Jr.:
Localization of low-density lipoproteins in athero-
sclerotic lesions from human normolipemics employ-
ing a purified fluorescent-labeled antibody. Biochim
Biophys Acta 351: 407-415, 1974.
Hoff HF, Jackson RL, and Gotto AM, Jr.: Apo-lipo-
protein localization in human atherosclerotic arter-
ies. Adv Exp Med Biol 67: 109-120, 1976.
Hoff HF and Gaubatz JW: Ultrastructural localiza-
tion of apolipoprotein B in human aortic and coro-
nary atherosclerotic plaques. Exp Mol Pathol 26: 214-
227, 1977.
Hoff HF, Heideman CL, Gaubatz JW, Scott DW,
Titus JL, and Gotto AM, Jr.: Correlation of
apolipoprotein B retention with the structure of ath-
erosclerotic plaques from human aortas. Lab Invest
38: 560-567, 1978a.
Hoff HF, Heideman CL, Gaubatz JW, Scott DW, and
Gotto AM, Jr.: Detergent extraction of tightly-bound
apoB from extracts of normal aortic intima and
plaques. Exp Mol Pathol 28: 290-300, 1978b.
Hoff HF, Heideman CL, Gaubatz JW, Titus JL, and
Gotto AM, Jr.: Quantitation of apo B in human aor-
tic fatty streaks. A comparison with grossly normal
intima and fibrous plaques. Atherosclerosis 30: 263-
272, 1978c.
Hoff HF and Gaubatz JW: Residual apo B in aortic
plaques extracted with hydrolytic enzymes. Artery
6: 89-107, 1979.
Hoff HF and Bond MG: Accumulation of lipopro-
teins containing Apo B in the aorta of cholesterol-
fed cynomolgus monkeys. Atherosclerosis 43: 329-
339, 1982.
Hoff HF and Gaubatz JW: Isolation, purification, and
characterization of a lipoprotein containing Apo B
from the human aorta. Atherosclerosis 42: 273-297,
1982.
Hoff HF and Bond MG: Apolipoprotein B localiza-
tion in coronary atherosclerotic plaques from cyno-
molgus monkeys. Artery 12: 104-116, 1983.
References
61
Hoff HF, O’Neil J, Chisolm GM, Cole TB,
Quehenberger O, Esterbauer H, and Jurgens G: Modi-
fication of low density lipoprotein with 4-
hydroxynonenal induces uptake by macrophages.
Arterioscler 9: 538-549, 1989.
Hoff HF and O’Neil J: Lesion-derived low density
lipoprotein and oxidized low density lipoprotein share
a lability for aggregation, leading to enhanced mac-
rophage degradation. Arterioscler Thromb 11: 1209-
1222, 1991.
Hoff HF, O’Neil J, and Cole TB: Macrophage deg-
radation of LDL extracted from human aortic plaques:
effect of isolation conditions. Exp Mol Pathol 54:
72-86, 1991.
Hoff HF, Whitaker TE, and O’Neil J: Oxidation of
low density lipoprotein leads to particle aggregation
and altered macrophage recognition. J Biol Chem 267:
602-609, 1992.
Hollander W: Unified concept on the role of acid
mucopolysaccharides and connective tissue proteins
in the accumulation of lipids, lipoproteins and cal-
cium on the atherosclerotic plaque. Exp Mol Pathol
25: 106-120, 1976.
Hollander W, Paddock J, and Colombo M: Lipopro-
teins in human atherosclerotic vessels. I. Biochemi-
cal properties of arterial low density lipoproteins, very
low density lipoproteins, and high density lipopro-
teins. Exp Mol Pathol 30: 144-171, 1979.
Hollmann J, Schmidt A, von Bassewitz DB, and
Buddecke E: Relationship of sulfated glycosami-
noglycans and cholesterol content in normal and ar-
teriosclerotic human aorta. Arterioscler 9: 154-158,
1989.
Holopainen JM, Subramanian M, and Kinnunen PKJ:
Sphingomyelinase induces lipid microdomain forma-
tion in a fluid phosphatidylcholine/sphingomyelin
membrane. Biochemistry 37: 17562-17570, 1998.
Hoover GA, McCormick S, and Kalant N: Interac-
tion of native and cell-modified low density lipopro-
tein with collagen gel. Arterioscler 8: 525-534, 1988.
Hulten LM, Lindmark H, Diczfalusy U, Bjorkhem I,
Ottosson M, Liu Y, Bondjers G, and Wiklund O:
Oxysterols present in atherosclerotic tissue decrease
the expression of lipoprotein lipase messenger RNA
in human monocyte-derived macrophages. J Clin
Invest 97: 461-468, 1996.
Hurt-Camejo E, Camejo G, Rosengren B, Lopez F,
Wiklund O, and Bondjers G: Differential uptake of
proteoglycan-selected subfractions of low density li-
poprotein by human macrophages. J Lipid Res 31:
1387-1398, 1990.
Hurt-Camejo E, Camejo G, Rosengren B, Lopez F,
Ahlstrom C, and Fager G: Effect of arterial
proteoglycans and glycosaminoglycans on low den-
sity lipoprotein oxidation and its uptake by human
macrophages and arterial smooth muscle cells.
Arterioscler Thromb 12: 569-583, 1992.
Hurt-Camejo E, Andersen S, Standal R, Rosengren
B, Sartipy P, Stadberg, and Johansen B: Localiza-
tion of nonpancreatic secretory phospholipase A2 in
normal and atherosclerotic arteries. Activity of the
isolated enzyme on low-density lipoproteins.
Arterioscler Thromb Vasc Biol 17: 300-309, 1997.
Hurt-Camejo E and Camejo G: Potential involvement
of type II phospholipase A2 in atherosclerosis. Ath-
erosclerosis 132: 1-8, 1997.
Hwang T-L and Shaka AJ: Water suppression that
works - excitation sculpting using arbitrary wave-
forms and pulse-field gradients. J Magn Reson 112A:
275-279, 1995.
Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida
Y, Imanaka T, and Takano: A monoclonal antibody
against oxidized lipoprotein recognizes foam cells in
atherosclerotic lesions. Complex formation of oxi-
dized phosphatidylcholines and polypeptides. J Biol
Chem 269: 15274-15279, 1994.
Iverius PH: The interaction between human plasma
lipoproteins and connective tissue glycosaminogly-
cans. J Biol Chem 247: 2607-2613, 1972.
Jaye M, Lynch KJ, Krawiec T, Marchadier D,
Maugeais C, Doan K, South V, Amin D, Perrone M,
and Rader DJ: A novel endothelial-derived lipase that
modulates HDL metabolism. Nat Genet 21: 424-428,
1999.
Jimi S, Sakata N, Matunaga A, and Takebayashi S:
Low density lipoproteins bind more to type I and III
collagens by negative charge-dependent mechanisms
than to type IV and V collagens. Atherosclerosis 107:
109-116, 1994.
Jonasson L, Bondjers G, and Hansson GK: Lipopro-
tein lipase in atherosclerosis: its presence in smooth
muscle cells and absence from macrophages. J Lipid
Res 28: 437-445, 1987.
References
62
Kaartinen M, Penttilä A, and Kovanen PT: Mast cells
of two types differing in neutral protease composi-
tion in the human aortic intima. Demonstration of
tryptase- and tryptase/chymase-containing mast cells
in normal intimas, fatty streaks, and the shoulder re-
gion of atheromas. Arterioscler Thromb 14: 966-972,
1994.
Kalant N and McCormick S: Inhibition by serum
components of oxidation and collagen-binding of
low-density lipoprotein. Biochim Biophys Acta 1128:
211-219, 1992.
Kalant N, McCormick S, and Parniak MA: Effects
of copper and histidine on oxidative modification of
low density lipoprotein and its subsequent binding
to collagen. Arterioscler Thromb 11: 1322-1329,
1991.
Kalant N, McCormick S, and Parniak MA: Non-en-
zymic glycation of collagen inhibits binding of oxi-
dized low-density lipoprotein. Biochem J 293: 661-
666, 1993.
Kao CH, Chen JK, and Yang VC: Ultrastructure and
permeability of endothelial cells in branched regions
of rat arteries. Atherosclerosis 105: 97-114, 1994.
Kao CH, Chen JK, Kuo JS, and Yang VC: Visual-
ization of the transport pathways of low density li-
poproteins across the endothelial cells in the branched
regions of rat arteries. Atherosclerosis 116: 27-41,
1995.
Kawabe Y, Cynshi O, Takashima Y, Suzuki T, Ohba
Y, and Kodama T: Oxidation-induced aggregation
of rabbit low-density lipoprotein by azo initiator. Arch
Biochem Biophys 310: 489-496, 1994.
Khoo JC, Miller E, McLoughlin P, and Steinberg D:
Enhanced macrophage uptake of low density lipo-
protein after self- aggregation. Arterioscler 8: 348-
358, 1988.
Khoo JC, Miller E, McLoughlin P, and Steinberg D:
Prevention of low density lipoprotein aggregation by
high density lipoprotein or apolipoprotein A-I. J Lipid
Res 31: 645-652, 1990.
Kleinman Y, Krul ES, Burnes M, Aronson W, Pfleger
B, and Schonfeld G: Lipolysis of LDL with phos-
pholipase A2 alters the expression of selected apoB-
100 epitopes and the interaction of LDL with cells. J
Lipid Res 29: 729-743, 1988.
Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC,
Jr., Innerarity TL, Blackhart B, Taylor WH, Marcel
Y, and Milne R: Complete protein sequence and iden-
tification of structural domains of human
apolipoprotein B. Nature 323: 734-738, 1986.
Kokkonen JO and Kovanen PT: Proteolytic enzymes
of mast cell granules degrade low density lipopro-
teins and promote their granule-mediated uptake by
macrophages in vitro. J Biol Chem 264: 10749-10755,
1989.
Kovanen PT and Kokkonen JO: Modification of low
density lipoproteins by secretory granules of rat se-
rosal mast cells. J Biol Chem 266: 4430-4436, 1991.
Kovanen PT: Mast cells in human fatty streaks and
atheromas: implications for intimal lipid accumula-
tion. Curr Opin Lipidol 7: 281-286, 1996.
Kovanen PT and Pentikäinen MO: Decorin links low-
density lipoproteins (LDL) to collagen. A novel
mechanism for retention and accumulation of LDL in
the atherosclerotic plaque. Trends Cardiovasc Med
9: 86-91, 1999.
Kramsch DM and Hollander W: The interaction of
serum and arterial lipoproteins with elastin of the ar-
terial intima and its role in the lipid accumulation in
atherosclerotic plaques. J Clin Invest 52: 236-247,
1973.
Kroon PA: The order-disorder transition of the core
cholesteryl esters of human plasma low density lipo-
protein. A proton nuclear magnetic resonance study.
J Biol Chem 256: 5332-5339, 1981.
Kroon PA: Fluorescence study of the motional states
of core and surface lipids in native and reconstituted
low density lipoproteins. Biochemistry 33: 4879-
4884, 1994.
Kruth HS: Filipin-positive, oil red O-negative par-
ticles in atherosclerotic lesions induced by choles-
terol feeding. Lab Invest 50: 87-93, 1984a.
Kruth HS: Localization of unesterified cholesterol in
human atherosclerotic lesions. Demonstration of
filipin-positive, oil- red-O-negative particles. Am J
Pathol 114: 201-208, 1984b.
Kruth HS and Shekhonin B: Evidence for loss of apo
B from LDL in human atherosclerotic lesions: extra-
cellular cholesteryl ester lipid particles lacking apo
B. Atherosclerosis 105: 227-234, 1994.
Kruth HS: Cholesterol deposition in atherosclerotic
lesions. Subcellular Biochem 28: 319-362, 1997.
References
63
Kwon HM, Sangiorgi G, Spagnoli LG, Miyauchi K,
Holmes DRJ, Schwartz, RS, and Lerman A: Experi-
mental hypercholesterolemia induces ultrastructural
changes in the internal elastic lamina of porcine coro-
nary arteries. Atherosclerosis 139: 283-289, 1998.
Kühn H, Belkner J, Zaiss S, Fährenklemper T, and
Wohlfeil S: Involvement of 15-lipoxygenase in early
stages of atherogenesis. J Exp Med 179: 1903-1911,
1994.
Kühn H, Heydeck D, Hugou I, and Gniwotta C: In
vivo action of 15-lipoxygenase in early stages of
human atherogenesis. J Clin Invest 99: 888-893,
1997.
Laemmli UK: Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Na-
ture 227: 680-685, 1970.
Lamb DJ, Mitchinson MJ, and Leake DS: Transition
metal ions within human atherosclerotic lesions can
catalyse the oxidation of low density lipoprotein by
macrophages. FEBS Lett 374: 12-16, 1995.
Law SW, Grant SM, Higuchi K, Hospattankar A,
Lackner K, Lee N, and Brewer HB, Jr.: Human liver
apolipoprotein B-100 cDNA: complete nucleic acid
and derived amino acid sequence. Proc Natl Acad
Sci U S A 83: 8142-8146, 1986.
Leake DS, Rankin SM, and Collard J: Macrophage
proteases can modify low density lipoproteins to in-
crease their uptake by macrophages. FEBS Lett 269:
209-212, 1990.
LeBaron RG, Zimmermann DR, and Ruoslahti E:
Hyaluronate binding properties of versican. J Biol
Chem 267: 10003-10010, 1992.
Lee FY, Lee TS, Pan CC, Huang AL, Chau, and LY:
Colocalization of iron and ceroid in human athero-
sclerotic lesions. Atherosclerosis 138: 281-288, 1998.
Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P,
Oh-ishi S, Steinbrecher UP, and Heinecke JW: Re-
active nitrogen intermediates promote low density
lipoprotein oxidation in human atherosclerotic intima.
J Biol Chem 272: 1433-1436, 1997a.
Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller
DM, Pennathur S, and Heinecke JW: Mass spectro-
metric quantification of markers for protein oxida-
tion by tyrosyl radical, copper, and hydroxyl radical
in low density lipoprotein isolated from human ath-
erosclerotic plaques. J Biol Chem 272: 3520-3526,
1997b.
Li F and Hui DY: Modified low density lipoprotein
enhances the secretion of bile salt-stimulated choles-
terol esterase by human monocyte-macrophages.
Species-specific difference in macrophage cholesteryl
ester hydrolase. J Biol Chem 272: 28666-28671,
1997.
Li F and Hui DY: Synthesis and secretion of the pan-
creatic-type carboxyl ester lipase by human endothe-
lial cells. Biochem J 329: 675-679, 1998.
Lindén T, Bondjers G, Camejo G, Bergstrand R,
Wilhelmsen L, and Wiklund O: Affinity of LDL to a
human arterial proteoglycan among male survivors
of myocardial infarction. Eur J Clin Invest 19: 38-
44, 1989.
Linton MF, Atkinson JB, and Fazio S: Prevention of
atherosclerosis in apolipoprotein E-deficient mice by
bone marrow transplantation. Science 267: 1034-
1037, 1995.
Liu H, Scraba DG, and Ryan RO: Prevention of phos-
pholipase-C induced aggregation of low density li-
poprotein by amphipathic apolipoproteins. FEBS Lett
316: 27-33, 1993.
Lookene A, Groot NB, Kastelein JJP, Olivecrona G,
and Bruin T: Mutation of tryptophan  residues in li-
poprotein lipase. Effects on stability, immunoreac-
tivity, and catalytic properties. J Biol Chem 272: 766-
772, 1997a.
Lookene A, Savonen R, and Olivecrona G: Interac-
tion of lipoproteins with heparan sulfate
proteoglycans and with lipoprotein lipase. Studies by
surface plasmon resonance technique. Biochemistry
36: 5267-5275, 1997b.
Lounila J, Ala-Korpela M, Jokisaari J, Savolainen
MJ, and Kesäniemi YA: Effects of orientational or-
der and particle size on the NMR line positions of
lipoproteins. Phys Rev Lett 72: 4049-4052, 1994.
Lucas M, Iverius P-H, Strickland DK, and Mazzone
T: Lipoprotein lipase reduces secretion of
apolipoprotein E from macrophages. J Biol Chem
272: 13000-13005, 1997.
Lund-Katz S and Phillips MC: Packing of choles-
terol molecules in human low-density lipoprotein.
Biochemistry 25: 1562-1568, 1986.
References
64
Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH,
Brown JH, and Gross E: Inhibition of lipoprotein
binding to cell surface receptors of fibroblasts fol-
lowing selective modification of arginyl residues in
arginine-rich and B apoproteins. J Biol Chem 252:
7279-7287, 1977.
Mahley RW, Weisgraber KH, and Innerarity TL: In-
teraction of plasma lipoproteins containing
apolipoproteins B and E with heparin and cell sur-
face receptors. Biochim Biophys Acta 575: 81-91,
1979.
Mahley RW and Huang Y: Apolipoprotein E: from
atherosclerosis to Alzheimer’s disease and beyond.
Curr Opin Lipidol 10: 207-217, 1999.
Makino K, Furbee JW, Jr., Scanu AM, and Fless GM:
Effect of glycation on the properties of lipoprotein(a).
Arterioscler Thromb Vasc Biol 15: 385-391, 1995.
Makoveichuk E, Lookene A, and Olivecrona G: Mild
oxidation of lipoproteins increases their affinity for
surfaces covered by heparan sulfate and lipoprotein
lipase. Biochem Biophys Res Commun 252: 703-710,
1998.
Mamo JC and Wheeler JR: Chylomicrons or their
remnants penetrate rabbit thoracic aorta as efficiently
as do smaller macromolecules, including low-den-
sity lipoprotein, high-density lipoprotein, and albu-
min. Coronary Artery Dis 5: 695-705, 1994.
Mann WA, Meyer N, Berg D, Greten H, and Beisiegel
U: Lipoprotein lipase compensates for the defective
function of apo E variants in vitro by interacting with
proteoglycans and lipoprotein receptors. Atheroscle-
rosis 145: 61-69, 1999.
Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer
R, Williams KJ, and Tabas I: Human vascular endot-
helial cells are a rich and regulatable source of secre-
tory sphingomyelinase. Implications for early athero-
genesis and ceramide-mediated cell signaling. J Biol
Chem 273: 4081-4088, 1998.
Marathe S, Kuriakose G, Williams KJ, and Tabas I:
Sphingomyelinase, an enzyme implicated in
atherogenesis, is present in atherosclerotic lesions and
binds to specific components of the subendothelial
extracellular matrix. Arterioscler Thromb Vasc Biol
19:2648-2658, 1999.
Masuda J and Ross R: Atherogenesis during low level
hypercholesterolemia in the nonhuman primate. I.
Fatty streak formation. Arterioscler 10: 164-177,
1990.
Mattjus P and Slotte JP: Does cholesterol discrimi-
nate between sphingomyelin and phosphatidylcho-
line in mixed monolayers containing both phospho-
lipids? Chemistry & Physics of Lipids 81: 69-80,
1996.
Mayne R: Collagenous proteins of blood vessels.
Arterioscler 6: 585-593, 1986.
Mazzone T and Reardon C: Expression of heterolo-
gous human apolipoprotein E by J774 macrophages
enhances cholesterol efflux to HDL3. J Lipid Res 35:
1345-1353, 1994.
McFarlane AS: Efficient trace-labelling of proteins
with iodine. Nature 182: 53, 1958.
Menschikowski M, Kasper M, Lattke P, Schiering
A, Schiefer S, Stockinger H, and Jaross W: Secre-
tory group II phospholipase A2 in human atheroscle-
rotic plaques. Atherosclerosis 118: 173-181, 1995.
Mora R, Lupu F, and Simionescu N: Prelesional
events in atherogenesis. Colocalization of
apolipoprotein B, unesterified cholesterol and extra-
cellular phospholipid liposomes in the aorta of hy-
perlipidemic rabbit. Atherosclerosis 67: 143-154,
1987a.
Mora R, Lupu F, and Simionescu N: Cytochemical
localization of beta-lipoproteins and their components
in successive stages of hyperlipidemic atherogenesis
of rabbit aorta. Atherosclerosis 79: 183-195, 1989b.
Morton RE, West GA, and Hoff HF: A low density
lipoprotein-sized particle isolated from human ath-
erosclerotic lesions is internalized by macrophages
via a non-scavenger-receptor mechanism. J Lipid Res
27: 1124-1134, 1986.
Murdoch AD, Liu B, Schwarting R, Tuan RS, and
Iozzo RV: Widespread expression of perlecan
proteoglycan in basement membranes and extracel-
lular matrices of human tissues as detected by a novel
monoclonal antibody against domain III and by in
situ hybridization. J Histochem Cytochem 42: 239-
249, 1994.
Murphy HC, Ala-Korpela M, White JJ, Raoof A, Bell
JD, Barnard ML, Burns SP, and Iles RA: Evidence
for distinct behaviour of phosphatidylcholine and
sphingomyelin at the low density lipoprotein surface.
Biochem Biophys Res Commun 234: 733-737, 1997.
Musliner TA and Krauss RM: Lipoprotein subspe-
cies and risk of coronary disease. Clinical Chemistry
34: B78-B83, 1988.
References
65
Nakashima Y, Ferrante ND, Jackson RL, and Pownall
HJ: The interaction of human plasma
glycoaminoglycans with plasma lipoproteins. J Biol
Chem 250: 5386-5392, 1975.
Navab M, Hough GP, Berliner JA, Frank JA, Fogelman
AM, and Haberland ME: Rabbit beta-migrating very
low density lipoprotein increases endothelial macro-
molecular transport without altering electrical resis-
tance. J Clin Invest 78: 389-397, 1986.
Nievelstein PFEM, Fogelman AM, Mottino G, and
Frank JS: Lipid accumulation in rabbit aortic intima
2 hours after bolus infusion of low density lipopro-
tein. A deep-etch and immunolocalization study of
ultrarapidly frozen tissue. Arterioscler Thromb 11:
1795-1805, 1991.
Nievelstein-Post P, Mottino G, Fogelman AM, and
Frank J: An ultrastructural study of lipoprotein accu-
mulation in cardiac valves of the rabbit. Arterioscler
Thromb 14: 1151-1161, 1994.
Nikkari ST, Jarvelainen HT, Wight TN, Ferguson M,
and Clowes AW: Smooth muscle cell expression of
extracellular matrix genes after arterial injury. Am J
Pathol 144: 1348-1356, 1994.
Noma A, Hirayama T, and Yachi A: Studies on the
binding of plasma low density lipoproteins to arte-
rial elastin. Atherosclerosis 11: 123-133, 1982.
Noma A, Hirayama T, and Yachi A: Inhibitory ef-
fect of high density lipoprotein subfractions on the
in vitro binding of low density lipoproteins to arte-
rial elastin. Atherosclerosis 49: 171-175, 1983.
Nordestgaard BG, Hjelms E, Jensen T, and Kjeldsen
K: Different efflux pathways for high and low den-
sity lipoproteins from porcine aortic intima.
Arterioscler 10: 477-485, 1990.
O’Brien KD, Gordon D, Deeb S, Ferguson M, and
Chait A: Lipoprotein lipase is synthesized by mac-
rophage-derived foam cells in human coronary ath-
erosclerotic plaques. J Clin Invest 89: 1544-1550,
1992.
O’Brien KD, Deeb SS, Ferguson M, McDonald TO,
Allen MD, Alpers CE, and Chait A: Apolipoprotein
E localization in human coronary atherosclerotic
plaques by in situ hybridization and immunohis-
tochemistry and comparison with lipoprotein lipase.
Am J Pathol 144: 538-548, 1994.
O’Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson
M, Hudkins K, Wight, TN, and Chait A: Compari-
son of apolipoprotein and proteoglycan deposits in
human coronary atherosclerotic plaques:
colocalization of biglycan with apolipoproteins. Cir-
culation 98: 519-527, 1998.
Olsson U, Bondjers G, and Camejo G: Fatty acids
modulate the composition of extracellular matrix in
cultured human arterial smooth muscle cells by al-
tering the expression of genes for proteoglycan core
proteins. Diabetes 48: 616-622, 1999.
Orekhov AN, Tertov VV, Mukhin DN, Koteliansky
VE, Glukhova MA, Khashimov KA, and Smirnov
VN: Association of low-density lipoprotein with par-
ticulate connective tissue matrix components en-
hances cholesterol accumulation in cultured suben-
dothelial cells of human aorta. Biochim Biophys Acta
928: 251-258, 1987.
Otvos JD, Jeyarajah EJ, Bennett DW, and Krauss
RM: Development of a proton nuclear magnetic reso-
nance spectroscopic method for determining plasma
lipoprotein concentrations and subspecies distribu-
tions from a single, rapid measurement. Clinical Chem-
istry 38: 1632-1638, 1992.
Paananen K and Kovanen PT: Proteolysis and fusion
of low density lipoprotein particles independently
strengthen their binding to exocytosed mast cell gran-
ules. J Biol Chem 269: 2023-2031, 1994.
Paananen K, Saarinen J, Annila A, and Kovanen PT:
Proteolysis and fusion of low density lipoprotein
particles strengthen their binding to human aortic
proteoglycans. J Biol Chem 270: 12257-12262, 1995.
Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner
GC, Socher SS, Butler, SW, Parthasarathy S, Carew
TE, Steinberg D, and Witztum JL: Low density lipo-
protein undergoes oxidative modification in vivo.
Proc Natl Acad Sci U S A 86: 1372-1376, 1989.
Pasquali-Ronchetti I, Fornieri C, Baccarani-Contri M,
and Quaglino D: Ultrastructure of elastin. Ciba Foun-
dation Symposium 192: 31-42, 1995.
Pasquinelli G, Preda P, Vici M, Gargiulo M, Stella
A, D’Addato M, and Laschi R: Electron microscopy
of lipid deposits in human atherosclerosis. Scanning
Microsc 3: 1151-1159, 1989.
Penn MS, Rangaswamy S, Saidel GM, and Chisolm
GM: Macromolecular transport in the arterial intima:
comparison of chronic and acute injuries. Am J
Physiol 272: H1560-H1570, 1997.
References
66
Pentikäinen MO, Öörni K, and Kovanen PT: Hy-
pochlorite oxidizes lysine residues of heparin-bound
LDL, and releases LDL from immobilized heparin.
Atherosclerosis 134: 216, 1997. Abstract.
Pentikäinen MO, Öörni K, Ala-Korpela M, and
Kovanen PT: Modified LDL - trigger of inflammation
and atherosclerosis in the arterial intima. J Intern Med,
2000, In Press.
Piha M, Lindstedt L, and Kovanen PT: Fusion of
proteolyzed LDL in the fluid phase: a novel mecha-
nism generating atherogenic lipoprotein particles.
Biochemistry 34: 10120-10129, 1995.
Pillarisetti S, Paka L, Sasaki A, Vanni-Reyes T, Yin
B, Parthasarathy N, Wagner WD, and Goldberg IJ:
Endothelial cell heparanase modulation of lipopro-
tein lipase activity. Evidence that heparan sulfate oli-
gosaccharide is an extracellular chaperone. J Biol
Chem 272: 15753-15759, 1997.
Podet EJ, Shaffer DR, Gianturco SH, Bradley WA,
Yang CY, and Guyton JR: Interaction of low density
lipoproteins with human aortic elastin. Arterioscler
Thromb 11: 116-122, 1991.
Polacek D, Byrne RE, and Scanu AM: Modification
of low density lipoproteins by polymorphonuclear
cell elastase leads to enhanced uptake by human
monocyte-derived macrophages via the low density
lipoprotein receptor pathway. J Lipid Res 29: 797-
808, 1988.
Pollard H, Scanu AM, and Taylor EW: On the geo-
metrical arrangement of the protein subunits of hu-
man serum low-density lipoprotein: evidence for a
dodecahedral model. Proc Natl Acad Sci U S A 64:
304-310, 1969.
Porn MI, Ares MP, and Slotte JP: Degradation of
plasma membrane phosphatidylcholine appears not
to affect the cellular cholesterol distribution. J Lipid
Res 34: 1385-1392, 1993.
Portman OW and Alexander M: Metabolism of
sphingolipids by normal and atherosclerotic aorta of
squirrel monkeys. J Lipid Res  11: 23-30, 1970.
Posner I, Wang C-S, and McConathy WJ: The com-
parative kinetics of soluble and heparin-Sepharose-
immobilized bovine lipoprotein lipase. Arch Biochem
Biophys 226: 306-316, 1983.
Proctor SD and Mamo JC: Retention of fluorescent-
labelled chylomicron remnants within the intima of
the arterial wall—evidence that plaque cholesterol
may be derived from post-prandial lipoproteins. Eur
J Clin Invest 28: 497-503, 1998.
Rachmilewitz D, Eisenberg S, Stein Y, and Stein O:
Phospholipases in arterial tissue. I. Sphingomyelin
cholinephosphohydrolase activity in human, dog,
guinea pig, rat and rabbit arteries. Biochim Biophys
Acta 144: 624-632, 1967.
Radhakrishnamurthy B, Ruiz HA, Jr., and Berenson
GS: Isolation and characterization of proteoglycans
from bovine aorta. J Biol Chem 252: 4831-4841,
1977.
Radhakrishnamurthy B, Tracy RE, Dalferes ERJ, and
Berenson GS: Proteoglycans in human coronary ar-
teriosclerotic lesions. Exp Mol Pathol 65: 1-8, 1998.
Rapp JH, Lespine A, Hamilton RL, Colyvas N,
Chaumeton, AH, Tweedie-Hardman J, Kotite L,
Kunitake ST, Havel RJ, and Kane JP: Triglyceride-
rich lipoproteins isolated by selected-affinity anti-
apolipoprotein B immunosorption from human ath-
erosclerotic plaque. Arterioscler Thromb 14: 1767-
1774, 1994.
Redgrave TG, Roberts DCK, and West CE: Separa-
tion of plasma lipoproteins by density-gradient ul-
tracentrifugation. Anal Biochem 65: 42-49, 1975.
Renier G, Skamene E, DeSanctis JB, and Radzioch
D: High macrophage lipoprotein lipase expression
and secretion are associated in inbred murine strains
with susceptibility to atherosclerosis. Arterioscler
Thromb 13: 190-196, 1993.
Riessen R, Isner JM, Blessing E, Loushin C, Nikol
S, and Wight TN: Regional differences in the distri-
bution of the proteoglycans biglycan and decorin in
the extracellular matrix of atherosclerotic and
restenotic human coronary arteries. Am J Pathol 144:
962-974, 1994.
Robert L, Robert AM, and Jacotot B: Elastin-elastase-
atherosclerosis revisited. Atherosclerosis 140: 281-
295, 1998.
Rokosova B, Rapp JH, Porter JM, and Bentley JP:
Composition and metabolism of symptomatic distal
aortic plaque. J Vasc Surg 3: 617-622, 1986.
References
67
Romano M, Romano E, Bjorkerud S, and Hurt-
Camejo E: Ultrastructural localization of secretory
type II phospholipase A2 in atherosclerotic and
nonatherosclerotic regions of human arteries.
Arterioscler Thromb Vasc Biol 18: 519-525, 1998.
Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, and
Zhang L: Heparan sulfate proteoglycans of the car-
diovascular system. Specific structures emerge but
how is synthesis regulated?. [Review] [88 refs]. J Clin
Invest 99: 2062-2070, 1997.
Rutledge JC and Goldberg IJ: Lipoprotein lipase (LpL)
affects low density lipoprotein (LDL) flux through
vascular tissue: evidence that LpL increases LDL ac-
cumulation in vascular tissue. J Lipid Res 35: 1152-
1160, 1994.
Rutledge JC, Woo MM, Rezai AA, Curtiss LK, and
Goldberg IJ: Lipoprotein lipase increases lipoprotein
binding to the artery wall and increases endothelial
layer permeability by formation of lipolysis products.
Circ Res 80: 819-828, 1997.
Sakata N, Imanaga Y, Meng J, Tachikawa Y,
Takebayashi S, Nagai R, Horiuchi S, Itabe H, and
Takano T: Immunohistochemical localization of dif-
ferent epitopes of advanced glycation end products
in human atherosclerotic lesions. Atherosclerosis 141:
61-75, 1998.
Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S,
Korpela H, Salonen R, Nyyssonen K, Palinski W,
and Witztum JL: Autoantibody against oxidised LDL
and progression of carotid atherosclerosis. Lancet
339: 883-887, 1992.
Sambandam T, Baker JR, Christner JE, and Ekborg
SL: Specificity of the low density lipoprotein-gly-
cosaminoglycan interaction. Arterioscler Thromb 11:
561-568, 1991.
Sandberg LB, Soskel NT, and Leslie JG: Elastin struc-
ture, biosynthesis, and relation to disease states. N
Engl J Med 304: 566-579, 1981.
Sando GN, Ma GP, Lindsley KA, and Wei YP: In-
tercellular transport of lysosomal acid lipase medi-
ates lipoprotein cholesteryl ester metabolism in a
human vascular endothelial cell-fibroblast coculture
system. Cell Regulation 1: 661-674, 1990.
Sartipy P, Johansen B, Camejo G, Rosengren B,
Bondjers G, and Hurt-Camejo E: Binding of human
phospholipase A2 type II to proteoglycans. Differ-
ential effect of glycosaminoglycans on enzyme ac-
tivity. J Biol Chem 271: 26307-26314, 1996.
Sartipy P, Bondjers G, and Hurt-Camejo E: Phos-
pholipase A(2) type-II binds to extracellular matrix
biglycan - Modulation of its activity on LDL by
colocalization in glycosaminoglycan matrixes.
Arterioscler Thromb Vasc Biol 18: 1934-1941, 1998.
Saxena U, Witte LD, and Goldberg IJ: Release of en-
dothelial cell lipoprotein lipase by plasma lipopro-
teins and free fatty acids. J Biol Chem 264: 4349-
4355, 1989.
Saxena U, Klein MG, Vanni TM, and Goldberg IJ:
Lipoprotein lipase increases low density lipoprotein
retention by subendothelial cell matrix. J Clin Invest
89: 373-380, 1992.
Saxena U, Ferguson E, Auerbach BJ, and Bisgaier
CL: Lipoprotein lipase facilitates very low density
lipoprotein binding to the subendothelial cell matrix.
Biochem Biophys Res Commun 194: 769-774, 1993b.
Saxena U, Ferguson E, and Bisgaier CL:
Apolipoprotein E modulates low density lipoprotein
retention by lipoprotein lipase anchored to subendot-
helial matrix. J Biol Chem 268: 14812-14819, 1993a.
Schissel SL, Schuchman EH, Williams KJ, and Tabas
I: Zn2+-stimulated sphingomyelinase is secreted by
many cell types and is a product of the acid
sphingomyelinase gene. J Biol Chem 271: 18431-
18436, 1996.
Schissel SL, Tweedie-Hardman J, Rapp JH, Graham
G, Williams KJ, and Tabas I: Rabbit aorta and human
atherosclerotic lesions hydrolyze the sphingomyelin
of retained low-density lipoprotein. J Clin Invest 98:
1455-1464, 1996.
Schissel SL, Jiang X, Tweedie-Hardman J, Jeong T,
Camejo EH, Najib J, Rapp JH, Williams KJ, and
Tabas I: Secretory sphingomyelinase, a product of
the acid sphingomyelinase gene, can hydrolyze
atherogenic lipoproteins at neutral pH. Implications
for atherosclerotic lesion development. J Biol Chem
273: 2738-2746, 1998.
Schuh J, Fairclough GFJ, and Haschemeyer RH:
Oxygen-mediated heterogeneity of apo-low-density
lipoprotein. Proc Natl Acad Sci U S A 75: 3173-3177,
1978.
Schwenke DC and Carew TE: Initiation of athero-
sclerotic lesions in cholesterol-fed rabbits. II. Selec-
tive retention of LDL vs. selective increases in LDL
permeability in susceptible sites of arteries.
Arterioscler 9: 908-918, 1989a.
References
68
Schwenke DC and Carew TE: Initiation of athero-
sclerotic lesions in cholesterol-fed rabbits. I. Focal
increases in arterial LDL concentration precede de-
velopment of fatty streak lesions. Arterioscler 9: 895-
907, 1989b.
Schönherr E, Järveläinen HT, Sandell LJ, and Wight
TN: Effects of platelet-derived growth factor and
transforming growth factor-beta 1 on the synthesis
of a large versican-like chondroitin sulfate
proteoglycan by arterial smooth muscle cells. J Biol
Chem 266: 17640-17647, 1991.
Schönherr E, Järveläinen HT, Kinsella MG, Sandell
LJ, and Wight TN: Platelet-derived growth factor and
transforming growth factor- beta 1 differentially af-
fect the synthesis of biglycan and decorin by mon-
key arterial smooth muscle cells. Arterioscler Thromb
13: 1026-1036, 1993.
Schönherr E, Witsch-Prehm P, Harrach B, Robenek
H, Rauterberg J, and Kresse H: Interaction of biglycan
with type I collagen. J Biol Chem 270: 2776-2783,
1995.
Seccia M, Albano E, Maggi E, and Bellomo G: Cir-
culating autoantibodies recognizing peroxidase-oxi-
dized low density lipoprotein. Evidence for new an-
tigenic epitopes formed in vivo independently from
lipid peroxidation. Arterioscler Thromb Vasc Biol 17:
134-140, 1997.
Segrest JP, Jones MK, Mishra VK, Anantharamaiah
GM, and Garber DW: apoB-100 has a pentapartite
structure composed of three amphipathic alpha-heli-
cal domains alternating with two amphipathic beta-
strand domains. Detection by the computer program
LOCATE. Arterioscler Thromb 14: 1674-1685, 1994.
Semenkovich CF, Coleman T, and Daugherty A:
Effects of heterozygous lipoprotein lipase deficiency
on diet-induced atherosclerosis in mice. J Lipid Res
39: 1141-1151, 1998.
Shaikh M, Wootton R, Nordestgaard BG, Baskerville
P, Lumley JS, LaVille AE, Quiney J, and Lewis B:
Quantitative studies of transfer in vivo of low den-
sity, Sf 12- 60, and Sf 60-400 lipoproteins between
plasma and arterial intima in humans. Arterioscler
Thromb 11: 569-577, 1991.
Shamir R, Johnson WJ, Morlock-Fitzpatrick K,
Zolfaghari R, Li L, Mas E, Lombardo D, Morel DW,
and Fisher EA: Pancreatic carboxyl ester lipase: a
circulating enzyme that modifies normal and oxidized
lipoproteins in vitro. J Clin Invest 97: 1696-1704,
1996.
Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda
T, Harada K, Katsuki M, Yazaki Y, and Yamada N:
Inhibition of diet-induced atheroma formation in
transgenic mice expressing apolipoprotein E in the
arterial wall. J Clin Invest 95: 469-476, 1995.
Simionescu N, Vasile E, Lupu F, Popescu G, and
Simionescu M: Prelesional events in atherogenesis.
Accumulation of extracellular cholesterol-rich lipo-
somes in the arterial intima and cardiac valves of the
hyperlipidemic rabbit. Am J Pathol 123: 109-125,
1986.
Singh TK, Scraba DG, and Ryan RO: Conversion of
human low density lipoprotein into a very low den-
sity lipoprotein-like particle in vitro. J Biol Chem 267:
9275-9280, 1992.
Sivaram P, Choi SY, Curtiss LK, and Goldberg IJ:
An amino-terminal fragment of apolipoprotein B
binds to lipoprotein lipase and may facilitate its bind-
ing to endothelial cells. J Biol Chem 269: 9409-9412,
1994.
Slatter RS and Smith EB: The microdissection of
large atherosclerotic plaques to give morphologically
and topographically defined fractions for analysis.
2. Studies on “Nile blue” cells. Atherosclerosis 15:
57-69, 1972.
Smith C, Mitchinson MJ, Aruoma OI, and Halliwell
B: Stimulation of lipid peroxidation and hydroxyl-
radical generation by the contents of human athero-
sclerotic lesions. Biochem J 286: 901-905, 1992.
Smith EB: The influence of age and atherosclerosis
on the chemistry of aortic intima: Part 2. Collagen
and mucopolysaccharides. J Atheroscler Res 5: 241-
248, 1965.
Smith EB, Evans PH, and Downham MD: Lipid in
the aortic intima. The correlation of morphological
and chemical characteristics. J Atheroscler Res 7: 171-
186, 1967.
Smith EB, Slater RS, and Chu PK: The lipids in raised
fatty and fibrous lesions in human aorta. A compari-
son of the changes at different stages of development.
J Atheroscler Res 8: 399-419, 1968.
Smith EB: Transport, interactions and retention of
plasma proteins in the intima: the barrier function of
the internal elastic lamina. Eur Heart J 11 Suppl E:
72-81, 1990.
References
69
Snelting-Havinga I, Mommaas M, Van Hinsbergh VW,
Daha MR, Daems WT, and Vermeer BJ:
Immunoelectron microscopic visualization of the
transcytosis of low density lipoproteins in perfused
rat arteries. Eur J Cell Biol 48: 27-36, 1989.
Sommer A, Prenner E, Gorges R, Stutz H, Grillhofer
H, Kostner GM, Paltauf F, and Hermetter A: Organi-
zation of phosphatidylcholine and sphingomyelin in
the surface monolayer of low density lipoprotein and
lipoprotein(a) as determined by time-resolved fluo-
rometry. J Biol Chem 267: 24217-24222, 1992.
Srinivasan SR, Dolan B, Radhakrishnamurthy B,
Pargaonkar PS, and Berenson GS: Lipoprotein-acid
mucopolysaccharide complexes of human atheroscle-
rotic lesions. Biochim Biophys Acta 388: 58-70, 1975.
Srinivasan SR, Yost C, Radnakristnamurthy B,
Dalferes ER, Jr., and Berenson GS: Lipoprotein-elas-
tin interactions in human aorta fibrous plaque lesions.
Atherosclerosis 38: 137-147, 1980.
Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus
D, McIntyre TM, Gray, PW, Young SG, and Prescott
SM: Molecular basis of the interaction between
plasma platelet-activating factor acetylhydrolase and
low density lipoprotein. J Biol Chem 274: 7018-7024,
1999.
Stary HC, Blankenhorn DH, Chandler AB, Glagov S,
Insull, Jr W, Richardson M, Rosenfeld ME, Schaffer
SA, Schwartz CJ, and Wagner WD: A definition of
the intima of human arteries and of its atherosclero-
sis-prone regions. A report from the Committee on
Vascular Lesions of the Council on Arteriosclerosis,
American Heart Association. Arterioscler Thromb 12:
120-134, 1992.
Stary HC, Chandler AB, Glagov S, Guyton JR, Insull
WJ, Rosenfeld ME, Schaffer SA, Schwartz CJ,
Wagner WD, and Wissler RW: A definition of ini-
tial, fatty streak, and intermediate lesions of athero-
sclerosis. A report from the Committee on Vascular
Lesions of the Council on Arteriosclerosis, Ameri-
can Heart Association. Arterioscler Thromb 14: 840-
856, 1994.
Stary HC, Chandler AB, Dinsmore RE, Fuster V,
Glagov S, Insull WJ, Rosenfeld ME, Schwartz CJ,
Wagner WD, and Wissler RW: A definition of ad-
vanced types of atherosclerotic lesions and a histo-
logical classification of atherosclerosis. A report from
the Committee on Vascular Lesions of the Council
on Arteriosclerosis, American Heart Association.
Circulation 92: 1355-1374, 1995.
Steinberg D: Low density lipoprotein oxidation and
its pathobiological significance. J Biol Chem 272:
20963-20966, 1997.
Steinbrecher UP and Lougheed M: Scavenger recep-
tor-independent stimulation of cholesterol esterifica-
tion in macrophages by low density lipoprotein ex-
tracted from human aortic intima. Arterioscler
Thromb 12: 608-625, 1992.
Steinbrecher UP, Parthasarathy S, Leake DS, Witztum
JL, and Steinberg D: Modification of low density
lipoprotein by endothelial cells involves lipid
peroxidation and degradation of low density lipopro-
tein phospholipids. Proc Natl Acad Sci U S A 81:
3883-3887, 1984.
Stins MF, Maxfield FR, and Goldberg IJ: Polarized
binding of lipoprotein lipase to endothelial cells.
Implications for its physiological actions. Arterioscler
Thromb 12: 1437-1446, 1992.
Suarna C, Dean RT, May J, and Stocker R: Human
atherosclerotic plaque contains both oxidized lipids
and relatively large amounts of alpha-tocopherol and
ascorbate. Arterioscler Thromb Vasc Biol 15: 1616-
1624, 1995.
Suits AG, Chait A, Aviram M, and Heinecke JW:
Phagocytosis of aggregated lipoprotein by macroph-
ages: low density lipoprotein receptor-dependent
foam-cell formation. Proc Natl Acad Sci U S A 86:
2713-2717, 1989.
Sukhova GK, Shi GP, Simon DI, Chapman HA, and
Libby P: Expression of the elastolytic cathepsins S
and K in human atheroma and regulation of their pro-
duction in smooth muscle cells. J Clin Invest 102:
576-583, 1998.
Suzu S, Ohtsuki T, Yanai N, Takatsu Z, Kawashima
T, Takaku F, Nagata N, and Motoyoshi K: Identifi-
cation of a high molecular weight macrophage
colony-stimulating factor as a glycosaminoglycan-
containing species. J Biol Chem 267: 4345-4348,
1992.
Tailleux A, Torpier G, Caron B, Fruchart J-C, and
Fievet C: Immunological properties of apoB-contain-
ing lipoprotein particles in human atherosclerotic ar-
teries. J Lipid Res 34: 719-728, 1993.
Tamminen M, Mottino G, Qiao JH, Breslow JL, and
Frank JS: Ultrastructure of early lipid accumulation
in ApoE-deficient mice. Arterioscler Thromb Vasc
Biol 19: 847-853, 1999.
References
70
Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG,
Orekhov, and AN: Lipoprotein aggregation as an
essential condition of intracellular lipid accumula-
tion caused by modified low density lipoproteins.
Biochem Biophys Res Commun 163: 489-494, 1989.
Tertov VV, Orekhov AN, Sobenin IA, Gabbasov ZA,
Popov, EG, Yaroslavov AA, and Smirnov VN: Three
types of naturally occurring modified lipoproteins
induce intracellular lipid accumulation due to lipo-
protein aggregation. Circ Res 71: 218-228, 1992.
Tertov VV, Bittolo-Bon G, Sobenin IA, Cazzolato G,
Orekhov AN, and Avogaro P: Naturally occurring
modified low density lipoproteins are similar if not
identical: more electronegative and desialylated lipo-
protein subfractions. Exp Mol Pathol 62: 166-172,
1995.
Tertov VV, Kaplun VV, Sobenin IA, and Orekhov
AN: Low-density lipoprotein modification occurring
in human plasma Possible mechanism of in vivo li-
poprotein desialylation as a primary step of athero-
genic modification.  Atherosclerosis 138: 183-195,
1998.
Tew DG, Southan C, Rice SQ, Lawrence MP, Li H,
Boyd HF, Moores K, Gloger IS, and MacPhee CH:
Purification, properties, sequencing, and cloning of
a lipoprotein-associated, serine-dependent phospho-
lipase involved in the oxidative modification of low-
density lipoproteins. Arteriosclerosis, Thrombosis &
Vascular Biology 16: 591-599, 1996.
Tirziu D, Dobrian A, Tasca C, Simionescu M, and
Simionescu N: Intimal thickenings of human aorta
contain modified reassembled lipoproteins. Athero-
sclerosis 112: 101-114, 1995.
Tokita K, Kanno K, and Ikeda K: Elastin sub-frac-
tion as binding site for lipids. Atherosclerosis 28: 111-
119, 1977.
Torzewski M, Klouche M, Hock J, Messner M,
Dorweiler B, Torzewski J, Gabbert HE, and Bhakdi
S: Immunohistochemical demonstration of enzymati-
cally modified human LDL and its colocalization with
the terminal complement complex in the early ath-
erosclerotic lesion. Arterioscler Thromb Vasc Biol
18: 369-378, 1998.
Tozer EC and Carew TE: Residence time of low-den-
sity lipoprotein in the normal and atherosclerotic rab-
bit aorta. Circ Res 80: 208-218, 1997.
Tsen G, Halfter W, Kroger S, and Cole GJ: Agrin is
a heparan sulfate proteoglycan. J Biol Chem 270:
3392-3399, 1995.
Vasile E, Simionescu M, and Simionescu N: Visual-
ization of the binding, endocytosis, and transcytosis
of low-density lipoprotein in the arterial endothelium
in situ. J Cell Biol 96: 1677-1689, 1983.
Via DP, Craig IF, Jacobs GW, Van Winkle WB,
Charlton SC, Gotto AM, Jr., and Smith LC:
Cholesteryl ester-rich microemulsions: stable protein-
free analogs of low density lipoproteins. J Lipid Res
23: 570-576, 1982.
Vijayagopal P, Srinivasan SR, Radhakrishnamurthy
B, and Berenson GS: Interaction of serum lipopro-
teins and a proteoglycan from bovine aorta. J Biol
Chem 256: 8234-8241, 1981.
Vijayagopal P, Srinivasan SR, Radhakrishnamurthy
B, and Berenson GS: Hemostatic properties and se-
rum lipoprotein binding of a heparan sulfate
proteoglycan from bovine aorta. Biochim Biophys
Acta 758: 70-83, 1983.
Vijayagopal P, Figueroa JE, Guo Q, Fontenot JD, and
Tao Z: Marked alteration of proteoglycan metabo-
lism in cholesterol-enriched human arterial smooth
muscle cells. Biochem J 315: 995-1000, 1996.
Vilella E, Joven J, Fernández M, Vilaró S, Brunzell
JD, Olivecrona T, and Bengtsson-Olivecrona G: Li-
poprotein lipase in human plasma is mainly inactive
and associated with cholesterol-rich lipoproteins. J
Lipid Res 34: 1555-1564, 1993.
Vogel KG, Paulsson M, and Heinegård D: Specific
inhibition of type I and type II collagen fibrillogenesis
by the small proteoglycan of tendon. Biochem J 223:
587-597, 1984.
Völker W, Schmidt A, and Buddecke E:
Compartmentation and characterization of different
proteoglycans in bovine arterial wall. J Histochem
Cytochem 34: 1293-1299, 1986.
Völker W, Schmidt A, and Buddecke E: Mapping of
proteoglycans in human arterial tissue. Eur J Cell Biol
45: 72-79, 1987.
Wagner WD and Salisbury BG: Aortic total gly-
cosaminoglycan and dermatan sulfate changes in ath-
erosclerotic rhesus monkeys. Lab Invest 39: 322-328,
1978.
Wagner WD, Rowe HA, and Connor JR: Biochemi-
cal characteristics of dissociatively isolated aortic
proteoglycans and their binding capacity to hyalu-
ronic acid. J Biol Chem 258: 11136-11142, 1983.
References
71
Wagner WD, Salisbury GJ, and Rowe HA: A pro-
posed structure of chondroitin 6-sulfate proteoglycan
of human normal and adjacent atherosclerotic plaque.
Arterioscler 6: 407-417, 1986.
Wagner WD, Goldberg IJ, Parthasarathy N, and Bot-
toms JD: Lipoprotein lipase enhances binding of
decorin but not biglycan to low density lipoprotein.
Circulation 96: I-39-I-40, 1997. Abstract.
Walton KW and Williamson NJ: Histological and im-
munofluorescent studies on the evolution of the hu-
man atheromatous plaque. J Atheroscler Res 8: 599-
624, 1968.
Wang J, Liu H, Sykes BD, and Ryan RO: Identifica-
tion and localization of two distinct microenviron-
ments for the diacylglycerol component of lipophorin
particles by 13C NMR. Biochemistry 34: 6755-6761,
1995.
Wang LJ, Lee TS, Lee FY, Pai RC, and Chau LY:
Expression of heme oxygenase-1 in atherosclerotic
lesions. Am J Pathol 152: 711-720, 1998.
Weinstock PH, Bisgaier CL, Aalto-Setala K, Radner
H, Ramakrishnan R, Levak-Frank S, Essenburg AD,
Zechner R, and Breslow JL: Severe
hypertriglyceridemia, reduced high density lipopro-
tein, and neonatal death in lipoprotein lipase knock-
out mice. Mild hypertriglyceridemia with impaired
very low density lipoprotein clearance in heterozy-
gotes. J Clin Invest 96: 2555-2568, 1995.
Weisgraber KH and Rall SC, Jr.: Human
apolipoprotein B-100 heparin-binding sites. J Biol
Chem 262: 11097-11103, 1987.
Wight TN and Ross R: Proteoglycans in primate arter-
ies. I. Ultrastructural localization and distribution in
the intima. J Cell Biol 67: 660-674, 1975.
Wight TN: The vascular extracellular matrix. In Ath-
erosclerosis and coronary artery disease. Fuster V,
Ross R, and Topol EJ eds. Lippincott-Raven, Phila-
delphia. 1996, 421-440.
Winlowe CP, Parker KH, and Ewins AR: Reversible
and irreversible interactions between elastin and
plasma lipoproteins. Biochim Biophys Acta 838: 374-
380, 1985.
Winlowe CP, Parker KH, and Ewins AR: Some fac-
tors influencing the interactions of plasma lipopro-
teins with arterial elastin. Artery 15: 292-303, 1988.
Woodard JF, Srinivasan SR, Zimny ML,
Radhakrishnamurphy, and Berenson GS: Electron
microscopic features of lipoprotein-glycosaminogly-
can complexes from human atherosclerotic plaques.
Lab Invest 34: 516-521, 1976.
Wu RR and Couchman JR: cDNA cloning of the base-
ment membrane chondroitin sulfate proteoglycan core
protein, bamacan: a five domain structure including
coiled-coil motifs. J Cell Biol 136: 433-444, 1997.
Xu XX and Tabas I: Sphingomyelinase enhances low
density lipoprotein uptake and ability to induce
cholesteryl ester accumulation in macrophages. J Biol
Chem 266: 24849-24858, 1991.
Yang CY, Chen SH, Gianturco SH, Bradley WA,
Sparrow JT, Tanimura M, Li WH, Sparrow DA,
DeLoof H, and Rosseneu M: Sequence, structure,
receptor-binding domains and internal repeats of
human apolipoprotein B-100. Nature 323: 738-742,
1986.
Yao LY, Moody C, Schonherr E, Wight TN, and
Sandell LJ: Identification of the proteoglycan versican
in aorta and smooth muscle cells by DNA sequence
analysis, in situ hybridization and immunohistochem-
istry. Matrix Biology 14: 213-225, 1994.
Ylä-Herttuala S: Is oxidized low-density lipoprotein
present in vivo? Curr Opin Lipidol 9: 337-344, 1998.
Ylä-Herttuala S, Jaakkola O, Ehnholm C, Tikkanen
MJ, Solakivi T, and Nikkari T: Characterization of
two lipoproteins containing apolipoproteins B and E
from lesion-free human aortic intima. J Lipid Res  29:
563-572, 1988.
Ylä-Herttuala S, Palinski W, Rosenfeld ME,
Parthasarathy S, Carew TE, Witztum JL, and
Steinberg D: Evidence for the presence of oxidatively
modified low density lipoprotein in atherosclerotic
lesions of rabbit and man. J Clin Invest 84: 1086-
1095, 1989.
Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S,
Glass CK, Sigal E, and Steinberg D: Colocalization
of 15-lipoxygenase mRNA and protein with epitopes
of oxidized low density lipoprotein in macrophage-
rich areas of atherosclerotic lesions. Proc Natl Acad
Sci U S A 87: 6959-6963, 1990a.
Ylä-Herttuala S, Palinski W, Rosenfeld ME,
Steinberg D, and Witztum JL: Lipoproteins in nor-
mal and atherosclerotic aorta. Eur Heart J 11 Suppl
E: 88-99, 1990b.
References
72
References
Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg
IJ, and Steinberg D: Macrophages and smooth muscle
cells express lipoprotein lipase in human and rabbit
atherosclerotic lesions. Proc Natl Acad Sci U S A 88:
10143-10147, 1991a.
Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal
E, Sarkioja T, and Steinberg D: Gene expression in
macrophage-rich human atherosclerotic lesions. 15-
lipoxygenase and acetyl low density lipoprotein re-
ceptor messenger RNA colocalize with oxidation spe-
cific lipid- protein adducts. J Clin Invest 87: 1146-
1152, 1991b.
Ylä-Herttuala S, Palinski W, Butler SW, Picard S, and
Steinberg D: Rabbit and human atherosclerotic lesions
contain IgG that recognizes epitopes of oxidized LDL.
Arterioscler Thromb 14: 32-40, 1994.
Yurchenco PD and Schittny JC: Molecular architec-
ture of basement membranes. FASEB J 4: 1577-1590,
1990.
Zambon A, Schmidt I, Beisiegel U, and Brunzell JD:
Dimeric lipoprotein lipase is bound to triglyceride-
rich plasma lipoproteins. J Lipid Res 37: 2394-2404,
1996.
Zilversmit DB: A proposal linking atherogenesis to
the interaction of endothelial lipoprotein lipase with
triglyceride-rich lipoproteins. Circ Res 33: 633-638,
1973.
Öörni K, Pentikäinen MO, Annila A, and Kovanen
PT: Oxidation of low density lipoprotein particles
decreases their ability to bind to human aortic
proteoglycans: dependence on oxidative modifica-
tion of the lysine residues. J Biol Chem 272: 21303-
21311, 1997.
Öörni K, Hakala JK, Annila A, Ala-Korpela M, and
Kovanen PT: Sphingomyelinase induces aggregation
and fusion, but phospholipase A(2) only aggregation,
of low density lipoprotein (LDL) particles - Two dis-
tinct mechanisms leading to increased binding
strength of LDL to human aortic proteoglycans. J
Biol Chem 273: 29127-29134, 1998.
